Novel methodology to characterise how asthma and chronic obstructive pulmonary disease patients use their inhalers and methods to improve their inhaler technique 

Objective assessment of how patients use inhalers by Azouz, Wahida Ahmed Abugrara
University of Huddersfield Repository
Azouz, Wahida Ahmed Abugrara
Novel methodology to characterise how asthma and chronic obstructive pulmonary disease patients 
use their inhalers and methods to improve their inhaler technique Objective assessment of how 
patients use inhalers 
Original Citation
Azouz, Wahida Ahmed Abugrara (2012) Novel methodology to characterise how asthma and 
chronic obstructive pulmonary disease patients use their inhalers and methods to improve their 
inhaler technique Objective assessment of how patients use inhalers. Doctoral thesis, University of 
Huddersfield.
This version is available at http://eprints.hud.ac.uk/17484/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not-for-profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
  
 
 
NOVEL METHODOLOGY TO CHARACTERISE  
HOW ASTHMA AND CHRONIC OBSTRUCTIVE  
PULMONARY DISEASE PATIENTS USE THEIR 
INHALERS AND METHODS TO IMPROVE 
THEIR INHALER TECHNIQUE 
 
Objective assessment of how patients use inhalers 
 
 
 
 
 
WAHIDA AHMED ABUGRARA AZOUZ  
B.Sc.(Pharm)., M.Sc.(Pharm) 
 
Submitted for the Degree of Doctor of Philosophy (PhD) 
Division of Pharmacy and Pharmaceutical Sciences, 
School of Applied Sciences, University of Huddersfield, 
United Kingdom 
 
 
 
 
 
2012 
  
ii 
 
 
Copyright Statement 
 
i. The author of this thesis (including any appendices and / or schedules to this 
thesis) owns any copyright in it (the „Copyright‟) and she has given the 
University of Huddersfield the right to use such Copyright for any 
administrative, promotional, educational and / or teaching purposes. 
ii. Copies of this thesis, either in full or in extracts, may be made only in 
accordance with the regulations of the University Library. Details of these 
regulations may be obtained from the Librarian. This page must form part of 
any such copies made. 
iii. The ownership of any patents, designs, trademarks and any and all other 
intellectual property rights except for the Copyright (the „Intellectual Property 
Rights‟) and any reproductions of copyright works, for example graphs and 
tables („Reproductions‟), which may be described in this thesis, may not be 
owned by the author and may be owned by third parties. Such Intellectual 
Property Rights and Reproductions cannot and must not be made available 
for use without the prior written permission of the owner(s) of the relevant 
Intellectual Property Rights and / or Reproductions.  
  
iii 
 
Abstract  
KEY WORDS: Pressurised Metered Dose Inhalers, Dry Powder Inhalers, Inhalation 
Characteristics, Inhalation Profiles, Asthma, COPD  
Inhaled administration is the mainstay of asthma and chronic obstructive pulmonary 
disease (COPD) management using either a pressurised metered dose inhaler (pMDI) or 
a dry powder inhaler (DPI). Poor disease control and increased hospitalisations is linked 
to poor inhaler technique. Previous studies to assess inhaler technique have used 
subjective measures and there is very limited data about the inhalation characteristics 
used by patients when they use their inhalers. 
Inhalation flow profiles when patients use their pMDI and inhalation pressure profiles 
when they use DPIs have been measured using 659 subjects (106 children with asthma 
[CHILD], 361 adults with asthma [ADULT], 142 COPD [COPD] and 50 healthy 
volunteers [HEALTHY]) in 5 separate studies. All patient studies used their real life 
inhaler technique. One of the studies also evaluated the value of using a pMDI co-
ordination aid and training these patients to prolong their inhalation whilst a different 
one investigated the impact of using enhanced training when using a DPI. 
The first study, 20 CHILD, 57 ADULT and 32 COPD subjects, revealed that the mean 
(SD) inhalation flows through a pMDI were 108.9 (40.4), 146.0 (58.8) and 107 (50.6) 
L/min, respectively and only 7, 10 and 10 used a slow flow. In the second pMDI study 
involving, 20 CHILD, 130 ADULTS, 31 COPD patients, their flows were 70.5 (36.4), 
131.4 (60.8) and 70.9 (28.1) L/min and 5, 53 and 10 used their pMDI with good co-
ordination. However only 3, 6 and 9 patients had good co-ordination and slow flow. In 
the third study, 71 ADULT patients, the mean (SD) pMDI inhalation flow was 155.6 
(61.5) L/min which decreased (p<0.001) to 112.3 (48.4) when the pMDI was fitted with 
a co-ordination aid. This was due to the increased resistance to airflow from the aid. 
Inhalation flow further reduced (p<0.001) to 73.9 (34.9) L/min when patients were 
trained to prolong their inhalations. Their inhaled volumes did not change whereas 
mean (SD) inhalation times were 1.60 (0.21), 1.92 (0.80) and 2.66 (1.03) seconds (p< 
0.001) respectively. There was a good correlation between their inhaled volume and 
forced vital capacity with a ratio of 0.7 suggesting that the patient used a full inhalation. 
A DPI study, involving 16 CHILD, 53 ADULT and 29 COPD patients, measured 
inhalation characteristics through different DPIs (low to high resistance) when patients 
used their real life DPI inhalation manoeuvres. The inhalation characteristics were 
lower in CHILD and highest in ADULT. Overall flows were higher when using low 
resistance DPIs but the pressure changes and the acceleration of the inhalation flow 
were significantly higher with high resistance DPIs which suggest more efficient de-
aggregation of the formulation. There was a tendency for more problems with low 
resistance DPIs than high resistance DPIs. The last study involved CHILD, ADULT, 
COPD and HEALTHY subjects (50 of each) when they inhaled through a Spiromax and 
a Turbuhaler (similar resistance) after standard verbal inhalation technique training and 
when using enhanced training with an IN-Check Dial. The order of inhalation 
characteristics was HEALTHY > ADULT > COPD > CHILD. Significant (p<0.001) 
improvements in the inhalation flows, pressure changes and acceleration of the flow 
were achieved in all groups after the enhanced training.  
The studies provide an insight into the inhalation characteristics of patients when they 
use different inhalers. The main problem with pMDI use was short inhalation times and 
when patients were trained to prolong their inhalation then flows reduced. Enhanced 
training when using a DPI significantly improved the technique of all patients. 
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1.0 Introduction 
Respiratory disorders are steadily increasing in prevalence, and impose a significant 
economic burden all over the world. Asthma and chronic obstructive pulmonary 
disease (COPD) are obstructive lung diseases and are two of the most common 
healthcare burdens worldwide. According to mortality statistics COPD is the fifth 
leading cause of death and the latest WHO estimates have predicted it to become the 
third leading cause of death by the year 2020 (Stockley et al., 2006). On the 
international scale, the prevalence of asthma is between one percent and 18 percent 
of the population in different countries according to the Global Initiative for the 
Asthma Management (GINA, 2008) report. There are approximately 3 deaths per day 
in the UK that are attributed to asthma and these are mostly in children and young 
adults and most of these are preventable. 
The inhaled route of administration is the optimal method of drug delivery for the 
treatment of patients with obstructive airway diseases (Pauwels et al., 1997). The 
most important advantage of inhaled therapy is that drugs are delivered directly onto 
the sites of action producing higher local concentrations for better efficacy and with 
significantly less systemic exposure hence a reduced of risk of side effects (Toogood, 
1989; Lipworth, 1999; Broeders et al., 2009). The therapeutic drugs used in the 
treatment of asthma and COPD, mostly bronchodilators and corticosteroid anti-
inflammatory agents, therefore have been formulated as inhaled aerosols. 
Consequently, a wide array of inhalation devices have been introduced to the market 
and have become the prime methods for drug administration in the treatment of 
patients with obstructive pulmonary diseases (van Beerendonk et al., 1998). 
The pressurised metered dose inhaler (pMDI) is presently the most commonly used 
inhaler. Alternatively, drugs can be administrated by a dry powder inhaler (DPI) or a 
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nebuliser. Nebulisation is not routinely used and usually reserved for administering 
large doses especially during acute exacerbations, antibiotics or drugs that are 
difficult to formulate in a pMDI or DPI. Each class of inhaler device has its pros as 
well as cons. Despite the pressurised metered dose inhaler (pMDI) being widely 
prescribed, many patients do not obtain the full therapeutic benefit because their 
inhalation technique is poor (Paterson and Crompton, 1976; Crompton, 1982b; 
Pedersen et al., 1986; Larsen et al., 1994; Lenney et al., 2000). Thus the benefits of 
inhaled therapy are accompanied by the drawbacks, particularly the challenges 
patients face when using their inhaler devices. Although inhaled therapy has 
revolutionised the management of patients with obstructive lung disease, it is well 
known that the inhalation technique used with pMDIs can substantially influence the 
clinical response to inhaled medications.  
Several studies have highlighted inhaler technique problems; 14% to 89% of the 
patients using their pMDI have either made at least one technique error or completely 
misused their inhaler (Paterson and Crompton, 1976; Epstein et al., 1979; Larsen et 
al., 1994). Frequent misuse of inhaler devices has been documented for patients 
prescribed pMDIs as well as those using dry powder inhalers (Liard et al., 1995; 
Cochrane et al., 2000; Molimard et al., 2003; Molimard and Le Gros, 2008; Giraud et 
al., 2011). Despite the availability of efficacious therapies, asthma control is often 
poor (Chapman et al., 2008; Giraud et al., 2011) and the improper use of inhaler 
devices is one major cause of poor disease control (Crompton, 2006; Molimard and 
Le Gros, 2008; Virchow et al., 2008). It has been suggested that approximately 50% 
of patients do not obtain sufficient benefit from their inhalers because of poor inhaler 
technique (Crompton and Duncan, 1989). A correct inhaler technique by the patient 
is crucial for the success of the therapy (Horsley and Bailie, 1988; Larsen et al., 
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1994; Virchow et al., 2008). It has been acknowledged that the most commonly 
encountered pMDI technique problems by patients are; poor coordination of 
inhalation with inhaler actuation, stopping to inhale shortly after activating the pMDI 
and inspiration through the nose (Crompton, 1982b). It has also been demonstrated 
that many patients fail to inhale slowly and deeply through their MDI to achieve the 
desirable flow rate of < 90 l/min for sufficient lung deposition (Al-Showair et al., 
2007a). Only 8% of patients use a slow inhalation with good co-ordination (Al-
Showair et al., 2007a). Studies have shown that poor inhaler technique is linked to 
poor disease control (Giraud & Roche, 2002) and increased hospitalisation (Melani 
et al., 2011). 
Frequent inhaler training technique and proper inhaler handling are recommended 
particularly by asthma management guidelines, and that inhaler technique should be 
checked regularly during follow-up (Newman et al., 1980; Broeders et al., 2003a). 
However, the provision of inhaler technique training remains irregular. The majority 
of studies suggested that a large proportion of patients do have problems using their 
inhalers but they are subjective assessments. The studies of this thesis have been 
designed to provide objective assessments of inhaler technique by measuring 
inhalation profiles when the patients use their inhalers and at the same time to 
quantify how patients use their inhalers. The studies have been designed to measure 
the inhalation flow rate, the time between the start of an inhalation and the pressing 
of the canister (co-ordination) and inhaled volume when patients inhale through an 
empty pMDI. In addition the inhalation profiles of patients have been used to solve 
inhalation technique problems through pMDIs. 
Dry powder inhalers (DPIs) were introduced to the market to overcome the problems 
associated with the use of pMDI and to solve the problems caused by the damage to 
  
29 
 
the ozone layer by the propellants in pMDIs (Keating and Faulds, 2002; Lavorini et 
al., 2008b). All DPIs are classified as passive devices because the patient‟s inhalation 
reacts with the resistance inside the inhalation channel of a DPI to provide a 
turbulent force that de-aggregates the formulation. The drug particles that are 
emitted, after the de-aggregation, have the greatest likelihood for deposition in the 
airways. It is now recognized that inhalers differ in their efficiency of drug delivery 
to the lungs, depending on the form of the device, its internal resistance, formulation 
of the medication, particle size, velocity of the aerosol cloud and ease with which 
patients can use the device (Bisgaard et al., 2002). 
Due to the de-aggregation process all DPIs currently available have a flow dependent 
dose emission property. Different studies have demonstrated that there is a 
relationship between the DPI‟s resistance and the inspiratory flows achieved by the 
patient through each DPI and also the amount of the drug emitted and hence 
deposited in the lung (Clark and Hollingworth, 1993; Pauwels, 1997; Al-Showair et 
al., 2007a; Chrystyn, 2009). Generally, patients using DPIs are required to inhale as 
hard and deep as they can for as long as they can and that this fast inhalation should 
begin to create a sufficient acceleration rate in order to maximise de-aggregation of 
the emitted dose and drug delivery to lung (Chege and Chrystyn, 1994; Borgstrom, 
2001; Van der Palen, 2003). It is normally accepted that a minimum peak inhalation 
flow (PIF) of 30 l/min is required through the inhaler to provide sufficient de-
aggregation to create a total emitted dose with fine drug particles able to deposit in 
the lung (Chrystyn, 2009). However, not all patients are able to achieve a sufficient 
inhalation flow through their device (Al-Showair et al., 2007). Therefore, instructing 
and training the patients on the correct inhalation technique to improve their inhaler 
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use is required (Newman et al., 1980; Horsley and Bailie, 1988; Broeders et al., 
2003a).  
Methods of assessing a patient‟s DPI inhalation technique are mostly subjective 
whereas it is possible to measure their inhalation flow with respect to time (Bisgaard 
et al., 1998; Broeders et al., 2003a; Chrystyn and Price, 2009a). These inhalation 
profiles through a DPI would provide objective data such as the peak inhalation flow, 
the time to the peak inhalation flow, the duration of the inhalation, the inhalation 
volume and the acceleration of the inhalation flow. These can be designed as simple 
methods that can be used in the clinic with the inhaler that the patient uses. Using 
this simple method patient inhalation profiles can be electronically captured using 
their untrained technique when they visit the clinic. Hence information about their 
real life inhalation technique can be obtained. These methods would objectively 
highlight the scale of the problem with respect to inhalation technique. Linked to this 
methodology, simple and novel solutions to improve inhaler technique can be 
indentified and validated. Since these electronic methods are simple and non-
invasive and patients inhale through empty inhalers then it is convenient to measure 
inhalation profiles of children with asthma, adults with asthma and patients with 
COPD. 
The inhalation profile of patients using their real life inhaler technique can be 
captured using simple electronic methods. The captured inhalation characteristics can 
be used to highlight the problems made by patients and also to identify simple 
methods to implement during the inhaler technique training of patient. 
The work in this thesis has identified and designed electronic methodology to capture 
inhalation profiles during inhalation use and demonstrate the problems faced by 
patients (including children with asthma, adults with asthma and COPD) when they 
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use their inhalers (pMDIs and DPIs). Using these objective methods (scale 
measurements) the errors made by patients can be identified. From those 
measurements simple training methods have been implemented to solve the critical 
errors that the profiles have identified. The values of these have been evaluated by 
measuring further inhalation profiles. 
The results drawn from these research studies may have future implications on the 
improvement on pMDI and DPI development as well as on clinical and 
pharmaceutical practice. 
Following this introduction (Chapter 1) there is a literature review in Chapter 2. The 
review briefly explains the management of asthma and COPD to highlight that 
inhaled therapy is the major route of administration. The chapter describes particle 
deposition in the lungs and the importance of using the correct inhalation technique 
with each device. It also includes a review of the problem patients have using the 
different type of inhalers. Chapter 3 is a pilot study including children with asthma, 
adults with asthma and COPD patients, when they use their pMDI, a pMDI attached 
to Volumatic and when attached to an AeroChamber spacer and also through an 
EasiBreathe. This pilot study was carried out to pilot the requirement and value of 
using sophisticated electronic methodology to measure inhalation profiles. Chapter 4 
extends Chapter 3 by measuring electronic inhalation profiles using sophisticated 
methodology. This study looks at pMDI use in children with asthma, adults with 
asthma and COPD patients. Measurements include the inhalation time of co-
ordination, peak inhalation flow, inhaled volume and duration of inhalation. 
Chapter 5 also uses the measurement of inhalation profiles in adult patients with 
asthma. The focus of study in this chapter is to investigate the value of using a simple 
co-ordination aid and a simple instruction to increase inhalation time. It is intended 
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that these will cause the peak inhalation flow to decrease and that the co-ordination 
problems are solved. 
Chapter 6 is similar to Chapter 3 except that DPIs are used. This study includes 
children with asthma, adults with asthma and COPD patients when they inhale 
through different DPIs. Peak inhalation flow (PIF), the maximum pressure change 
inside the DPI, time to peak flow, the acceleration rate, inhalation volume and 
duration of the inhalation are measured. 
Chapter 7 concludes the studies. This Chapter measure inhalation profiles and hence 
the inhalation parameters when children with asthma, adults with asthma, COPD 
patients and healthy volunteers inhale through a Spiromax and a Turbuhaler DPI.   
This study includes an assessment of training subjects to inhale faster using the In-
Check Dial. 
The thesis concludes with a summary of the work in chapter 8 and some 
recommendations for future work.  
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Chapter 2: Literature Review 
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2.1 Respiratory System 
The respiratory system is a complex structure responsible for the delivery of oxygen 
(O2) to the body and the elimination of carbon dioxide (CO2). The respiratory 
system, in Figure 2.1 is a series of branching tubes called bronchi and bronchioles 
and this branching in the human lung represents an inverted tree without the leaves. 
The airways branch 23 times from the trachea down to the terminal alveoli. Figure 
2.1 shows that the respiratory system is divided into three-compartments (Hinds, 
1999). The head region that is referred to as the “upper respiratory tract” includes the 
nose, nasal cavity, mouth, pharynx and larynx.  
 
Figure 2.1. The major features of the lungs include the bronchi, the bronchioles, and 
the alveoli. http://www.mcgill.ca/mmimediasampler2002/images/eidelman-
12no3.gif. 
The second compartment, down to branch 16, is known as the conducting airways 
and includes the trachea, bronchi, and bronchioles. The trachea (windpipe) extends 
the larynx directly into the lower respiratory tract. The trachea or windpipe is about 
10-12 cm long and 2 cm in diameter with C-shaped cartilages. The entry point to the 
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lung, where the trachea branches into the 2 main bronchi, is called the “hilum” or the 
root. Each bronchus divides again forming the bronchial tubes. Branching becomes 
more numerous with tiny sub-segmental bronchi and bronchioles (Marieb and & 
Hoehn, 2010). Smooth muscle surrounds the bronchi and bronchioles and is inverted 
by the autonomic nerve system (autonomic receptor), receiving both cholinergic and 
adrenergic stimuli. Sympathetic stimulation leads to a relaxation of smooth muscle in 
the wall of the bronchioles, and this leads to the bronchodilation of the respiratory 
passageways. In contrast parasympathetic activation leads to constriction of the 
smooth muscle which leads to a narrowing of the passage airways. Thus using an 
anti-cholinergic agent blocks the constriction thereby facilitating a dilation of the 
airways. 
The third compartment, shown in Figure 2.1 from branch 16-23, represents the 
respiratory zone of the lungs where the terminal bronchioles connect to tiny sacs 
called alveoli (alveolar sac). Table 2.1 describes how the airways get narrower with 
each branch and the surface area increases exponentially. 
The alveolar region contains approximately 300 to 600 million sacs providing a very 
large surface area for the process of gaseous exchange. All the alveoli have very thin 
membranes, and are close to each other and are surrounded by numerous pulmonary 
capillaries. Venous blood delivered to the lungs by the pulmonary vein is pumped 
through these capillaries. This blood takes up oxygen and expels carbon dioxide and 
leaves the pulmonary artery to the heart and is then pumped round the body. In 
adults, the total surface area of the respiratory membrane is about 70 m
2
 which is 
about the size of half a tennis court (Colbert et al., 2009). 
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 Table 2.1. A schematic representation of airway branching in the human lungs 
(Weibel, 1963). 
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The receptors for inhaled bronchodilators are distributed throughout the lungs  
(Carstairs et al., 1985; Mak and Barnes, 1990), but they have the greatest effect on 
the receptors of the airways where smooth muscle is located, hence in the conducting 
airways. Therefore, by targeting these receptors dilates the airways. Corticosteroids 
receptors are also present throughout the airways (Adcock et al., 1996) and 
inflammation has been shown to exist in all regions of the lungs (Hogg et al., 2004). 
Hence for inhaled anti-inflammatory agents it is beneficial for the inhaled dose to be 
spread throughout the airways. 
  
37 
 
2.1.1 The Lungs 
The lungs are the principle organ of respiration and considered as the largest organ in 
the body with respect to volume. Each lung is soft, spongy, elastic and is conical in 
shape and surrounded by the pleural cavity. The right lung, which weighs 
approximately 620 gm, is larger and situated a little higher than the left lung. It is 
divided into three lobes. The left one weighs about 520 gm and is divided into two 
lobes. It is smaller because the heart is accommodated in the medial aspect of the 
lung. Table 2.1 shows that the structure of the lungs provides a large surface area for 
gas exchange and presents minimal resistance to airflow and gas diffusion. The lungs  
can be damaged by dust, gases, the response to allergens and by infective agents 
(Kumar and Clark, 2002). The lungs, heart and vessels are protected by the chest 
frame. This frame is a bony and cartilaginous structure to provide protection and also 
facilities the movement of the thoracic cage to accommodate breathing. The 
breathing or ventilation of the air into and out of the lungs takes place when air is 
inhaled and exhaled. 
During inhalation the diaphragm contracts and flattens. The intercostals muscles 
between the ribs contract thereby pulling the ribcage upward and outward. During 
exhalation, the intercostals muscles and the diaphragm relax, pulling the ribcage 
down and contracting the lungs. Inspiration occurs when the intrapulmonary pressure 
is negative which facilitates the contraction of intercostals muscles and the 
diaphragm. This results in an increase in the volume of the thoracic cavity and 
promotes the flow of air into the lungs. 
An abnormality of breathing (inspiration or expiration) such as shortness of breaths 
breathlessness or wheezing may indicate a lung function disorder and significantly 
affects a subject‟s breathing pattern. The two main types of disorders that impair 
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ventilation or breathing are either restrictive (e.g. pulmonary fibrosis and sarcoidosis) 
or obstructive (asthma, chronic obstructive disease) disorders. In restrictive 
disorders, the normal lung expansion is restricted and there is a decrease of the 
inhaled volume. In obstructive lung disease the airway becomes narrow with an 
increase in resistance to airflow, such as asthma and COPD. 
2.1.2 Lung Function Test and Spirometry 
Spirometry is a pulmonary function test (PFTs) that is a useful screening test, which 
measures various aspects of the capacity of the lungs. Figure 2.2 describes the 
normal breathing process of an individual with respect to different lung volumes. 
This figure shows that the tidal volume (TV) is the amount of air moved in and out of 
the lung during a normal breath. The amount of air remaining in the lungs after a 
maximal exhalation is called the residual volume (RV). The vital capacity (VC) is 
the maximum volume of air that can be exhaled after the lungs are filled by a 
maximum inhalation and then exhaled as much as possible. This vital capacity 
manoeuvre can be done with an exhalation that is as fast as the subject can achieve 
and continued until the subject exhales no more air. So, when the vital capacity is 
forcibly exhaled, the measurement is called the Forced Vital Capacity (FVC). From 
this manoeuvre the indices of spirometry are: Peak Expiratory Flow Rate (PEF), the 
Forced Expiratory Volume in one second (FEV1) and Forced Vital Capacity (FVC) 
(Ward, 2006). Sophisticated measurements that make very frequent measurements 
during the time of this forced manoeuvre provide a variety of other indices with 
respect to flow and volume. 
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Figure 2.2. Lung Volumes. 
Spirometry is considered as the preferred method to measure airflow limitation and 
used to confirm diagnosis of asthma and COPD (GINA, 2009). 
 The Forced Expiratory Volume in one second (FEV1) is reported in litres. It 
is the volume of air that is exhaled during the first second of a forced 
expiratory manoeuvre. The FEV1 is the most frequently used parameter as an 
index for assessing airway obstruction, bronchoconstriction or 
bronchodilatation and it is considered as the standard index for assessing and 
quantifying airflow limitation. It can be further expressed as a percentage of 
the Forced Vital Capacity (FVC). When the lungs are normal this ratio is 
normally 80%. 
 Peak Expiratory Flow (PEF) is generally reported in litres/minute. It is the 
maximal flow rate (or speed) achieved during a maximal forced expiration.  
 Forced Expiratory Vital Capacity (FVC) is reported in litres. This is the 
volume of air that can be forcibly blown out (exhalation) after a full 
inspiration and continued with as much force as possible until the subject can 
expel no more air. 
Spirometry measurements are frequent expressed as predicted values based on the 
subject‟s height, age and gender (Quanjer et al., 1993). 
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2.2 Obstructive Lung Disease 
2.2.1 Asthma 
Asthma originating from the Greek word for “panting” is defined as “a chronic 
inflammatory disorder of the airways in susceptible individuals, inflammatory 
symptoms are usually associated with a widespread but variable airflow obstruction 
and increase in airway response to a variety of stimuli. Obstruction is often 
reversible, either spontaneously or with treatment" (GINA, 2009). This inflammation 
is associated with airway hyper responsiveness (AHR) with recurrent episodes of 
symptoms such as wheezing, breathlessness, chest tightness and coughing, 
particularly at night or in the early morning.  Sometimes these symptoms become so 
severe that breathing is severely impaired – in this situation the term acute 
exacerbation is used. 
Worldwide the prevalence of asthma is increasing in the last decades despite 
considerable improvements in asthma pathogenesis, knowledge and in medical 
treatment. This poses a serious global health problem in adults and children (Chung 
et al., 2002). It is estimated to affect about 5-10% of the world‟s population (300 
million people) (Lavorini and Corbetta, 2008), and is expected to increase each 
decade (Braman, 2006). Asthma is one of the chronic diseases that has a huge 
economic burden on healthcare resources in terms of cost of treatment and 
hospitalization. Thus, one of the main aims of the GINA guidelines is to reduce 
morbidity and mortality by improving asthma control (Lavorini and Corbetta, 2008). 
The current GINA challenge for each country is to reduce hospitalisation rates by 
50% over the next 5 years (Fitzgerald et al., 2011). 
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2.2.1.1 Pathogenesis of Asthma 
Asthma is an inflammatory lung condition in which the airways respond when 
exposed to inducers or triggers factors. Asthma can be categorised into two types‟ 
“extrinsic” (atopic asthma) and “intrinsic” (non- atopic asthma) (Holgate, 2008). 
Extrinsic or allergic asthma occurs when the subject is exposed to a specific allergen 
(environmental factors) such as dust, pollen or a non-specific stimulus such as a 
chemical irritant, cold air or exercise. This type of asthma develops in childhood and 
is considered to be the most common type. Intrinsic or non-atopic asthma occurs 
when there are no external factors associated with the disease such as mucosal 
inflammation, emotional stress or following a respiratory infection. 
In atopic asthma, the environmental stimuli or triggers (allergens) cause 
hypersensitivity of the airway that initiate a multi-cellular inflammatory process 
(Schieken, 2002) as shown in Figure 2.3. This process of inflammation leads to the 
activation of many different inflammatory cells in the asthmatic airways. 
Inflammatory cells produce a variety of chemical mediators, in particular mast cells, 
eosinophils and T lymphocytes, which act on the cell walls of the airways  (airway 
epithelium) (Holgate, 2010) to produce the typical features of asthma (Barnes et al., 
1996). These mediators enhance airway constriction and cause oedema of the 
airways and this leads to bronchial narrowing (or obstruction) and a  spasm of the 
airways with increases of the classical symptoms of asthma (Currie et al., 2005). 
Figure 2.4 shows the difference between the bronchioles of a normal and an 
asthmatic subject. 
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Figure 2.3. The inflammatory pathways of atopic asthma  (Holgate, 2010). 
 
Figure 2.4. Normal and Asthmatic bronchioles (www.mywembd.com).  
Symptoms of asthma  
Asthma is characterized by episodes of breathlessness, chest tightness, coughing and 
wheezing. The characteristics of these symptoms, which are variable, are often 
paroxysmal and provoked by allergic or non allergic stimuli and irritants. These 
symptoms are useful in the diagnosis of asthma. These symptoms vary in severity 
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and frequency from person to person, and may occur several times in a day or a week 
in affected individuals. Some asthmatics become worse during physical activity or 
many have more symptoms at night. One of the recognised symptoms is wheezing. 
Wheezing symptoms heard on auscultation of the chest increases the probability of 
asthma (BTS/SIGN., 2009) and is more specific to asthma than other symptoms 
(Masoli et al., 2004). 
During exacerbations of asthma, the inflammatory response increases the micro 
vascular permeability and thus cellular infiltration, fibro genesis and smooth muscle 
airway wall changes (Bradding et al., 2006; Holgate et al., 2009). This leads to a 
spasm and more obstruction with extra mucus secretion creating a constriction or 
complete blockage of the airways associated with a decline in the peak expiratory 
flow (PEF) and forced expiratory volume in one second (FEV1). 
2.2.1.2 Diagnosis and Classification of Asthma  
The history of a patient is considered as the key factor to make a diagnosis of asthma. 
The GINA (2011) guidelines and the British Thoracic Society (BTS/SIGN) 
Guidelines (2009) have stressed that diagnosis should be based on a clinical history 
of subjects and consideration of the classical symptoms of asthma (wheezing, 
coughing, shortness of breathing and nocturnal awakening). Widespread wheezing 
heard on auscultation of the chest increases the probability of asthma (BTS/SIGN 
2009). Moreover, objective measurements are needed to confirm the diagnosis of 
asthma and to assess its severity. Spirometry provides useful information about the 
degree of obstruction (BTS/SIGN 2009). The GINA guidelines (2008,2011) suggest 
that the confirmation of asthma diagnosis can be clarified by the response to inhaled 
β2- agonists (bronchodilator in an acute dose situation or over time with chronic 
inhaled corticosteroid therapy). This is characterized by an increase of >15% in the 
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FEV1 or an increase in the PEF by ≥ 20% from the baseline approximately 30 
minutes after an inhaled bronchodilator. This provides evidence of reversibility 
(Everard, 2003). However, some patients do not show this degree of reversibility 
particularly those with normal or near to normal lung function which can occur either 
on its own or with appropriate anti-asthma therapy. The ratio of FEV1/FVC is used to 
express the airflow limitation and it is useful for differentiating between asthma and 
chronic obstructive pulmonary disease (COPD).  
The classification of asthma severity is based on three equally weighted domains; 
daytime symptoms, nocturnal symptoms and pulmonary function. According to 
GINA (2009) guidelines, the severity of asthma can be classified according to the 
degree of obstruction and its severity as described in Table 2.2. A more simple 
classification is to categorise asthma into mild, moderate and severe according to 
their predicted FEV1 ( > 80%, 60-80% and < 60%, respectively). 
During an acute attack, or uncontrolled asthma, the peak expiratory flow (PEF) and 
forced expiratory volume in one second (FEV1) can decrease to less than 30% of the 
subject‟s predicted values. This is characterised by exhaustion, cyanosis, 
bradycardia, hypotension and difficulty in breathing and this can lead to coma and to 
death. Normally people with no smoking history or never had asthma should be able 
to blow-out 75-80 % or more of their total lung capacity within the first second of a 
forced exhalation. The reduction in this ratio below 70% indicates an obstructive 
lung disease (Hughes and Pride, 2000). 
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Table 2.2. Severity Classification of asthma (GINA 2008). 
Intermittent 
 Symptoms < once a week 
 Brief exacerbation, Nocturnal symptoms not more 
than twice a month 
 FEV1 or PEF ≥80% Predicted 
 PEF or FEV1 variability < 20% 
Mild Persistent 
 Symptoms more than once a week but less than 
once a day 
 Exacerbations may affect activity and sleep, 
Nocturnal symptoms not more than twice a month 
 FEV1 or PEF ≥80% Predicted 
 PEF or FEV1 variability < 20%-30 
Moderate Persistent 
 Symptoms daily 
 Exacerbations may affect activity and sleep, 
Nocturnal symptoms more than once a week and 
daily use of inhaled SABA 
 FEV1 or PEF 60-80 % Predicted 
 PEF or FEV1 variability > 30% 
Persistent Severe 
 Symptoms daily 
 Frequently exacerbations, frequently nocturnal 
symptoms, Limitation of  physical activity 
 FEV1 or PEF < 60 Predicted 
 PEF or FEV1 variability > 30% 
 
2.2.1.3 Pharmacotherapy of Asthma  
The principles of asthma management are to improve the patient‟s quality of life and 
to provide optimal long term control of the disease. The GINA guidelines are 
designed to increase the awareness of asthma, reduce asthma morbidity and 
mortality, and improve asthma therapy. A recent initiative is to decrease 
hospitalisation by 50% over the next 5 years (Fitzgerald et al., 2011). 
The goal of asthma management has been defined as no day or nocturnal symptoms, 
no limitations of daily activities, no need for reliever treatment, normal or near-
normal lung function results and no exacerbations (GINA, 2011). A stepwise 
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approach to the pharmacological treatment is recommended by GINA guidelines 
(GINA, 2011) and BTS/SIGN (2009) in attempt to achieve optimal asthma control. 
These guidelines contain a step-up process until no disease control is achieved or as 
asthma worsens. Once control of asthma has been achieved and maintained for a 
sufficient period of time (usually at least 3 months) a gradual reduction of the 
maintenance therapy is recommended to identify the minimum therapy required to 
maintain control (BTS/SIGN., 2009). 
The pharmacotherapy for the treatment of asthma is generally divided into two main 
categories: reliever (bronchodilators) and controllers (corticosteroids). Inhaled drug 
administration is used because this method delivers medication to the site of action, 
has a faster onset of action and minimizes systemic effects. The latter is due to the 
lower doses and improves the ratio of the therapeutic benefit to the potential side-
effects (Pauwels et al., 1997; Lavorini and Corbetta, 2008). Figure 2.5 and 2.6 
provide a summary of the BTS/SIGN guidelines for the management of chronic 
asthma in adults and asthmatic children.  
A short course of oral prednisolone (e.g. 40 to 60 mg per day for 5 days in adults, 20 
mg daily in toddlers) is effective for acute exacerbations. Tailing off the dose should 
be considered when a patient receives more than 2 courses in one year. 
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Figure 2.5. The asthma stepwise approach in adults. 
 
Figure 2.6. The asthma stepwise approach in children (5-12 years old). 
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2.2.1.4 Measuring Asthma Control 
The level of a patient‟s asthma control can be obtained by the use of validated 
questionnaires. Asthma management guidelines have defined asthma control as 
having no or minimal daytime nocturnal symptoms, no or minimal use of rescue 
bronchodilators, no acute exacerbation and normal or near normal lung function 
(GINA, 2009). The guidelines  also, stress that the objective of any asthma treatment 
plan is to achieve optimal asthma control and to maintain this control in the future 
(GINA, 2009). However, despite the availability of effective medications it is well 
documented that a delay in diagnosis, an under estimation of disease severity and 
consequently under treatment, the choice of inhaler device and insufficient patient 
education on correct inhaler technique and compliance may lead to poor asthma 
control (Horne, 2006; Laforest et al., 2006; Virchow et al., 2008). In clinical practice, 
patients are usually monitored by registration of their symptoms, physical 
examination, spirometry, and medication. The questionnaires are designed to identify 
which impairments are the most troublesome for patients with asthma. In many 
asthmatic patients, physical activity such as sports, shopping or scaling stairs induces 
symptoms. Other factors that may trigger symptoms are environmental stimuli, such 
as cigarette smoke, seasonal allergens, strong smells or weather conditions 
interfering with social activities. 
In clinical practice, symptoms have always been evaluated through simple questions. 
These questions have been developed into validated and reliable questionnaires that 
provide insights into the patients' well-being. Such questionnaires reveal functional 
impairments that influence daily life. Currently, several validated, questionnaires, 
with strong measurement properties, are available. Some of the questionnaires are 
short, easily understood and in self-administrable formats (Juniper et al., 1997). 
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These questionnaires, referred to as instruments (questionnaires), are used to either 
follow up patients in clinical practice or to investigate the outcome of an intervention 
in clinical research. (Nantel and Newhouse, 1999; Horne et al., 2007). The ones used 
in asthma are 
 Asthma Control Questionnaires (ACQ; Juniper et al., 1999a) 
 Asthma Control Test ™ (ACT; Nathan et al., 2004) 
 Childhood Asthma Control Test (C-ACT; Liu et al., 2007a) 
 The RCP's "Three Key Questions" (Pearson and Bucknall, 1999; Thomas et 
al., 2009) 
 The Asthma Quality of Life Questionnaire (AQLQ; Juniper et al., 1992) 
 Mini Asthma Quality of Life Questionnaire (Mini-AQLQ; Juniper et al., 
1999b) 
 Paediatric Asthma Quality of Life Questionnaire (PAQLQ; Juniper et al., 
1996a) 
 Paediatric Asthma Caregiver‟s Quality of Life Questionnaire (PACQLQ; 
(Juniper et al., 1996). 
2.2.1.4. The Asthma Control Questionnaires (ACQ)  
The Asthma Control Questionnaire (ACQ) was designed and validated to measure 
asthma control in adult asthmatics (Juniper et al., 1999a). It is simple and can be 
completed by patients in the clinic. The ACQ has strong measurement properties and 
has been fully validated for use in both clinical practice and clinical trials. For 
clinical practice, clinical trials and epidemiological studies, the ACQ has strong 
discriminative and evaluative properties which mean that it can detect small 
differences between patients with different levels of asthma control and it is very 
sensitive to within patient change in asthma control over time. 
 The ACQ has 7 questions (the top scoring 5 symptoms, FEV1% pred. and daily 
rescue bronchodilator use). Patients are asked to recall how their asthma has been 
during the previous week and to respond to the symptom and bronchodilator use 
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questions on a 7-point scale (0=no impairment, 6= maximum impairment). Their 
FEV1% predicted is also scored using a 7-point scale. The questions are equally 
weighted and the ACQ score is the mean of the 7 questions and therefore between 0 
(totally controlled) and 6 (severely uncontrolled). 
Development and validation studies have shown that the ACQ was very responsive 
to change in asthma control (Juniper et al., 1999a). Cross-sectional and longitudinal 
validity was supported by correlations between the ACQ and other measures of 
asthma health status. The ACQ, therefore, has strong evaluation and discriminative 
properties and can be used with confidence to measure asthma control in both 
longitudinal research and cross-sectional surveys, respectively, as well as in clinical 
practice (Juniper et al., 1999a). 
The ACQ is presented in Table 2.3. Many leave out the last question about the 
response to a bronchodilator.  Several studies have shown that the measurement of 
validity, responsiveness and reliability of the shortened versions, 6 questions, of the 
ACQ are similar to those of the original 7-item ACQ. Therefore the shortened ACQ 
versions can be used without compromising asthma control assessment (Juniper et 
al., 2001; Juniper et al., 2005). In general, patients with a score below 1.0 will have 
adequately controlled asthma and above 1.0 their asthma will not be well controlled 
(Juniper et al., 2006). However, there is a very grey area between 0.75 and 1.25 
where patients are on the borderline of adequate control. In general a score of < 0.75 
indicates a “well-controlled” asthma, whilst a cut-point of ≥ 1.50 pinpoints an 
“inadequately-controlled” condition (Juniper et al., 2006). A change or difference in 
the ACQ score of 0.5 is the smallest that can be considered clinically important 
(Juniper et al., 2006). 
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Table 2.3. The Asthma Control Questionnaire. 
1. On average, during the past week, how often were you 
woken by your asthma during the night? 
 
0  Never 
1  Hardy ever 
2  A few minutes 
3  Several times 
4  Many times 
5  A great many times 
6  Unable to sleep because of  asthma 
2. On average, during the past week, how bad were your 
asthma symptoms when you woke up in the morning? 
 
0  No symptoms 
1  Very mild symptoms 
2  Mild symptoms 
3  Moderate symptoms 
4  Quite severe symptoms 
5  severe symptoms 
6  Very severe symptoms 
3. In general, during the past week, how limited were you in 
your activities because of your asthma? 
 
0  Not limited at all 
1  Very slightly limited 
2  slightly limited 
3  Moderately limited 
4  Very limited 
5  Extremely limited 
6  Totally limited 
4. In general, during the past week, how much shortness of 
breath did you experience because of your asthma? 
 
0  None 
1  A very little 
2  A little 
3  A moderate amount 
4  Quite a lot 
5  A great deal 
6  A very great deal 
5. In general, during the past week, how much of the time did 
you wheeze?  
 
0  Not at all 
1  Hardly any of the time 
2  A little of the time 
3  A moderate amount of the time 
4  A lot of the time 
5  Most of the time 
6  All the time 
6. On average, during the past week, how many puffs of 
short-acting bronchodilator (e.g. Ventolin) have you used 
each day? 
 
0  None 
1  1-2 puffs most days 
2  3-4 puffs most days 
3  5-8 puffs most days 
4  9-12 puffs most days 
5  13-16 puffs most days 
6  More than 16 puffs most days 
7. To be completed by a member of clinic staff 
Pre bronchodilator FEV1 (litres)......... 
Predicted FEV1 (litres)........................ 
FEV1 (% predicted)............................. 
0  >95% 
1  90-95% 
2  89-80% 
3  79-70 
4  69-60 
5  59-50 
6  <50% 
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2.2.2 Chronic Obstructive Pulmonary Disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease and 
worldwide is responsible for more than 3 million deaths each year. It currently ranks 
as the fifth leading cause of death in the UK (NICE, 2010), and is projected to 
become the third most common cause of mortality and the third leading burden of 
disease worldwide by the year 2020 (Murray and Lopez, 2000; Murray et al., 2002; 
NICE, 2010). COPD represents a massive and growing burden with respect to direct 
and indirect costs. Hence it poses economic as well as social burdens on the patients‟ 
themselves, their families and healthcare systems (GOLD-Guidelines, 2006). 
COPD is a slow progressive respiratory disorder that is characterized by airflow 
obstruction and destruction that is not fully reversible. It varies very little from day to 
day and month to month until obstruction is severe and so it is relatively unnoticed 
until diagnosed during an acute exacerbation. The damage is due to local respiratory 
irritants commonly smoking. COPD is a general term for a spectrum of diseases that 
includes chronic bronchitis and emphysema as well as others such as small airway 
disease and chronic asthma that is unresponsive to therapy (Bellamy and Booker, 
2004). Chronic bronchitis or emphysema can occur on their own but frequently they 
occur together. Several lung societies have provided statements in an attempt to 
define COPD and distinguish it from asthma as well as to deal with the important 
aspects of COPD management. The American Thoracic Society (ATS), and the 
European Respiratory Society (ERS) definition of COPD defines chronic bronchitis 
and emphysema. The Global Initiative for Chronic Obstruction Lung Disease 
(GOLD) proposes a definition that focuses on the progressive nature of airflow 
limitation and its association with abnormal inflammatory response of the lungs to 
various noxious particles or gases.  
  
53 
 
The National Institute for Clinical Excellence (NICE) guideline (2010) has defined 
COPD as “a disease characterized by airflow obstruction. The airflow obstruction is 
usually progressive, not fully reversible and does not change markedly over several 
months. The disease is predominantly caused by smoking". (NICE, 2010). Hence, 
tobacco smoking is the major risk factor leading to the progress of COPD and that 
correlates with the prevalence and severity of chronic bronchitis and emphysema 
(Gold-Guidelines, 2009 ). These diseases are currently more common in males over 
55 years although the incidence in females is increasing, paralleling the increase in 
cigarette smoking by women. Smoking cessation is therefore, the first line 
management for those with COPD. Other risk factors, which include air pollution or 
infection, can produce a chronic inflammation of the bronchi (Jensen et al., 2000). 
Furthermore, occupational exposures (e.g. coal dust) may also contribute to the 
development of COPD (Fujita and Nakanishi, 2007). In the absence of an identified 
inhaled irritant there is a genetic link that is associated with someone presenting with 
emphysema at a young age (< 40 years old). These unfortunate patients have a 
marked deficiency of alpha α-1 antitrypsin (dAlmaine Semple et al., 1980; Tobin et 
al., 1983), and occurs in about 1-2% of COPD causes (Bellamy and Booker, 2004). 
2.2.2.1 Pathophysiology of COPD 
The pathological entity of COPD involves bronchitis and emphysema (either alone or 
together). Inflammation associated with irritant factors which can produce a chronic 
inflammation of the airways which causes physiological changes (Hunninghake and 
Crystal, 1983; Jensen et al., 2000). These changes are associated with an increase in 
mucus and predominance of inflammatory cells in various parts of the lungs and 
airway walls. Figure 2.7 describes how neutrophils, macrophages and CD8+ T 
lymphocytes
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Figure 2.7. Disease processes in chronic 
obstructive pulmonary disease (Reproduced from 
Branes (2000). 
 
(Barnes, 2000b) as well as 
other mediators, (including 
leukotriene B4, interleukin 8, 
and tumours necrosis factor) 
contribute to the 
inflammatory process. 
Further amplification of the 
inflammatory status in the 
airway can be triggered by 
factors such as viral or 
bacterial infection. These 
inflammatory cells particularly the neutrophils are responsible for the release of 
elastase-proteolytic enzymes (anti-elastase) that destroy elastin in the lung. This 
results in damage to the airways and lung tissue (elastically breakdown) with a loss 
of alveolar wall integrity. The loss of lung elastin, especially in emphysema, 
contributes to airway collapse, particularly during exercise. Alpha-1-antitrypsin is a 
natural defence mechanism to these changes and it is those with low levels of this 
agent that are more susceptible to these effects caused by inhaled irritant, and these 
are more prone to COPD.  
As time progresses and the subject continues to smoke physiological abnormalities 
gradual continue. This leads to mucus hyper secretion, airways wall thickening with 
bronchial fibrosis, airflow limitation and hyperinflation. Hyperinflation is a natural 
process by the body to try to keep the airways open. This is achieved by a flattening 
of the diaphragm, which results in less effective contraction and reduced alveolar 
efficiency, which in turn leads an increase in the residual volume (RV). Over time 
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this leads to severe airflow obstruction, resulting in insufficient expiration to allow 
the lung to deflate fully prior to the next inspiration and leading to air trapping. This 
can be translated or indicated by a decline in the FEV1 and a decreased FEV1/FVC 
ratio to < 70% (Nathell et al., 2007). There is also a raised total lung capacity (TLC), 
residual volume (RV) and functional residual capacity (RFC). 
Furthermore, destruction in the alveolar walls leads to a decrease in the effective 
respiratory membrane surface area that causes decreased gas exchange. There is an 
increase in blood carbon dioxide concentrations, which causes an increase of 
respiratory rate of COPD patients, hence a pink appearance of these patients is 
observed. Moreover, there is increasing evidence that COPD involves systemic 
features, particularly in severe stages. Cachexia (loss of fat mass), weakness and loss 
of skeletal muscle mass, osteoporosis and chronic anaemia may develop in COPD 
patients (GOLD-Guidelines, 2006; Cazzolaet al., 2007). 
A main response of some individuals to the irritant effects, mainly from cigarette 
smoking, is to increase mucus production which leads to classical chronic bronchitis. 
Mucus cells proliferate and the excessive production leads to a cough, breathlessness 
and impaired oxygen saturation. An acute exacerbations often occur, where there is a 
rapid and sustained worsening of symptoms beyond normal day-to- day variations 
(GINA, 2011). 
2.2.2.2 Diagnosis and classification of COPD 
The diagnosis and classification of COPD depends upon individual findings based on 
age, severity, medical history and physical examination, and is confirmed by 
spirometry, the degree of breathlessness and exercise tolerance. Spirometry is a 
standardized and reproducible test that objectively confirms the presence of airflow 
obstruction. Characteristically, spirometry shows a decreased forced expiratory 
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volume in one second (FEV1) and a decreased FEV1/FVC ratio (Pauwels et al., 
2001). Figure 2.8 describes the link between the reduction in the FEV1 with age and 
smoking and explains why smoking cessation is the first line management for those 
with COPD (Fletcher and Peto, 1977). 
 
Figure 2.8. The relationship between FEV1, age and smoking history  (Fletcher and 
Peto, 1977).  
NICE (2011) states that "diagnosis of COPD should be considered in patients over 
the age of 35 [over 40 according to the GOLD Guideline, 2009] who are exposed to 
one risk factors (predominately smoking) and who have COPD symptoms and signs 
including; breathlessness, chronic cough, regular sputum production, frequent winter 
„bronchitis‟ or wheeze (Pauwels et al., 2001). According to NICE, COPD Guidelines 
(2011) the criteria to consider a COPD person is a FEV1/FVC ratio < 0.70 and an 
FEV1 < 80 % of predicted values. Clinical symptoms and exercise tolerance together 
with smoking history and spirometry are used to confirm COPD. Spirometry pre and 
post a bronchodilator usually shows irreversible airflow limitation (NICE, 2010). 
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Assessment of the COPD severity level is crucially important to initiate the proper 
pharmacotherapy treatment and subsequently evaluate the disorder prognosis. The 
severity stage determination, thus, should include the degree of airflow obstruction, 
exacerbations frequency and other prognostic factors 
Table  2.4. Classification of severity of airflow obstruction GOLD (2008), and the 
NICE (2010) classification of COPD 
  
NICE 
 (2004) 
ATS/ERS4 
2004 
GOLD 
(2008) 
NICE (2010) 
Post- 
bronchodilator 
FEV1/FVC 
FEV1 % 
predicted 
Severity of airflow obstruction 
   
Post-
bronchodilator 
 
Post -
bronchodilator 
 
Post-
bronchodilator 
< 0.7 
 
≥ 80%  Mild Stage 1 –Mild Stage 1 –Mild* 
< 0.7 50–79% Mild Moderate 
Stage 2 – 
Moderate 
Stage 2 – 
Moderate 
< 0.7 30–49% Moderate Severe 
Stage 3 – 
Severe 
Stage 3 – 
Severe 
< 0.7 < 30% Severe Very severe 
Very severe** 
Stage 4 – 
Stage 4 – 
Very severe** 
*Symptoms should be present to diagnose COPD in people with mild airflow obstruction 
**Or FEV1 %< 50with respiratory failure. 
The Medical Research Council (MRC) dyspnoea scale (Fletcher et al., 1959) is a 
valid method for assessing severity which correlates with formal exercise tests, 
quality of life and activities of daily living, but it does not include a lung function 
test. This dyspnoea scale Table 2.5, has been recommended to be used to assess the 
grade of breathlessness according to the level of exertion required. 
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Table 2.5. Medical Research Council (MRC) dyspnoea scale, NICE (2010), adapted 
from Fletcher et al (1959). 
Grade Degree of breathlessness related to activities 
1 
Not troubled by breathlessness except on strenuous 
exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 
Walks slower than contemporaries on level ground 
because of breathlessness, or has to stop for breath when 
walking at own pace 
4 
Stops for breath after walking about 100 m or after a few 
minutes on level ground 
5 
Too breathless to leave the house, or breathless when 
dressing or undressing 
 
Recently, several studies have recommended using a multidimensional grading 
scheme to classify the severity and impact of COPD because it is more useful than 
the predicted percentage of FEV1 measurement alone (Celli et al., 2005; Cazzola et 
al., 2007). This index, called “BODE” (for body mass index (BMI), obstruction, 
dyspnoea, and exercise capacity) has been shown to a better predictor of survival in 
COPD than FEV1 alone (Celli et al., 2004). 
The Bode index is the body-mass index (B), the degree of airflow obstruction (O) 
and functional dyspnea (D), and exercise capacity (E) according to the criteria 
described in Table 2.6. Values between 0 and 10 are obtained and the higher the 
score then the higher is the risk of death in patients with COPD. 
Table 2.6. The Bode Index. 
Variable *Points on BODE Index 
   0 1 2 3 
FEV1 (% predicted)  ≥65 50-64 36-49 ≤35 
6-Minute Walk Test (meters)  ≥350 250-349 150-249 ≤149 
MMRC Dyspnea Scale 0-1 2 3 4 
Body Mass Index >21 ≤21 
*Body Mass Index (BMI) weight (kg)/height (m2). If the BMI is < 20, this reflects a 
Poor prognosis 
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2.2.2.3 Management of Stable COPD 
The main goals for the management of COPD are to achieve better standards for 
diagnosis, treatment, improvement of health status and quality of life, and a reduction 
of mortality (GINA, 2011). These should be achieved by relieving symptoms and by 
preventing disease progression (deterioration) and exacerbations. COPD 
management programs include pharmacological and non-pharmacological options, 
patient education and the modification of risk factors (NICE Guideline, 2004, Gold 
Guidelines, 2009). Smoking cessation is the cornerstone of management and confers 
many benefits, including a slowing of the accelerated rate of FEV1 decline as shown 
in Figure 2.8, and an improvement in COPD symptoms (Celli et al., 2004), thereby 
reducing mortality (Calverley et al., 2008). Several studies have addressed and 
confirmed that the risk factors particularly cigarette smoking are associated with the 
progression of COPD (Watson et al., 2006; Cazzola et al., 2007). Fletcher and Peto 
(1977) in their study, described in Figure 2.8, first highlighted that smoking is the 
most significant cause of airflow obstruction with an accelerated loss of lung 
function that some smokers develop.  
Beyond education and smoking cessation, the goals of pharmacologic treatments are 
to enhance survival, quality of life, and the functional status as well as lessen 
mortality. 
2.2.2.3.(a) Pharmacotherapy of COPD  
Pharmacological management for COPD includes bronchodilators, corticosteroids, 
antibiotics, and mucolytics (Cazzola et al., 2007). A summary of the National 
Institute for Clinical Excellence (NICE) recommendation (2010) for the management 
of stable COPD is presented in Table 2.7 with the Pharmacotherapy described in 
more detail in Table 2.8. 
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 Bronchodilators (Relievers) 
Inhaled Bronchodilators; including short and long acting (β2-adrenergic agonists and 
anti-cholinergic agents) are considered the mainstay of COPD treatment. These are  
effective in alleviating symptoms of bronchoconstriction that relax smooth muscle 
around the airways, increase the caliber of the airways and improve air flow and 
improve exercise capacity, with increases in the FEV1, although in some patients 
these changes are small (ATS, 2009). 
Table 2.7 shows that inhaled bronchodilators are progressively introduced and 
increased to the combination of an inhaled long acting β2 agonist and an inhaled long 
acting anti-cholinergic. The combination of these two drugs in one inhaler is not yet 
available. A short and long acting β2 – adrenergic agonist can be used together but if 
a long acting anti-cholinergic is used then a short acting anti-cholinergic should not 
be prescribed. 
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Table 2.7. The NICE guideline recommended management of stable COPD reproduced from (NICE, 2004). 
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Table 2.8. Pharmacotherapy for breathlessness and exercise limitation. 
 
 Corticosteroids 
 Inhaled corticosteroid (ICSs), have a limited role in the management of COPD 
patients, and their effectiveness is still controversial (Calverley et al., 2003; Man and 
Sin, 2005). However ICS is considered as the cornerstone of asthma therapy. The 
reason is that different mediators cause inflammation (eosinophil, mast cell) in 
asthma and (neutrophils, macrophage) in COPD (Barnes, 2000b). The mediators that 
cause inflammation in COPD have only a limited responsiveness to corticosteroids, 
while those mediators responsible for inflammation in asthma are dramatically 
affected by inhaled corticosteroids (Barnes, 2000b). Several studies using ICS agents 
in patients with mild COPD have shown no effect on the rate of FEV1 decline 
(Pauwels et al., 1999; Smith et al., 2004; Sutherland and Cherniack, 2004). However, 
they have been shown to decrease acute exacerbations in those with either moderate 
or severe COPD (Calverley and Koulouris, 2005). It is recommended that ICS can be 
prescribed to patients with FEV1 ≤ 50% predicted and who have 2 or more 
exacerbations per year (NICE, 2010; Gold-Guidelines, 2009 ). Adding an inhaled 
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corticosteroid to an established long-acting β2- agonist regime does reduce acute 
exacerbations and slow the rate of decline in health status (Macie et al., 2006).  
A study showed that a combination a of a ICS (fluticasone) with salmeterol (a 
LABA) resulted in improved lung function, prolonged frequency time of an 
exacerbation and improved the quality of life compared with mono therapy or 
placebo treatment (Calverley et al., 2003). However the decreased mortality rate just 
failed to reach significance level and there was an increase in the number of 
pneumonias. The study was not dose finding and used the highest recommended 
dose. Another study conducted by Soriano et al (2002) showed that regular use of 
“fluticasone propionate” either alone or in combination with salmeterol is associated 
with an improved survival of COPD, with an initial improvement in the first three to 
six months (Bellamy and Booker, 2004) but no effect on the subsequent rate of 
decline in the FEV1 (Soriano et al., 2002). 
A combination therapy of long- acting β2-agonist and ICS (budesonide/ formoterol) 
combined in a single DPI, called Symbicort®, provided improved lung function, a 
prolonged time to the first exacerbation (Calverley et al., 2003) and improved quality 
of life compared with either mono-therapy or placebo therapy (Welte et al., 2009). 
Also, other studies have confirmed the benefit of budesonide in combination with 
formoterol when compared to the individual components or placebo (Szafranski et 
al., 2003) and reduced the risk of exacerbations by approximately 20%-25% (Welte 
et al., 2009). Moreover, this combination has been shown to decrease lung 
hyperinflation and to increase exercise tolerance (O'Donnell et al., 2006). 
After all options, described in Table 2.8 above have been exhausted then patients are 
usually prescribed oral prednisolone despite the high risk to benefit ratio. However, 
the NICE-2004 and GOLD 2006 Guidelines for the management of COPD do not 
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recommend the use of oral corticosteroids as long term maintenance therapy in 
patients with stable of COPD. For acute exacerbations, systemic corticosteroids have 
been shown to improve airflow limitations, and symptoms (Teresa  and Martin, 
2010). Other therapeutic options include mucolytics as well as annual influenza 
vaccination. 
2.2.2.3.(b) Non-Pharmacological Management of COPD 
Non- pharmacological management of COPD is useful in parallel with therapeutic 
management to achieve the overall goals of the disease management plan. Non- 
pharmacological management includes pulmonary rehabilitation and long term 
oxygen therapy (LTOT). The rehabilitation programs include physical exercise 
training and disease education. It has been shown that the pulmonary rehabilitation 
results in an improvement in multiple outcome of considerable importance to the 
COPD patient (Folgering and van Herwaarden, 1993; Singh et al., 1998; Cazzola et 
al., 2007) and health- related quality of life (HRQoL) (Reardon et al., 2005). 
2.2.2.4 Differences between Asthma and COPD. 
Although there are some overlaps between asthma and COPD, they are separate 
disorders with different aetiologies, pathologies, natural history and responses to 
treatment (Barnes, 2008). Table 2.9 summarises the main differences between 
asthma and COPD. 
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Table 2.9. The main difference between asthma and COPD. 
 COPD Asthma 
Smoker or ex-smoker Nearly all Possibly 
Symptom under age 35 Rarely Often 
Chronic productive 
cough 
Common 
Uncommon- 
may occur during 
exacerbations 
Breathlessness 
Persistent / 
progressive 
Variable 
Night time waking with 
breathlessness and/or 
wheeze 
Uncommon Common 
Significant diurnal or 
day-to-day variable of 
symptoms 
Uncommon Common 
 
2.3 Drug delivery and Inhalation Route  
Smoking the leaves of the Atropa belladonna plant to reduce cough in India, 
approximately 2000 BC, is frequently mentioned as the first reference to pulmonary 
drug delivery (Grossman, 1994; Bisgaard et al., 2002). The treatment by inhalation 
of various chest infections and tuberculosis was used in Europe (UK) in the 17
th
 and 
19
th
 century (O‟Callaghan and Wright, 2002). 
The asthma cigarette was considered as the first portable inhaler (Everard, 2003). 
This was followed by the jet nebulizer in the 1930s and then by the glass and rubber 
bulb nebulisers for delivering adrenaline. Later on in 1950s, more convenient 
portable devices called “pMDIs” were introduced despite their disadvantages. 
The pressurised metered dose inhaler (pMDI) was first introduced in 1956 for 
delivering doses of either adrenaline or isoprenaline for the treatment of asthma. Its 
popularity with isoprenaline was demonstrated by a 600% increase in prescriptions 
and sales between 1959 (Crompton, 2006). However, pMDI sales dramatically 
decreased following an increase in deaths attributed to the isoprenaline pMDI and a 
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Figure 2.9. Onset of action using inhaled and oral 
routs of administration (Webb et  al., 1982; Everard., 
2003). 
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warning issued by the Committee of Safety Medicines in 1966. In 1969 the 
salbutamol pMDI subsequently replaced the isoprenaline pMDI, to become the most 
frequently prescribed short-acting β-agonist inhaler. In 1972, the inhaled 
corticosteroid beclometasone dipropionate was also introduced via a pMDI. Dry 
powder inhalers were first introduced as single dose capsules that had to be broken 
inside a device prior to inhalation. The Spinhaler containing sodium cromoglycate 
was introduced in 1967 and was followed by the Rotahaler. The first multidose dry 
powder inhaler was the 
Turbuhaler in 1987 and 
was then followed by 
single doses inside an 
inhaler (Diskhaler and 
then Accuhaler). Many 
others types of DPI have 
followed.  
The pulmonary route 
allows inhaled medication 
to be delivered directly to 
the therapeutic sites in the airways of the lungs (Virchow et al., 2008). Due to this 
direct delivery a low dose is required compared to a therapeutically equivalent oral 
dose hence there is a large reduction in systemic adverse effects. There is a fast onset 
of action as shown in Figure 2.9 (Webb et al., 1982), and a lower rate of side-effects 
(Pauwels et al., 1997). A high therapeutic ratio is achieved compared with systemic 
delivery (Newman et al., 1981a; Virchow et al., 2008). Therefore, this route is 
considered as the optimum route for administering the majority of the drugs for the 
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treatment of obstructive lung disease (Toogood, 1989; Pauwels, 1997). In addition, to 
asthma and COPD, inhaled therapy can be used to treat other respiratory diseases 
such as: bronchopulmonary dysplasia and cystic fibrosis (De Boeck and Breysem, 
1998) where large doses of antibiotics are inhaled (mostly by nebulisation). 
Furthermore, other drugs are under development for systemic therapy using aerosol 
delivery. These include insulin to treat diabetes, gene therapy vectors to treat cystic 
fibrosis (CF), vaccines for measles, chemotherapy agents for lung cancer, morphine 
to relieve pain and for acute pain management and ergotamine for migraine.  
Different inhaler devices are available to deliver these drugs; pressurised metered 
dose inhalers (pMDIs), which are used either alone or attached to a spacer or valved 
holding chambers (VHCs), dry powder inhalers (DPIs) and nebulisers. These 
inhalation devices produce an aerosol cloud of medication that provides an emitted 
dose that is capable to deposit medicine into the lungs during an inhalation 
manoeuvre. The fraction of the emitted dose with this capability is termed the fine 
particle dose. The fine particle dose is the amount of particles in the emitted dose that 
have an aerodynamic diameter of less than 5 µm. Particles below this size range have 
the greatest likelihood to be deposited on the airways in the lungs during an 
inhalation (Rees et al., 1982; Newman, 1985; Chrystyn, 1999). 
A summary of the aerodynamic characteristics of the dose emitted from an inhaler is 
presented in Table 2.10. (Laube et al., 2011). These terms are derived from in-vitro 
measurements. 
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Table 2.10. Definitions of commonly used in-vitro terms that describe an aerosol 
(Laube et al., 2011). 
Term Abbreviation Definition 
Labelled dose or 
nominal dose* 
 The mass of drug that is available within the aerosol 
generator per actuation. This is the dose that is 
metered. 
Total emitted dose 
or delivered dose 
TED The mass of drug emitted per actuation that is 
actually available for inhalation at the mouth. 
 
Fine-particle dose 
FPD The mass of particles, 5 mm in size within the total 
emitted dose. 
Fine-particle 
fraction 
FPF The fine particle dose divided by the total emitted 
dose. 
Aerodynamic 
equivalent diameter 
dae 
The diameter of a fictitious sphere of unit density (1 
g
.cm-3
) that has the same gravitational (settling) 
velocity in the same gas as the actual particle. 
Mass median 
aerodynamic 
diameter 
 
dae,µm or 
MMAD 
The MMAD divides the aerosol size distribution in 
half. It is the diameter at which 50% of the particles 
of an aerosol by mass are larger and 50% are smaller. 
Geometric standard 
deviation 
 
σg or GSD 
The GSD measures the dispersion of particle 
diameter and is defined as the ratio of the median 
diameter to the diameter at ¡1 SD (s) from the median 
diameter. In a cumulative distribution plot of the 
aerodynamic diameter and mass of particles, the GSD 
is calculated as the ratio of the median diameter to the 
diameter at 15.9% of the probability scale, or the ratio 
of the diameter at 84.1% on the probability scale to 
the median diameter. Aerosols with a GSD ≥1.22 are 
considered polydisperse. Most therapeutic aerosols 
are polydisperse and have GSDs in the range of 2–3. 
* Lung deposition can be presented as a percentage of the nominal or emitted dose. Note that 
these two parameters are not the same. 
Drug delivery via the pulmonary airways is more complex than oral therapy. To 
achieve successful therapy requires a delivery system that during an inhalation 
generates drug particles of an appropriate size, that have the capability to penetrate 
beyond the oropharynx and larynx and deposit onto the target area in the lungs 
(Labiris and Dolovich, 2003) to have a pharmacological effect (Byron and Patton, 
1994). 
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To achieve effective targeting within the airways there are a number of factors that 
can govern the penetration and deposition of inhaled aerosols. Aerodynamic diameter 
is generally thought to be the most important particle related factor that affects 
aerosol deposition. Figure 2.10 shows that there is a relationship between 
aerodynamic diameters and lung deposition (Köbrich et al., 1994). There are three 
main mechanisms of particle deposition that have been suggested to be responsible 
for the deposition of inhaled aerosol particles depending upon on their size. The three 
main mechanisms are impaction, sedimentation and Brownian diffusion as shown in  
Figure 2.11. 
 
 
 
Figure 2.10. The relationship between aerodynamic diameter and lung deposition 
(Köbrich et al., 1994; Laube et al., 2011).  
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Figure 2.11. Respiratory drug particles deposition mechanisms in human lung (Yu 
and Chien., 1997). 
This figure also shows that other effects such as interception impaction and 
electrostatic forces are responsible for some deposition in smaller airways (Heyder et 
al., 1986). Inertial impaction (inertial particle transport) is a physical phenomenon, 
which mainly influences the deposition of larger particles. When the dose is emitted 
from an inhaler the airflow (at the mouth) is fast especially from a pMDI. The 
particles in the emitted dose join the airflow down into the airways. In the mouth and 
down to the larynx and further down the trachea the airflow is fast and so large 
particle (those larger than 5 μm) will deposit in the oro-pharyngeal region. These 
particles will be swallowed and the drug absorbed into the systemic circulation after 
gastro-intestinal absorption. Particles < 5 µm will enter the lungs via the right and 
left bronchus and down into the large airways. Here the airflow is still relatively fast 
and thus particles just below 5 μm will deposit by impaction at the bifurcation of 
these larger airways (Labiris and Dolovich, 2003). 
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The second important mechanism is Sedimentation, i.e. “gravitational attraction" 
which is responsible for deposition of smaller particle sized < 5µm and towards 1μm. 
As the inhaled airstream flows down the narrowing airways the flow becomes slower 
and slower. In the smaller airways of the conducting zone of the lungs the particles 
are suspended in a very slow moving airflow. These particles will deposit due to 
gravity. This process of sedimentation is proportional to the aerodynamic particle 
size and to the period during which the drug particles stay in the lungs (Newman et 
al., 1981a; Everard, 2003). Consequently the chance of sedimentation increases with 
residence time in these more peripheral airways (Newman et al., 1982). For this 
reason, a breath holding manoeuvre after an inhalation is important (Everard et al., 
1997; Hillery et al., 2001). 
The third mechanism is Brownian diffusion which is the primary transport 
mechanism for very small particles especially those from 1μm to 0.1-1µm in 
diameter. The particles are suspended in a very slow moving airstream and move by 
colliding into each other and if they collide with the airway wall then the particles 
deposit otherwise they are exhaled (Labiris and Dolovich, 2003). This mechanism is 
inversely proportional to the particle size and directly proportional with length of 
stay in the lungs (Hillery et al., 2001). Again a breath hold is important. 
A high and slow airflow has a profound effect on the overall deposition of inhaled 
drug particles in the lung (Everard, 2003). An increase in the inspiratory flow will 
enhance deposition by inertial impaction in the upper airways as well as the 
oropharynx (Usmani et al., 2005). Also, an increased inhalation volume will lead to 
an increase in the penetration of particles deeper into lung and thus enhance 
deposition into the alveolar region (Pavia et al., 1977). Also, the period of breath 
holding increases particle deposition by gravitational sedimentation and diffusion 
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(because it increases the time that particles stay in the lung (Dhand and Fink, 1999). 
Training the patient the correct inhalation technique improves drug delivery to the 
lungs (Newman et al., 1991b), particularly in terms of the rate at which the patients 
inhale, and the period of breath holding (Newman et al., 1980; Newman et al., 
1991b). The most significant factor for pulmonary deposition is the patient‟s 
inhalation technique. This is covered extensively later. 
In addition, important patient related factors play a role in pulmonary drug delivery. 
These include the morphology of the oropharynx and larynx and the patient‟s 
inspiratory volume and flow rate. The airway calibre also influences the amount of 
drug deposited into the airways (Lipworth and Clark, 1997). 
2.3.1 Inhalation Devices and Drug delivery 
A number of inhaler devices have been introduced to provide medications to the 
lungs. The most frequently used inhalers are the pressurized metered dose inhalers 
(pMDI or MDIs) and dry powder inhalers (DPIs), while nebulizers are sometimes 
used in specific circumstances. 
2.3.1.1 Pressurized Metered Dose Inhaler (pMDI or MDI) 
The pMDI was introduced in the 1950s, and the first portable multi-dose inhaler 
designed to deliver a fine aerosol drug to the lungs (Vaswani and Creticos, 1998; 
Fink, 2000). It is frequently prescribed to deliver inhaled bronchodilators (β2 agonists 
and anti-cholinergic agents) and anti-inflammatory agents (corticosteroids) for the 
management of lung disease. The pMDI is the most widely prescribed inhaler device 
worldwide (Pauwels et al., 1997; Lavorini and Corbetta, 2008) and, it is still the most 
popular inhalation method in the UK (Vaswani and Creticos, 1998; Crompton, 
2004). pMDIs have a number of advantages in that they are compact, cheap, 
portable, relatively inexpensive, provide consistent dose emission, and are multidose 
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with up to 200 metered dose (Newman, 1991). They are available to deliver different 
inhaled formulations (Lavorini and Corbetta, 2008). A pMDI, shown in Figure 2.12 
consists of a pressurised aluminium canister containing the formulation that fits into 
a holder which is the mouthpiece. The nozzle of the canister fits into a holder which 
has an aperture through which the dose is discharged from the canister when it is 
pressed. Inside the canister a metering valve with a spring allows a dose to be 
dispersed and emitted. The formulation in the canister is traditionally either a 
suspension of micronized active drug suspended or dissolved in a propellant. The 
formulation also contains surfactants and lubricants (Newman et al., 1981a), as 
appropriate, to maintain the action of the spring valve. 
 
Figure 2.12. A schematic of the pMDI (source: 
www.solvaychemicals.com/docroot/fluor/static_files/images/solkane_227_134a_pha
rma_application) 
Pressing the top of the canister in the actuator‟s (mouthpiece) seating opens the 
metering valve resulting in its contents being expelled. The liquefied propellants 
vaporise and provide the required potential energy to expel a hetero-disperse aerosol 
of droplets that consist of tiny drug particles. When the depression of the canister is 
released the canister nozzle closes and the metering cup encases the next dose from 
the formulation inside the canister therefore, it is important to shake the pMDI 
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immediately before dose actuation. The dose release pressure is 3-5 times 
atmospheric pressure, thus the initial velocity of dose leaving the mouthpiece is high, 
approximately 100 k/hr or 70 miles/hr. After dose actuation, the aerosol particles 
rapidly decelerate and the propellant evaporates. During inhalation the propellant gas 
may cause cough, throat irritation and paradoxical bronchoconstriction whilst the 
cool temperature hitting the back of the throat can involuntarily stop the patient‟s 
inhalation. This latter phenomena is called the Cold Freon Effect (Crompton, 1982a; 
Newman and Clarke, 1983). There is a high degree of oro-pharyngeal deposition 
which is enhanced if there is inadequate co-ordination of the start of an inhalation 
and dose actuation and when the inhalation is too fast (Crompton, 1982a; Newman 
and Clarke, 1983). Poor co-ordination and inhaling too fast are common problems 
(Al-Showair et al., 2007a). These common problems associated with pMDI use are 
the reason why most patients cannot use pMDIs correctly, even after repeat tuitions 
(Crompton, 2004: Crompton et al., 2006: Virchow et al 2008). To overcome these 
problems associated with pMDIs, breath actuated pMDIs (BA-pMDIs), spacers 
(Bisgaard et al., 2002), and dry powder inhalers (DPIs) have been introduced. 
Until recently, the propellants used in the pMDI formulations were 
chlorofluorocarbons (CFCs). These were very useful dispersion mediums for the 
drug substance and other excipients (Young et al., 2003). Traditionally all 
formulations were a suspension of micronized drug particles suspended in the CFC 
propellant. Due to the damage to the ozone layer by CFCs (Molina and Rowland, 
1974) and in accordance with the Montreal Protocol (1994) on substances that 
deplete the ozone layer, the CFCs have been now been replaced with the more 
environmental friendly hydrofluoroalkanes (HFAs). This change is now almost 
complete and at present time there are only a few pMDIs that still contain CFCs 
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(Laube et al., 2011). The hydrofluoroalkanes (HFAs) have different physical and 
chemical properties which meant that all pMDIs had to be reformulated. The primary 
aim was to formulate pMDIs with the same dose emission characteristics as their 
CFC counterparts (Cripps et al., 2000). 
The HFAs have a higher boiling point than CFCs. Hence, the HFA formulations emit 
an aerosol with  a slower velocity at initial release and it is warmer (Gabrio et al., 
1999). Thus the potential of the Cold Freon Effect and oro-pharyngeal deposition is 
reduced with a greater potential for better lung deposition (Leach et al., 1998). 
The reformulation of pMDIs with HFAs did present a challenge to the 
pharmaceutical industry because different excipients were required. Most products 
were formulated with dose emission characteristics similar to the CFC-pMDI 
counterpart but this was not possible for some drugs. Hence some corticosteroids, 
notable beclometasone dipropionate, were difficult to reformulate. This problem was 
solved by formulating a solution rather than a suspension of drug particles. This 
meant that the aerosolised dose emitted contained much smaller particles, referred to 
as extrafine or ultrafine particles. This produced a significant improvement in lung 
deposition, increased systemic delivery and clinical efficacy compared to its CFC 
counterpart (Leach et al., 1998; Leach et al., 2002). Figure 2.13 shows the lung 
deposition (53%) from a HFA-BDP compared (4%) to a CFC BDP (Leach et al., 
2005). 
The greater lung deposition is due to the fact that these HFA pMDIs emit extrafine 
beclometasone dipropionate particles with a MMAD of 1.1µm (Fergusson et al., 
1991). It also leads to more efficient peripheral lung deposition and lower 
oropharyngeal deposition compared to the CFC formulation (Leach et al., 1998; 
Leach et al., 2002). 
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Figure 2.13. Scintigraphic images of enhanced lung deposition from  HFA-BDP 
versus the same patient inhaling CFC-BDP (Leach et al., 2005). 
Consequently, this formulation has been shown to provide an equivalent clinical 
response at half the dose of the innovator CFC-BDP (Becotide
®
, Galxo-SmithKline) 
formulation (Busse et al., 1999). The brand name of this product is Qvar
®
 (Teva 
Pharmaceuticals). An alternative approach for BDP was to re-formulate pMDIs with 
HFA propellants using Modulite
®
 Technology to control the size of the particles 
emitted from the pMDI (Ganderton et al., 2002; Lewis et al., 2005). The 
aerodynamic characteristic of the emitted dose are the same as the CFC-BDP pMDI.  
The dose for this product, Clenil
®
 (Chiesi Pharmaceuticals), is the same as that of the 
innovator product.  Due to the difference between the recommended doses for Qvar
®
 
and Clenil
®
 the MHRA have recommended that these products should be prescribed 
by brand name. Becotide has been discontinued. 
2.3.1.1.(a) Spacers 
In the 1980s spacers were introduced to overcome the co-ordination problems 
associated with the use of the conventional pMDI. Spacers act as a simple extension 
tube attached to the pMDI mouthpiece that is designed with a chamber to enable the 
dose emitted from a pMDI to slow down. The patient inhales from a static cloud and 
this helps with better lung deposition (Barry and O'Callaghan, 1996; Richards et al., 
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2001; Roller et al., 2007; Lavorini and Fontana, 2009). The large particles emitted 
from a pMDI are left in the spacer during an inhalation. Oropharyngeal deposition is 
reduced (Toogood et al., 1984) and there is also a reduction in the systemic delivery 
because less is swallowed (Barry and O'Callaghan, 1996; Richards et al., 2001; 
Roller et al., 2007; Lavorini and Fontana, 2009). 
Spacer may improve the effect of inhaled medications, particularly for patients who 
they are not able to use their inhaler (pMDI) properly (Godden and Crompton, 1981; 
Newman and Newhouse, 1996). Holding chambers have shown to improve 
pulmonary deposition from approximately 10% (with pMDI alone) to ≥ 20% 
(Newman et al., 1995b). A range of studies have investigated the value of spacers 
with regards to coordination, but the literature contains mixed results and many use 
bronchodilator doses at the plateau of the dose response relationship. 
Godden and Crompton (1981) first demonstrated an improved bronchodilatation 
response in asthmatic patients by improved FEV1 after using the spacer compared to 
the conventional pMDI (Godden and Crompton, 1981). In accordance to these 
outcomes, a similar study confirmed that the addition of a tube extension 
significantly increased PEFR values compared with the original pMDI (Langaker 
and Hidinger, 1982). Others have shown that a pMDI used with a spacer provided 
increased responses to short acting β-adrenergic bronchodilators, even for patients 
with adequate technique compared to the pMDI used alone (Fontana et al., 1999; 
Lavorini et al., 2004; Lavorini et al., 2006; Lavorini et al., 2008a). In contrast, a 
number of studies have demonstrated that spacers did not add any clinical 
advancement compared to a standard pMDI, since there was no significant difference 
in the bronchodilator effect (Gomm et al., 1980; Epstein et al., 1983). However this 
could be due to using doses at the top of dose response course (Newman, 1985). 
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Spacers differ by volume, length, shape, construction material and are valved or non 
valved systems. Versions referred to as  holding chambers contain a one way valve in 
the mouthpiece which direct air that is exhaled out away from the chamber while 
during an inhalation the air is pulled through the chamber. This type of spacer is 
known as a valved holding chamber (VHC) and can be used with an inhalation that 
uses a normal tidal breathing pattern. Spacers attached to pMDIs are recommended 
for patients who have  difficulties with pMDIs particularly co-ordination 
(BTS/SIGN, 2009; GINA, 2009). A spacer attached to pMDI is the recommended 
inhalation method for children < 6 years old. 
Figure 2.14. Shows that spacers have different sizes and designs. The Volumatic™ 
spacer (GlaxoSmithKline, UK) is the most widely used worldwide (Chuffart et al., 
2001). It is a diamond shaped large, valved spacer with a volume of 750 ml.  In-vitro 
studies have shown an increased fine particle dose delivery (Barry and O'Callaghan, 
1994), and in-vivo studies have shown an increase in lung deposition compared to 
the pMDI alone (Newman, 2004). Another spacer with a large volume is the 
Nebuhaler® spacer (AstraZeneca, Sweden) but this has now been discontinued. The 
AeroChamber Plus® spacer (Truddell International, Canada) is a 149 ml tube design 
that is available as infant, child and adult versions depending on the size of the mask. 
These are colour coded; the version with an adult a mask is blue and this is also 
available with a mouthpiece instead of the mask, children with a mask is yellow, and 
for infants with a mask it is orange. (Kraemer, 1995). Another spacer the Babyhaler® 
(GlaxoSmithKline, UK) has a volume of 350ml (Newman, 2004). The 
Nebuchamber® (AstraZenaca, Sweden) was made of metal and had anti-static 
properties but has now been withdraw. 
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Figure 2.14. Different Types of Spacers A) Neubhaler (Metal spacer  B) The 
Volumatic™ spacer C) Babyhaler® D) Nebuhaler® spacer (E)The Aero-Chamber 
Plus® spacers (Trudell Medical International (TMI), Canada 
It has been found that during an acute attack, the use of multiple single doses of a 
short-acting β2-agonist through a pMDI plus spacer is an effective alternative to a 
nebuliser (Duarte et al., 2000; Cates et al., 2003). GINA (2008) also states that the 
use of a spacer attached to a pMDI is preferred during the treatment of an acute 
asthma exacerbation instead of using a nebulizer. A study demonstrated that 5 
separate doses from a pMDI and a spacer provided the same relative lung deposition 
as 5mg nebulised from a jet nebulizer during acute exacerbations in patients with 
asthma and COPD (Mazhar and Chrystyn, 2008). 
Despite, the efficiency of spacers and their advantages, they suffer from the obvious 
disadvantage of making the spacer more bulky and less portable than a pMDI 
(Onyirimba et al., 2003; Nair et al., 2008). This can affect patient compliance and 
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acceptance (Brown et al., 1990; Newman, 2004). Recent studies have highlighted the 
patient‟s lack of acceptance regarding the use of spacers over other devices (Lenney 
et al., 2000). 
Other problems associated with spacers are that there are made of polycarbonate 
plastic material and so are prone to develop a static electrical charge on the inner 
walls which may result in  inconsistent medication delivery (Lavorini and Fontana, 
2009). Thus, the proportion of the inhaled dose may vary greatly with different 
spacers. Changing from one spacer to another may be unimportant with some drugs 
but be critical for others (Lavorini and Fontana, 2009). Static can be reduced or  
solved by washing a spacer with household detergent without rinsing it with water 
and then allowing it to air dry (Kenyon et al., 1998). Also, coating the inner walls 
with antistatic lining can reduce static (O'Callaghan et al., 1993). The AeroChamber 
Plus will soon be introduced with an anti-static lining. A non- static spacer that is 
made of metal also limits the effect of the static charge e.g. Nebuchamber
®
, but this 
has been withdrawn. The Vortex
®
, is a non-static spacer due to its extremely thin 
metal layer on the inner surface of a plastic spacer. Generic and comprehensive 
instructions on the how to use a pMDI attached to a spacer have been published by 
Laube et al (2011). Table 2.11 shows generic and comprehensive instructions on the 
how to use a pMDI attached with a spacer (Laube et al., 2011). 
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Table 2.11. Detailed instructions on how to use pressurised metered-dose inhalers 
(pMDIs) with spacers: for patients ≥ 6 yrs old.  
 (Caregiver should determine if child can perform this technique correctly) 
1) Shake four or five times if suspension formulation. 
2) Take the cap off. 
3) Prime the inhaler (refer to the PIL for specific instructions). 
4) Insert the mouthpiece of the pMDI into the open end of the spacer and ensure a 
tight fit. If a reverse flow spacer is used, insert the valve stem of the pMDI into the 
port on the mouthpiece of the spacer. 
5) Place the mouthpiece of the spacer in the patient‟s mouth with the teeth over the 
mouthpiece and the lips sealed around it. 
6) Instruct the child to exhale slowly, as far as comfortable (to empty their lungs). 
7) Actuate one dose into the chamber of the spacer and start to inhale slowly through 
the mouthpiece. Some spacers will make a whistling noise if inspiration is too fast. 
8) Maintain a slow and deep inhalation through the mouth, until the lungs are full of 
air. This should take a child 2–3 s and an adult 5 s. 
9) At the end of the inhalation, take the inhaler out of the mouth and close the lips. 
10) Continue to hold the breath for as long as possible for up to 10 s before breathing 
out. 
11) Breathe normally. 
12) If another dose is required, repeat steps 1–11. 
13) If ICSs are used, rinse mouth afterwards. 
 
2.3.1.1.(b) Breath Actuated Pressurised Aerosol (BA-pMDI) 
Breath-actuated metered-dose inhalers (BA-pMDI) were introduced to achieve good 
synchronisation between dose actuation and start of an inhalation, These devices 
contain a conventional pressurised canister with a flow-triggered system driven by a 
spring to release a dose automatically during the start of an inhalation (Newman et 
al., 1991b), so that firing and inhaling are automatically coordinated. Figure 2.15 
shows that lung deposition from BA-pMDI is the same as good coordination. The 
  
82 
 
Autohaler® was the first to be introduced to the market in the early 1990‟s (Newman 
et al., 1991b) followed by the EasiBreathe®. The actuation occurs at a flow of 
approximately 20 L/min for the EasiBreathe and ≈30 l/min for the Autohaler (Hardy 
et al., 1996; Laube et al., 2011). In one study, only  < 5 % of patients were unable to 
achieve the threshold inspiratory flow rate required for actuation of the Autohaler 
and there were fewer errors (Fergusson et al., 1991), compared with using a standard 
pMDI (Molimard et al., 2003). These inhalers are considering as an alternative to the 
standard pMDI for patients who are not able to use a conventional pMDI correctly 
(Bisgaard et al., 2002). Figure 2.15 shows how lung deposition increased in patients 
when they used a BA-pMDI. 
 
Figure 2.15. Mean (SD) lung deposition in good and poor coordinator and when the 
poor coordinators used a breath actuated device  (Newman et al., 1991b). 
The effectiveness of BAI-pMDIs was reported in a large (n=5556) patient study of 
new asthmatics using GP visits and the number of SABA and ICS prescriptions as 
outcome measures. The study showed that the asthmatics using a BA–pMDI had 
fewer prescriptions and used less healthcare resources (Price et al., 2003). The 
EasiBreathe BA-pMDI has many features over conventional pMDIs that include ease 
of use with less frequent errors (Lenney et al., 2000; Newman, 2004). Moreover, 
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healthcare professionals found it easier to teach and patients easier to learn and to 
use than a conventional pMDI (Price et al., 1999). It has been found that the errors 
when using BA-pMDIs are less frequent than when using a standard pMDI (Lenney 
et al., 2000; Crompton, 2004). The Autohaler BA-pMDI can be used easily by 
children over 7 years old (Pedersen and Mortensen, 1990). 
A major disadvantage of BA-MDIs is that they are only available with salbutamol 
and BDP (Qvar®). Furthermore the licence for the beclometasone dipropionate does 
not include children < 12 years of age. Another disadvantage is their item cost but 
they may prove to be cost effective in terms of resource saving in the long run 
(Langley, 1999). 
2.3.1.1.(c) The pMDI Inhalation Technique  
Soon after the pMDI was introduced the problems patients have using a pMDI were 
first reported (Saunders, 1965). After the introduction of salbutamol (1969) and 
beclometasone dipropionate (1972) pMDIs use increased. The issues about pMDI 
inhalation technique surfaced with reports from Paterson & Crompton (1976) and 
Crompton (1982). These showed that inhaling through the nose instead of the mouth, 
involuntary stopping the inhalation phase (the Cold-Freon Effect) and co-ordination 
between the start of an inhalation and the release of a dose as well as not breath 
holding after the inhalation manoeuvre were common mistakes made by patients.  
Many reports have followed but only a few have highlighted that not using a slow 
inhalation is the most common error made by patients (Nimmo et al., 1993; 
Hesselink et al., 2001; Al-Showair et al., 2007a). Incorrect or unsatisfactory use of 
the pMDI technique may lead to a sub-optimal therapeutic effect, especially for 
inhaled corticosteroids. This has been given as a reason why > 50% of adult patients 
do not get the maximum effectiveness from their inhalers (Crompton, 1990).  
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(i) Co-ordination between the start of an inhalation and actuation of the dose 
Poor co-ordination between the start of an inhalation and the actuation of a pMDI 
canister is one of the most common mistakes that patients made when using pMDIs  
(Newman et al., 1981a; Crompton, 1982b; Ganderton, 1997). Figure 2.15 shows that 
in asthmatics with poor co-ordination lung deposition was only 7% compared to 
22.8% in those with good co-ordination (Newman et al., 1991b). Hindle et al 
(1993a), using urinary salbutamol pharmacokinetic methodology, showed that no co-
ordination resulted in poor lung deposition as shown in Figure 2.16. 
 
Figure 2.16. Mean and individual values of the relative lung bioavailability of 
urinary salbutamol after inhalation by two different manoeuvres (Hindle et al., 
1993). 
The optimum actuation time (good co-ordination) has been defined by Goodman et 
al (1994) as 0 to 0.2 seconds between the start of an inhalation and pressing the 
canister to release a dose. This is based on the gamma scintigraphy studies of 
Newman et al (1980; 1981a; 1981b). More objective confirmation of this time for 
co-ordination was provided by Farr et al (1995). This study measured lung 
deposition using gamma scintigraphy following 5 different computer controlled 
inhalation manoeuvres. 
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 Slow/early: inhalation flow of 30 L/min and actuation after 300 ml hence the 
time of co-ordination is 0.6 second 
 Slow / late: inhalation flow of 30 L/min and actuation after 3000 ml hence 
the time of co-ordination is 6 second 
 Medium / early: inhalation flow of 90 L/min and actuation after 300 ml hence 
the time of co-ordination is 0.2 second 
 Fast / early: inhalation flow of 270 L/min and actuation after 300 ml hence 
the time of co-ordination is 0.1 second 
 Fast /late: : inhalation flow of 270 L/min and actuation after 3000 ml hence 
the time of co-ordination is 1 second 
Figure 2.17 shows that the medium/early provided the highest total lung deposition 
and more was deposited in the peripheral regions.  
 
Figure 2.17. The effect of co-ordination and flow rates on the mean (SD) lung 
deposition from a Smart Mist pMDI (Farr et al., 1995). 
 
0 
5 
10 
15 
20 
25 
Slow/early Slow/late Medium/early Fast/early Fast/late 
M
ea
n
 (
S
D
) 
D
ep
o
si
ti
o
n
 (
%
) 
a
t 
L
u
n
g
s 
a
n
d
 p
er
ip
h
er
a
l 
lu
n
g
 
%  Lung 
deposition  
  
86 
 
Broeders et al (2003) measured electronic profiles of adult asthmatic and COPD 
patients when they used a pMDI and used the 0-0.2 second criteria, recommended by 
Goodman et al (1994) for good co-ordination. She and her co-workers found that co-
ordination was inadequate in 40% of patients.  
The recent transition to HFA propellants has resulted in two different formulations of 
BDP (see section 2.3.1.1). One formulation (Qvar®) emits extrafine particles with a 
MMAD around 1µm. A similar formulation of ciclesonide is also available in a 
pMDI (Leach et al., 2006). A gamma scintigraphy study has shown that for pMDI 
formulations that emit extrafine particles then co-ordination is not critical as shown 
in Figure 2.18 (Leach et al., 2005). The study involved 7 mild asthmatics (mean 
FEV1 91% predicted) (Leach et al., 2005).  
 
Figure 2.18. Mean (SD) lung deposition of ultrafine beclometasone particles emitted 
from a HFA pMDI following different inhalation manoeuvres. 
The early was timed at 0.5 seconds before the start of an inhalation while the late 
was 1.5 seconds after the start. Subjects inhaled for 3 seconds with an inhalation 
volume of about 3 L which suggest that there flows would be approximately 60 
L/min. Furthermore Newman et al (1980; 1981) reported that co-ordination was not 
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important as long as the patient had started inhaling with a slow flow rate. The pMDI 
formulations used in these late studies would have been those that emit particles 
sizes similar to those of the common and traditional pMDI with MMADS around 
3µm. Although this was supported by Tomlinson et al (2005) using urinary 
salbutamol pharmacokinetic methodology the results are not consistent with those of 
Farr et al (1995) with respect to co-ordination timing and Newman et al (1981a, 
1981b) did show that when inhalation flow was faster a late inhalation did result in 
decreased lung deposition.  
In general most pMDI do not emit ultrafine particles (and of these there is only Qvar 
that is commonly prescribed) and most patients inhale too fast (Al-Showair et al, 
2007a). When there is no co-ordination or it is early than lung deposition will be 
low. Although a late actuation with a slow flow does result in some lung deposition 
and would not be a critical error the amount deposited in the lungs with good co-
ordination is better. In general, the criterion for good co-ordination used by 
Goodman et al (1994) and Broeders et al (2003), which was confirmed by gamma 
scintigraphy (Farr et al., 1995), would be 0 to 0.2 seconds.  
(ii) Slow Flow Rate  
Studies have shown that a slow flow rate provides better lung deposition than a fast 
flow. In the first study that reported about flow, seven patients inhaled using a flow 
of 30 L/min and 5 others used a flow of 90 L/min. Both groups used a breath-hold of 
10 seconds after each inhalation. Co-ordination for both was good and defined as 
dose actuation soon after the patient had started their inhalation. Mean (SD) lung 
deposition was 14.3(2.0) and 9.2(1.6) % respectively (Newman et al., 1982). 
Previously this lung deposition data had been reported by a simultaneous 
bronchodilator response in these patients; the percentage change in the FEV1 (15 
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minutes post dosing) was 29.5(14.3) and 16.6(11.6)% following the slow and fast 
inhalations (Newman et al., 1980). 
From the data in the above papers of Newman et al (1980; 1982), Goodman et al 
(1994) defined an acceptable inspiratory flow rate between 25-90 L/min whilst a 
more extensive review by Pauwels et al (1997) stated that flows should be 
<90L/min. This is confirmed by the data presented above by Farr et al (1994) in 
Figure 2.17. 
Further evidence of better lung deposition with a slow inhalation was reported in a 
study comparing gamma scintigraphy and urine pharmacokinetic methodology to 
identity lung deposition of terbutaline inhaled from a pMDI (Newman, 1995). The 
study involved 8 healthy volunteers using inhalations of 30 and 180 L/min. Figure 
2.19 shows the difference in total lung deposition using the urine method. This 
involved blocking the orally absorbed fraction with oral charcoal and collecting 
urine over a prolonged period post inhalation. 
 
Figure 2.19. Mean (SD) relative lung deposition  (Newman et al., 1995b). 
In contrast gamma scintigraphy suggested that there was no difference. This was due 
to a problem with gamma scintigraphy when using a fast inhalation that is highlight 
in Figure 2.20. This figure shows that as expected there is more deposition in the 
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central zone of the lungs with a fast inhalation. A part of this would be cleared by 
mucociliary clearance. In contrast urinary pharmacokinetic methodologies measure 
drug cleared from the lungs following systemic delivery. Since gamma scintigraphy 
measures amounts cleared from the lungs by systemic absorption and by mucociliary 
clearance then care should be exercised when interpreting gamma scintigraphy data 
when fast flows are used. 
 
Figure 2.20. Mean (SD) deposition into different zones of them lungs (from 
Newman et al, 1995).  
The above figure demonstrates that when the inhalation flow is fast then there is a 
tendency for more central lung deposition at the expense of peripheral deposition and 
that there is more peripheral deposition when the flow is slow. Faster inhalation 
flows give rise to greater deposition in the oropharyngeal area (Dolovich et al., 1981; 
Newman et al., 1981b) 
Using a urine salbutamol method Hindle et al (1992) demonstrated that the slower 
the inhalation flow then the better was the relative lung deposition as shown in 
Figure 2.21. Their slow flow was around 10 L/min whereas the faster flow was 50 
L/min. Using this method Tomlinson et al (2005) confirmed better lung deposition 
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from slow flow in asthmatic patients and this was complimented by better protection 
by salbutamol following broncho-provocation challenge with inhaled methacholine. 
 
Figure 2.21. Individual and mean relative lung deposition following slow and fast 
inhalations (Hindle et al, 1992). 
The study by Usmani et al (2005) quantified lung deposition using gamma 
scintigraphy following inhalation of different particle sizes and the effect of flow (30 
and 60 L/min). Figure 2.23 shows that there was increased peripheral and decreased 
central deposition with slower flows and that the influence of flow is dependent on 
the particle size (hence MMAD) of the aerosol. They showed that flow has little 
effect if extrafine particles are used. In practice this would only apply to Qvar and 
ciclesonide pMDIs whereas the majority of pMDIs have MMADS in the 3-6 µm 
range. Clinical evidence for the recommendation of a slow flow < 90L/min was 
provided in the study by AlShowair et al (2007). When 36 mild asthmatics (FEV1 
71.4% predicted) were trained to use a slow inhalation flow with their pMDI ( < 
90L/min) their Asthma Quality of Life changed by 0.74 (above the 0.5 clinical 
significance value). 
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Figure 2.22. Effect of fast and slow inhalation rates on aerosol deposition in central 
(C) and intermediate (I) and the peripheral (P) regions of the lung. Reproduced from 
(Usmani et al., 2005). 
There was no change in their FEV1. The authors concluded that the increase in the 
Asthma Quality of Life is due to their better asthma control and since there was no 
change in their FEV1 then the results reflect better delivery of their inhaled 
corticosteroids into the peripheral regions of the lungs. 
In summary an inhalation flow of < 90L/min is the most acceptable when using a 
pMDI and can be classified as a slow flow. 
(iii) Inhaled Volume. 
 
An inhalation that continues for as long as possible has been recommended (Laube et 
al, 2011). Since it has also been recommended that patients exhale gently as far as 
comfortable then an inhalation from residual volume (RV) to total lung capacity 
would be ideal. It has been found that the alveolar deposition increases ≈ 40% for 
each 1L increase in the inhaled volume when a slow deep inhalation technique is 
used (Pavia et al., 1977). Hindle et al (1993b) reported that relative lung deposition 
was greater when subjects exhaled before their inhalation as shown in Figure 2.23. 
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Figure 2.23. Mean and individual values of the relative lung deposition when 
inhaling from residual volume (RV) compared with inhaling from functional residual 
capacity (FRC) (Hindle et al., 1993) 
Farr et al (1994) reported that the inhaled volumes of nine healthy volunteers when 
they inhaled from a Smart Mist pMDI were a mean (SD) of 3.72(0.24) litres and 
Broeders et al (2003) found 2.7 (1.1) litres in 10 mild asthmatics (FEV1 96% 
predicted), and 2.9(0.7), 2.6 (0.2) and 2.3(0.2) litres in 16 mild, 16 moderate and 16 
severe COPD patients. All these were highly trained techniques so they would have 
used an exhalation before their inhalation. Farr et al (1995) reported an inhalation 
volume/forced expiratory volume ratios of 70.5(3.6)% for the inhalation manoeuvres 
with the highest inhalation volumes. This ratio for the best lung deposition (medium 
/early – see above) was 61.0 (5.4) %.  Goodman et al (1994) defined a deep 
inhalation as a ratio of >60% (based on the reports of Newman et al, 1980; 1981; 
1982 as well as Lawford et al, 1982; 1983). 
(iv) Breath hold  
Breath-holding is one of the essential steps during the inhalation manoeuvre (Laube 
et al., 2011). The principle of breath holding for as long as is comfortable after an 
inhalation is widely accepted as being essential for improved pulmonary deposition 
(Newman et al., 1981a; Hindle et al., 1993). This allows inhaled particles to settle in 
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the airways by gravitational sedimentation (Hillery et al., 2001). The likelihood of 
sedimentation increases with the residence time in the airway (Everard et al., 1997; 
Suarez and Hickey, 2000). Consequently, breath-holding is used to optimize 
pulmonary drug delivery (Dhand and Fink, 1999). 
Newman et al (1982) showed that lung deposition in asthmatics was greater for a 10 
second breath hold as shown in Figure 2.24. They also reported that there was a 
respective increase for deposition in the conducting airways and in the respiratory 
portion of the lungs.  
 
 
Figure 2.24. Percentages of dose deposited in the whole lung (Newman et al., 1982). 
Similar results were reported for the relative lung bioavailability of salbutamol post 
inhalation (Hindle et al., 1993) as shown in Figure 2.25. In this figure a slow 
inhalation was used and thus like in Figure 2.25 lung deposition does occur when 
there is no breath hold because of the residence time from the slow inhalation. 
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Figure 2.25. Mean and individual values of the relative lung bioavailability of 
salbutamol  with respect to breath hold after inhalation (Hindle et al., 1993). 
2.3.1.1.(d) The pMDI inhalation technique and clinical effectiveness 
The quantities of drug from a pMDI in the lung are small (Newman et al., 1981b; 
Borgström and Newman, 1993), in that only about 10-20% of the emitted dose 
reaches the lungs even when the correct inhalation technique is used (Pauwels et al., 
1997). A high proportion of the emitted drug particles are deposited in the mouth and 
oropharynx. Nevertheless, incorrect or unsatisfactory use of the pMDI may lead to 
less than the optimal therapeutic response (Newman et al., 1981a; Duerden and 
Price, 2002; Everard, 2003; Virchow et al., 2008). This issue of pMDI technique is 
more vital with the ICS than inhaled bronchodilators because the feedback of inhaled 
bronchodilator (as reliever drug) is an immediate response and these patients can 
compensate from a poor technique by inhaling another dose (Chrystyn & Price, 
2009). This practice is a good indicator that the patient‟s inhalation technique needs 
to be checked.  
The correct inhalation technique when using pMDIs involves firing the pMDI while 
breathing in deeply and slowly (Haughney et al., 2008), continuing to inhale after 
firing, and this should be followed by a breath-holding for around 5-10s (Ernst, 
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1998; Crompton and Barnes, 2006), to allow particle sedimentation (Newman et al., 
1981b). Table 2.12 describes the ideal inhalation technique with a pMD that was 
recently recommended by the ERS / ISAM Task Force (Laube et al, 2011). 
Table 2.12. The ERS /ISAM task force recommendation for the inhalation technique 
when using pMDI (Laube et al, 2011).  
1) Shake four or five times if suspension formulation. 
2) Take the cap off. 
3) Prime the inhaler (refer to the PIL for specific instructions). 
4) Exhale slowly, as far as comfortable (to empty the lungs). 
5) Hold the inhaler in an upright position. 
6) Immediately place the inhaler in the mouth between the teeth, with the tongue flat under 
the mouthpiece. 
7) Ensure that the lips have formed a good seal with the mouthpiece. 
8) Start to inhale slowly, through the mouth and at the same time press the canister to actuate 
a dose. 
9) Maintain a slow and deep inhalation, through the mouth, until the lungs are full of air. 
This should take an adult 4–5 seconds, a child 2-3 seconds. 
10) At the end of the inhalation, take the inhaler out of the mouth and close the lips. 
11) Continue to hold the breath for as long as possible, or up to 10 s before breathing out. 
12) Breathe normally. 
13) If another dose is required, repeat steps 4–12. 
A large study investigating the inhalation technique of 1173 asthmatic outpatients 
using their pMDI, found that fifty-one percent had co-ordination problem, 24 % of 
these patients stopped inhaling after actuation (cold freon effect) and 12% inhaled 
through their nose (Crompton, 1982b). Other studies have shown that between 8-
59% have poor or inadequate inhalation techniques when using their pMDI 
(Cochrane et al., 2000; Broeders et al., 2009). Only 7.6% of asthmatics could use 
their pMDI with a slow and deep inhalation with good co-ordination and the most 
common error was inhaling too fast. A series of studies performed by Crompton and 
colleagues between 1982 and 2000 assessed the inhalation technique after the 
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patients read the PIL. Between 21%-54% were unable to use their pMDI efficiently 
even after reading the PIL (Crompton, 1982b; Crompton and Duncan, 1989; Lenney 
et al., 2000). 
When an Aerosol Inhalation Monitor was used to evaluate pMDI technique in clinic 
settings a high incidence of errors with respect to co-ordination and flow were found 
and training did not improve the patient‟s pMDI technique (Harwell et al, 2010). An 
observation study using a checklist assessment of pMDI technique in asthma 
subjects and COPD, showed that at least 30 % of the  patients made at least one or 
more errors, and coordination technique was the essential mistake by all patients 
(Hesselink et al., 2001). In a real life study by Molimard et al (2003) the frequency 
of errors through the pMDI increased with age particularly patients over > 65 years. 
In addition to the traditional errors 31% of patients did not press the canister only 
once during their inhalation. A recent investigational study has found a strong 
association (p=0.008) between the misuse of inhalers and older age in a large sample 
of experiences outpatients. This later study also confirmed that inhaler misuse 
correlated (p<0.001) with an increase of hospital visits and good technique was 
associated with previous training (Melani et al., 2011). A summary of some of the 
inhaler technique reports is presented in Table 2.13. 
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Table 2.13. The percentage of patients making errors with each inhalation step as recommended by Laube et al (2011). [Key to references: A - 
Epstein et al, 1979; B - Pedersen et al, 1986; C - Pedersen et al. 1986; D - Scott -Smith, 1986; E - Horsley and Bailie, 1988; F - Manzella et a., 
1989; G - Goodman et al, 1994; H - van Beerendonk et al, 1998; I - Molimard et al, 2003; J - Melani et al, 2011]. 
Percentage (%) of errors user of inhalation techniques steps of pMDI based on the  steps in table 1 
Ref (n) A (68) B (132) C (85) D (2)7 E (84) F (234) G (59) H (56) I (552) J (843) 
Step 1 29 49 34 - 32 18 - 57 33.5 37 
Step 2 4 - - - 5 - - 5 - 0.15 
Step 3 - - - - - - - - -  
Step4 - 45 51 0 58 23 - 66 30.4 50 
Step 5 - - - - - 19 - - - 9 
Step 6 - - - - 15 30 - - - - 
Step 7 13 - - -  25 - - - .7 
Step 8 34 55 17  40  47 68 25.5 33 
Step 9 43 67 28 45  26 39-42 70 37.2 52 
Step 10 - - - - - - - - -  
Step11 43 42 39 59 66 31 24 53 31 53 
Step 12 - - - - 48 - - - - - 
Step 13 23 - - - 46 54 - - - - 
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2.3.1.1.(e) pMDI technique and asthma control 
In the first study by Saunders (1965) the bronchodilator response with respect to 
inhaler technique was first reported and this was followed by others (Newman et al, 
1980; Lawford et al, 1982; Rivlin et al, 1983; Lawford et al, 1983) and extended to 
methacholine challenge (Tomlinson et al, 2005). 
A large observational study of 3811 patients showed that about 76% of patients made 
at least an error when using their pMDI (Giraud and Roche, 2002) and that their 
asthma control deteriorated as the number of inhalation technique errors increased as 
shown in Figure2.26.  
 
 
Figure 2.26. Misuse of MDIs is directly linked to decreased asthma stability. (Giraud 
& Roche, 2002). 
In childhood asthma Kemps et al (2003) reported that the inhaled corticosteroid dose 
was decreased during detailed clinic management of children with asthma and the 
only other change was that their inhaler technique had improved. Another study 
involving asthmatic children reported that there was a significant improvement in 
their inhalation technique and their overall asthma severity scores when a good 
technique was used (Minai et al, 2004). In adult asthmatics that were trained to use a 
slow inhalation flow with good co-ordination a clinically significant improvement in 
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their asthma quality of life, of 0.74, was reported (Al-Showair et al., 2007a). In a real 
life study associations between inhaler misuse and an increased risk of 
hospitalisation (p=0.001), emergency room visits (p<0.001), courses of oral steroids 
(p<0.001) and antimicrobials (p<0.001) as well as poor disease control (p<0.00001) 
have been reported (Melani et al, 2011). 
Therefore, many recommendations have been published stressing the fact that 
patients should be trained how to use their inhalers efficiently and that there dose or 
inhaler should not be altered unless their inhaler technique as well as their level of 
compliance has been assessed (GINA, 2011; BTS/SIGN 2011). 
2.3.1.1.(f) Improving Inhalation Technique for pMDI and Training Tools 
The correct inhalation technique by patients is vital for efficient drug delivery, and 
so, it is important to improve inhalation technique to achieve the optimum 
therapeutically outcome with minimal side effects. Improving inhaler technique by 
patients is crucial, resulting in an increase in the effectiveness of response (Orehek et 
al., 1976). Paterson and Crompton as early as 1976 have emphasised that patients 
should be trained how to use a pMDI correctly in order to get maximum benefit. 
Training patients can significantly improve the pMDI technique. Gayrard and Orehek 
(1980) illustrated that only 28% of untrained patients demonstrated adequate 
technique with a pMDI compared to 52% that had been trained. Also, Horsley and 
Bailie (1988) found that the correct pMDI technique increased from 31% before 
counselling, to 72% immediately after counselling (Horsley and Bailie, 1988). A 
number of studies have suggested that pMDI techniques training significantly 
improve a patient‟s technique through the pMDI compared to leaving the patient to 
study the PIL (Patient Information leaflet) only (Crompton and Duncan, 1989; 
Nimmo et al., 1993). Demonstrations with verbal instruction have shown a 
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significant improvement of pMDI technique with asthmatic children (Kamps et al., 
2000) leading to reduced inhaled corticosteroid doses (Kamps et al., 2004). However, 
in a study of 100 adults tested for their ability to use six different inhalers only 21% 
were found to use their inhaler efficiently following instructions associated with the 
inhaler (Lenney et al., 2000). It has been found that even after pMDI technique 
counselling and subsequent demonstration by patients, only 50% used their pMDI 
correctly soon afterword (Shim and Williams, 1980). Another study has shown that 
using a multimedia programme for training inhaler technique was as good as using 
the PIL (Savage and Goodyer, 2003). A pMDI should only be prescribed to patients 
who have demonstrated that they can use it correctly. This problem is compounded 
by the fact that with time many patients lose the ability to use their pMDI correctly 
(Shim and Williams, 1980) and thus many patients revert back to an incorrect 
inhalation technique within a short period (Duerden and Price, 2002; Crompton, 
2006; Lavorini et al., 2010). The patient‟s inhalation technique should be checked 
regularly and they should receive repeated counselling and monitoring during follow 
up (Kamps et al., 2000; Crompton and Barnes, 2006; Broeders et al., 2009) so that 
there is improved disease control (Haughney et al., 2008). 
A number of inhalation training aids have been introduced to help patients use their 
inhalers correctly, these include; the Aerosol Inhalation Monitor (AIM, Vitalograph, 
Ltd, Buckingham, UK), the 2Tone Trainer™ (Canday Medical Ltd, UK) and the In-
Check Dial (Clement Clarke Ltd, UK). 
2.3.1.1.(i).1 Aerosol Inhalation Monitor 
The Aerosol Inhalation Monitor (Vitalgraph Ltd, UK) is an electronic device that is 
attached to a placebo pMDI. It measures the patient‟s inspiratory flow rate and 
monitors co-ordination. The required inhalation flow is 10-50 L/min and good co-
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ordination is related to this flow when the canister is depressed. The operator 
provides a subjective assessment of breath hold by pressing a button when the patient 
comes to the end of this. The AIM is programmed to accept a minimum 5 second 
hold between the end of the inhalation and the end of the breath hold. Feedback is by 
a green or red light system for coordination, flow and breath-hold. 
The device has been used in many studies to assess patients‟ inhalation technique 
with a pMDI (Wilson et al., 1997; Wilson and Lipworth, 1999). A significant 
increase in the percentage of correct pMDI technique was found after patient‟s were 
trained with the aerosol monitor (Skaer et al., 1996). In acute asthma the device has 
been used to verify correct inhalation technique of patients and as a trainer aid with 
variable success (Lavorini et al., 2010). A practice based study by Hardwell et al 
(2010) reported that a majority of asthmatic patients were unable to use pMDIs 
correctly (inadequate co-ordination and inhale too fast) and the training did not 
improve their techniques (Hardwell et al., 2010). In contrast a community pharmacy 
study reported that only 2 out of 33 patients used their inhaler correctly according to 
the AIM and after training sessions this increased by a further 15 patients (Sarvis et 
al., 2004). 
2.3.1.1.(ii).2 2Tone Trainer™ 
The 2Tone Trainer™ (Canday Medical Ltd) is a training tool to help slow the 
inhalation flow rate when using a pMDI. This training device is a simple plastic tool 
of similar shape and size to that of a pMDI but without a canister as shown in Figure 
2.27. Instead of a canister there are two “reeds” inside the device. These reeds are 
designed to make a one tone sound when the inhalation flow rate exceeds 30 l/min. 
Below 30 l/min, there is no noise and the inhalation flow is classified as too slow. 
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Above 60 l/min, the second reed is 
triggered producing a two- tone noise 
(high pitch) and this is classified as too 
fast. Between 30-60 l/min (the ideal 
inhalation flow rate through the pMDI) 
there is only the one tone sound that 
defines correct inhalation flow. 
Figure 2.27. The 2Tone Trainer (adapted from Al-showair et al 2007a) 
In a clinical study by Al-Showair et al (2007a) the potential of the 2Tone Trainer for 
improving the pMDI technique of asthmatic patients was demonstrated. In this study 
there were 3 groups: those with good pMDI technique without training (these 
demonstrated good co-ordination and inhalation flow < 90L/min) – GT Group, one 
group with inhalation flows of > 90L/min that received verbal pMDI technique 
training before they left the clinic – VT group and a final group (2T) that inhaled 
with flows > 90L/min and received pMDI training plus the 2Tone trainer to practice 
with before they left the clinic.  
Figure 2.28 shows that inhalation flow in the 2T group decreased significantly more 
than those in the VT group whilst those in the GT group remained unchanged. The 
reduction in flows in the 2T group were accompanied by a decrease in the Asthma 
Quality of Life score by > 0.5, as shown in Figure 2.29 indicating a significantly 
clinical improvement in asthma control. 
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Figure 2.28. The PIF of each individual using an MDI in the (left, a) GT group, 
(middle, b) VT group, and (right, c) 2T group (Al-Showair et al., 2007a). 
 
Figure 2.29. The AQLQ score of each individual using an MDI in the (left, a) GT 
group, (middle, b) VT group, and (right, c) 2T group (Al-Showair et al., 2007a). 
2.3.1.2 Dry Powder Inhalers (DPIs) 
Dry powder inhalers (DPIs) were originally introduced in order to avoid the known 
environmental problems of the CFC propellants and the poor inhalation technique 
associated with pMDIs (Vidgren et al., 1988; Prime et al., 1999; Tarsin et al., 2006; 
Virchow et al., 2008). All DPIs are breath-actuated, so patients do not have to 
coordinate between inhalation and actuation, therefore many patients find DPIs much 
easier to use than pMDIs (Bisgaard, 1997; Cegla, 2004; Virchow et al., 2008) and a 
convenient alternative for some patients.(Svedmyr et al., 1982). 
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The first portable DPI introduced to the market was the Spinhaler® (Fisons) in 1970 
for the delivery of disodium cromoglycate (Bell et al., 1971; Sanders, 2007). 
The first salbutamol DPI was the Rotahaler (GlaxoSmithKline, UK) which was 
introduced in 1977 (Hetzel and Clark, 1977). Both these devices were a single-dose 
system with a hard gelatine capsule containing a formulation of the dose. This was 
followed by the Diskhaler (GlaxoSmithKline, UK), in 1980 that contained 
formulations of salbutamol, beclometasone dipropionate and later salmeterol 
xinofoate formulations sealed inside a blister. A disk containing 4 or 8 blisters was 
inserted into the inhaler by the patient and replaced when all the blisters were empty. 
Other DPIs were also introduced to the market using different dosing principles. The 
Turbuhaler (AstraZeneca, UK) which was launched containing budesonide, in 1988, 
was the first multi reservoir-type device (Wetterlin, 1988). The Diskhaler was 
followed by the Accuhaler (GlaxoSmithKline, UK), known as the Diskus outside the 
UK, in 1994 as a multi-unit dose system (Pover et al., 1988) that contains the sealed 
blisters, containing the formulation, on a strip inside the device. Other multiple 
dosing reservoir DPIs followed (Clickhaler, Easyhaler Pulvinal, Novolizer and 
Twisthaler) all with different dose emission characteristics (Chrystyn, 2006). On the 
basis of these historical developments, DPIs are often classified depending on the 
device design, whether a single-dose, multi-dose or multi unit dose (Srichana et al., 
1998). 
DPIs are breath activated, so coordination of inhalation and actuation is not required 
and this makes them easier to use compared to a pMDI. Switching patients that have 
difficulty with coordinating pMDIs to DPIs has resulted in an improvement in 
outcomes (Borgstrom et al., 1994). However, breath actuation can be also be a 
disadvantage for DPIs because an initial highly inspiratory flow rate is required to 
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de-aggregate the formulation of a dry powder inside the DPI into respirable particles. 
Hence a forceful inhalation is required (Borgstrom et al., 1994). During an inhalation 
each DPI requires a certain minimum inspiratory flow to produce respirable particles 
and this could be an important potential limitation of DPIs as mentioned in the Table 
2.14 (below). Studies have shown that patients with asthma especially (pre-school) 
children (Pedersen et al., 1990) and those with COPD (Al-Showair et al., 2007b) 
have problems achieving these minimum flows through some DPIs and that 
inhalation flow is reduced during acute exacerbations (Bentur et al., 2004). The 
recommended technique for DPIs is a forceful, deep inhalation (Fink, 2000; 
Anderson, 2001; Laube et al., 2011) from the start that is maintained for as long as 
possible (Laube et al., 2011). The main advantages and disadvantages of DPI are 
presented in Table 2.14. 
Table 2.14. Advantages and disadvantages of dry powder inhalers (adapted from 
Chrystyn & Price 2009a). 
Advantages of DPIs Disadvantages of DPIs 
Breath-actuated and so no 
need for patient coordination 
required 
No propellant 
Most have dose counters 
Short treatment time 
Small and portable 
 
Some are single dose 
Some need to be shaken before use 
Dose preparation errors can be critical mistakes 
Attention required to orientation of inhaler during 
and after (before inhalation) dose preparation 
Flow dependent dose emission 
Needs a fast acceleration rate at the start of the 
inhalation 
Poor quality (or no) dose emitted if inhalation flow 
is too slow 
Uncertainty of dose emission during acute 
exacerbations 
Can result in high oro-pharyngeal deposition 
More expensive than MDIs 
Need to be stored in a cool and dry place 
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2.3.1.2.(a) De- aggregation of the formulation in a DPI 
In DPIs, the drug is formulated as finely micronized particles in a reservoir, blister or 
gelatine capsules. To ensure the likelihood of drug deposition in the airways during 
an inhalation then particles < 5µm need to be emitted from an inhaler. In general 
these particles do not have good flow properties because of their size, their surface is 
not smooth and the surface has a static charge. All these lead to poor powder flow 
properties whereas good powder flow is required for the formulation in a DPI. Good 
powder flow is essential during manufacture to ensure consistent and reproducible 
filling of inhalers or dose measuring for capsules and blisters. DPIs that are designed 
with a reservoir to contain the formulation and dose metering occurs prior to patient 
use also require good flow properties to ensure that dosing is accurate and consistent. 
The formulation for a DPI is therefore modified to improve its flow properties. Often 
the micronized active drug is mixed with large inert carrier particles, normally 
lactose, which prevents aggregation and improves the flow of the formulation. Some 
reservoir DPIs, notably the Turbuhaler, do not contain a coarse carrier and their drug 
particles are formulated as spheres which have good flow properties. When the dose 
is low (e.g. formoterol) then lactose is used as bulking agent when the spheres are 
formulated for the Turbuhaler. 
Currently, all DPIs are breath activated devices and rely on the inspiratory effort of 
the patient to release the powder dose from the metered cup, the dosing disk, the 
blister or the capsule. The same inspiratory effort also provides a turbulent energy 
(measured as a pressure change) source inside the inhalation channel of the DPI 
between the exposed dose (after dose preparation) and the exit of the mouthpiece. 
This energy is created inside the inhaler by the interaction between the internal 
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resistance of the DPI and the inhalation flow (Clark and Hollingworth, 1993) 
according to the relationship.  
√P=QxR 
Where P is the turbulent energy, Q is the inhalation flow and R is the resistance. The 
turbulent energy is represented by a pressure change inside each DPI during the 
inhalation manoeuvre. Pressure is measured by various units (all are related) with 
kilopascals (kPa) used for DPIs although cmH2O are sometimes used (1kPa=10.1972 
cmH2O). Hence DPIs are classified as passive inhalers. This energy breaks up (de-
aggregates) and transforms the metered powder formulation (drug-carrier) into an 
emitted dose that contains a FPD and MMAD that have the potential for lung 
deposition (Chrystyn, 2003; Chrystyn, 2009). Figure 2.30 described the process of 
de-aggregation in the inhalation channel of a DPI. 
 
 
Figure 2.30. Schematic design of the de-aggregation of the metered DPI dose during 
an inhalation (Chrystyn, 2003). 
The large carrier particles, such as lactose, emitted after the de-aggregation will 
impact in the mouth and the oro-pharynx and be swallowed. A sufficient inhalation 
flow rate (IFR) should be generated during an inhalation to create an internal 
turbulent energy that is capable of de-aggregating the formulation and generating a 
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respirable dose from each DPI device (Pitcairn et al., 1994; Srichana et al., 1998; 
Barnes, 2000a; Broeders et al., 2003a; Broeders et al., 2003b; Virchow et al., 2008) 
The faster the inhalation flow through a DPI then the greater energy will provide 
more efficient break-up of the formulation (Chrystyn, 2003) 
2.3.1.2.(b) DPI internal resistance 
The internal resistance of a DPI is a consequence of its design, and contains elements 
of flow restriction to increase the kinetic energy of the air flow through the device 
during an inhalation. Local pressure drops or high air velocities are necessary for 
adequate de-aggregation as well as dose entrainment in the inhaled airstream from 
the metering cup inside the DPI. The resistance of a DPI can be classified with 
respect to the inhalation flow required to produce a pressure drop of 4kPa with an 
inhalation of 4 litters and can be measured using the above equation by altering the 
flow (from 10 to 100 L/min) and measuring the corresponding pressure drop. Each 
type of DPI has its own unique resistance which ranges from those with high to low 
(Clark and Hollingworth, 1993; Laube et al., 2011) as shown in Figure 2.31. 
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Figure 2.31. The resistance of different dry powder inhalers (Chrystyn, 2009) 
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The figure confirms why Laube et al (2011) classified the resistance of DPIs from 
low (Aerolizer) to medium (Accuhaler) into medium/high (Turbuhaler) then to high 
(Easyhaler). Figure 2.32 also reveals that for a set turbulent energy the flow required 
through a DPI with low resistance will be faster than that required through a DPI 
with high resistance. This is a concept that is misunderstood by many because they 
focus on flow in isolation whereas it is turbulent energy that is important. The higher 
the resistance and the greater the patient‟s airflow obstruction then the lower will be 
their inhalation flow as shown in Table a 2.15 and Figure 2.32 (Chrystyn, 2009). 
Thus low flow does not necessarily translate to inadequate turbulent energy and de-
aggregation during patient use. 
Table 2.15. Mean (SD) inhalation flows achieved by patients (classified according to 
the severity of their disease – mild, moderate and severe) using different inhalers. N 
is the number of patients, age is reported in years and inhalation flows in L min
-1
. 
 ASTHMATIC CHILD ADULT ASTHMATIC COPD 
Severity MILD MOD SEV MILD MOD SEV MILD MOD SEV 
N 101 20 8 7 10 13 34 36 25 
Age 
10.5 
(4.2) 
9.5  
(3.6) 
10.3  
(3.2) 
48.3 
(14.7) 
53.3 
(19.7) 
66.0 
(10.0) 
78.5 
(10.2) 
75.6 
(9.4) 
72.6 
(9.9) 
MDI 112(16) 98(24) 109(18) >120 111(15) 106(16) 102(21) 100(23) 95 (28) 
Aerolizer 102(22) 82 (26) 91 (16) 108(16) 84 (22) 81 (23) 69 (21) 72 (24) 64 (22) 
Diskus 87 (23) 71 (23) 80 (17) 92 (19) 71 (22) 70 (21) 60 (17) 63 (21) 56 (16) 
Turbuhaler 72 (17) 58 (18) 66 (12) 76 (21) 56 (19) 54 (18) 47 (13) 48 (16) 43 (14) 
Clickhaler 73 (16) 57 (16) 65 (11) 72 (21) 54 (18) 53 (18) 47(13) 48 (17) 42 (14) 
Twisthaler 58 (12) 47 (14) 53 (10) 60 (18) 45 (16) 44 (15) 39 (11) 40 (14) 35 (11) 
Easyhaler 54 (11) 43 (14) 49 (7) 55 (13) 40 (12) 40 (12) 33 (10) 35 (13) 31 (10) 
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Figure 2.32. Mean (SD) peak inhalation flows of asthmatic patients through different 
DPIs (AERO – Aerolizer, ACC – Accuhaler, TBH – Turbuhaler, PTWH – 
Twisthaler, HANDI – Handihaler). 
Several, studies have shown that DPIs with a higher resistance provide more lung 
deposition than those with a lower resistance (Clark and Hollingworth, 1993; 
Chrystyn, 2009). This is due to the effects of inhaling against a resistance 
(Borgstrom, 2001). It could be also be due to the momentum of particles inhaled in 
that during a slow inhalation less will be deposited in the oro-pharyngeal zone and 
more will penetrate into the peripheral areas of the lungs. 
2.3.1.2.(c) Flow dependent dose emission 
The above equation of Clark and Hollingworth (1993) describes that for the same 
DPI then the faster the inhalation flow then the greater will be the generated 
turbulent energy. This will lead to more efficient de-aggregation of the dose. Ross 
and Schultz (1996) reported that dose emission from a salbutamol pMDI was not 
affected by flow but there was a difference between the dose emission from a 
salbutamol Diskhaler when using a slow and a fast flow as shown in Figure 2.33. 
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They reported similar results for a salbutamol Rotahaler and a terbutaline 
Turbuhaler. 
 
Figure 2.33. Mean (SD) dose emission from a salbutamol pMDI and Diskhaler at 
different inhalation flows (Ross & Schultz, 1996). 
Hill and Slater (1998) highlighted that de-aggregation was inhalation flow dependent 
by reporting a higher fine particle dose with flow from an Accuhaler and a 
Turbuhaler. De Koning (2001) investigated the effect of both PIF and IFR on more 
than one DPI device and concluded that the Turbuhaler is highly sensitive to IFR, 
producing a maximal fine particle fraction of 50% of label (budesonide) at 60L/min, 
while 23-33% for the fluticasone Diskus. Also he observed that the Accuhaler and 
Cyclohaler are only slightly IFR dependent (de Koning, 2001). A further study 
conformed  the greater flow dependent dose emission from the Turbuhaler compared 
to the Accuhaler and the Easyhaler (Palander et al., 2000) and from a single capsule 
DPI, the Aerolizer (Weuthen et al., 2002). 
An ex-vivo study by Tarsin et al (2006) also confirmed these results by reporting that 
the respirable dose emitted from the Seretide
®
 Diskus was more consistent and 
independent of IFR, while that from the Symbicort
®
 Turbuhaler DPI ( 
AstraZeneca,UK) was more  dependent on the patient‟s inhalation flow (Tarsin et al., 
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2006). In this study the authors collected electronic profiles of severe asthmatics 
when they inhaled through a Seretide Accuhaler and a Symbicort Turbuhaler and 
then replayed these in the electronic lung.  They showed the de-aggregation changes 
with flow by reporting the FPDs and MMADS as shown in Figure 2.34 and 2.35. 
 
Figure 2.34. The fine particle dose emitted from (a) Symbicort Turbuhaler and (b) 
Seretide Accuhaler when each electronic profile was replayed in the electronic lung 
(Tarsin et al, 2006). 
 
Figure 2.35. The mass median aerodynamic diameter of the dose emitted from (a) 
Symbicort Turbuhaler and (b) Seretide Accuhaler when each electronic profile was 
replayed in the electronic lung (Tarsin et al, 2006). 
The flow dependent dose emission phenomena have led to a debate on the optimal 
inhalation flow for each device and many studies have been carried out on how 
patients can/cannot achieve this flow. It has been shown that the in-vitro dose 
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emission characteristics translate to flow dependent lung deposition as shown in 
Figure 2.36 (Newman et al, 1991; Borgstrom et al, 1994). 
 
Figure 2.36. Mean (SD) flow dependent lung deposition from a Turbuhaler (a) 
terbutaline (Newman et al, 1991) and (b) Budesonide (Borgstrom et al, 1994). 
The studies in figure 2.36 revealed no charge in the peripheral: central lung zone 
ratios. The small MMADs with high flow will counteract the increased tendency for 
more central the lung deposition  
Differences in the in-vitro and in-vivo lung deposition results were show to translate 
to different clinical response (Nielsen et al., 1997). However some response was 
obtained at low flows. Therefore the argument about flow dependent dose emission 
is not clinically relevant. More importantly there is a flow below which de-
aggregation of the dose is inefficient as shown by the in-vitro study reported by 
Nadarassan et al (2010) that is  shown in Figure 2.37. This study used a formoterol 
Turbuhaler. 
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Figure 2.37. The effect of flow on the MMAD (dashed line) and the FDP (continuous 
line) of formoterol from a Turbuhaler (Nadarassan et al., 2010) 
The above figure shows that for the Turbuhaler there is a flow below which the de-
aggregation of the dose is inefficient. This is highlighted by marked change in the 
MMAD and the FPD below 30L/min. A patient study, involving asthmatic children, 
measuring FEV1 response to inhaled terbutaline confirmed the in-vitro results in that 
there is a critical flow below which de-aggregation occurs. The results of this clinic 
study are described in Figure 2.38 (Pedersen et al, 1990). 
 
Figure 2.38. Mean response post inhalation of terbutaline from a Turbuhaler at 
different inhalation flows.
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The above figure also demonstrates that caution should be exercised when 
interpreting bronchodilator results in studies using inhalers. Figure 2.38 clearly 
shows the lack of a difference between the 30 and 60 L/min results suggesting 
measurements at the top of the dose response curve. The main issue with respect to 
flow from a DPI is the rate below which therapeutic response is reduced (Laube et al, 
2010). The Easyhaler (Koskela et al., 2000) and Clickhaler (Newhouse et al., 1999) 
have both been shown to be effective at inhalation flows below 30 L/min.  Both these 
DPIs have a higher resistance than the Turbuhaler and so the turbulent energy 
equivalent to that in a Turbuhaler will be achieved at lower flows. This observation 
consolidates why inhalation flows should not be considered in isolation and that it is 
irrelevant to compare a low flow through a high resistance DPI directly to a faster 
flow through a DPI with low resistance (Azouz and Chrystyn, 2012). Neilsen et al 
(1998) reported that the Accuhaler was clinically effective at flows of 30L/min while 
for the Handihaler (Chodosh et al., 2001) this is probably below 30 L/min whereas 
>90 L/min needs to be achieved through the low resistance Aerolizer (Nielsen et al., 
1997). 
2.3.1.2.(d) Patient inhalation flows through DPIs 
 Studies have shown that patients with asthma especially children (Pedersen et al, 
1990) and those with COPD (Al-Showair et al., 2007b) have problems achieving 
these minimum flows through some DPIs and that the inhalation flow is reduced 
during acute exacerbations (Bentur et al., 2004). The Easyhaler has been shown to be 
effective at low flows even when the peak inhalation flow rate was 16 L/min because 
it has high resistance (Malmstrom et al, 1999). Figures 2.39 and 2.40 show the 
inhalation flow rates of children when they use a Turbuhaler (Pedersen et al, 1990) 
and an Easyhaler (Malmstrom et al., 1999). 
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Figure 2.39. Inhalation flows of children when they inhale through a Turbuhaler 
(Pedersen et al, 1990). 
 
Figure 2.40. Inhalation flows of children when they inhale through an Easyhaler 
(Malmstrom et al., 1999). 
A summary of the inhalation flows of patients through different DPIs is presented in 
Table 2.16. 
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Table 2.16. Patient inhalation flows when they use inhalers. 
Patients Comment reference 
Turbuhaler 
74 COPD 
Mean FEV1 41.9 (12.8) % predicted. Pre counselling <30, 30-40, 40-60 and >60 L/min 
numbers were 14, 31, 23 and 6. Post counselling these changed to 7, 16, 41 and 10. 
Nsour et al, 2001.   
24 Asthmatic 
Mean FEV1 57.0 (18.9) % predicted. Pre-counselling mean (SD) PIF 48.0 (16.8) and 
post counselling 54.7 (17.6) L/min. Inhaled volume pre and post counselling was 
1.75(0.68) and 1.94(0.62) L. Time to peak 0.54(0.46) and 0.43(0.23) seconds. 5 patients 
<30 pre counselling and 3 post counselling 
Hawksworth et al, 2000 
163 COPD 
Mean FEV1 47.8 (9.9) % predicted. Mean (SD) PIF was 45.9 (14.1) l/min. Pre 
counselling numbers <20, 20-29, 30-59, >60 were 4, 19, 114 and 26. 84 patients 
verbally trained and the 15 that inhaled <30 changed to 10 
Al-Showair et al, 2007 
20 Severe 
asthmatics 
Mean (SD) PEFR 52.7(6.0) % predicted. Mean (SD) PIF 76.8(26.2) L/min and inhaled 
volume of 2.4(0.8) Litres.  Patients highly trained.  
Tarsin et al, 2006 
110 COPD 
Mean (SD) FEV1 of 0.70(0.21) litres and PIFR of 53(12). Maximal inhalation. zero <28 
L/min. 83 generated 40-59 L/min and 32 >60L/min 
Dewar et al, 1999 
18 COPD 
Median (range) FEV1 54 (33-70) % predicted. Mean (range) PIF 59 (45-73) L/min and 
inhaled volume of 2.2 (1.39-3.42) Litres. Highly trained 
(Derom et al., 2007) 
48 COPD and 16 
asthmatic 
16 mild, moderate and severe. Mean (SD) PIF 76.0(4.6), 64.9(4.9) and 68.6 (4.1) L/min 
before training and 85.4(2.2), 84.4(2.7) and 73.3(4.1) post training. No one <30L/min. 
Slope significantly increased post training. Inhaled volumes were 2.6(0.2), 2.6(0.3) and 
2.3(0.2) litres pre and 2.8(0.2), 2.9(0.3) and 2.6(0.3) post training. 
10 asthmatics mean FEV1 96(7.8) % predicted. Mean (SD) PIFR 76.9(4.6) pre and 
82.1(3.4) post. Inhaled volumes of 2.9(0.3) and 3.1(0.3) litres 
Broeders et al, 2003 
Asthmatic children 
 
38 aged 3-6 years.- Mean PIF was 59L/min 
39 aged 7-10 years mean PIF was 70L/min 
(Stahl et al., 1996) 
Asthmatic children 
34 aged 4 to 13 years – see figure j 
15 with an acute attack (4 and 5 years old PIF range of 14-36 L/min 9 <28L/min 
Pedersen et al, 1990 
Asthmatic children 
72 , 36 in group A – training (n=12 aged 3 , 4 and 5 years each), group B no training 
(n=12 aged 3 , 4 and 5 years each). Baseline PIF values – 25 inhaled <30L/min 
especially in 3 and 4 year old. Mean PIF after training in the 4 and 5 year olds in Group 
A was 46.4L/min compared to group B which was 33.2 L/min (n=24 in each age group).  
The latter increased to 40.4 L/min after they had been trained.  In the 3 year olds group 
Agertoft and Pedersen, 1998  
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A 28L/min and group B 33.2 L/min.  
30 Adult 
asthmatics 
FEV1 88% predicted.  PIF average of 68 L/min and range of 55-95 L/min (Meijer et al., 1996) 
101 Asthmatic 
adults 
Four had a PIF <30L/min. Mean PIF was 59L/min range of 25-93 l/min (Engel et al., 1989) 
Acute asthma 
99 with acute exacerbations. FEV1 1.1(0.7) litres. Mean age 42 years. PIF with 
Turbuhaler was 152(77) L/min reduced to 60(20) with Turbuhaler. 2 patients less than 
30 L/min (both recorded 26 L/min) 
Brown et al, 1995 
Accuhaler 
163 COPD 
Mean FEV1 47.8 (9.9)% predicted. Mean (SD) PIF was 57.5 (17.9) l/min Pre 
counselling numbers <30, 30-59, 60-90, >90 were 0, 8, 79, 69, 7. 84 patients were 
verbally trained and none inhaled <30 L/min 
Al-Showair et al, 2007 
20 Severe 
asthmatics 
Mean (SD) PEFR 52.7(6.0)% predicted. Mean (SD) PIF 94.7 (32.9) L/min and inhaled 
volume of 2.8(1.1) Litres.  Patients highly trained 
Tarsin et al, 2006 
48 COPD and 16 
Asthmatic 
16 mild, moderate and severe. Mean (SD) PIF 107.8.(7.2), 91.8(6.8) and 95.9(6.3)) 
L/min before training and 124(2.8), 121.3(3.0) and 103(6.4) post training. No one 
<30L/min. Slope significantly increased post training. Inhaled volumes were 3.0(0.2), 
2.9(0.2) and 2.6(0.2) litres pre and 3.2(0.2), 3.1(0.2) and 2.8(0.2) post training. 
10 asthmatics mean FEV1 96(7.8)% predicted. mean (SD)  PIFR 111.6(6.8) pre and 
115.3(4.9) post. Inhaled volumes of 3.1(0.3) and 3.3(0.3) litres 
Broeders et al, 2003 
Asthmatic children N=129 aged 3-10 only 2 <30L/min – a 5 year old and a 10 year old..  Nielsen et al, 1998 
Easyhaler 
21 Asthmatics 
Mean PIFR 28.7(5.1) L/min. age range 7-65 years. Lowest PIF was 22 and similar 
bronchodilation to MDI+spacer. 
(Koskela et al., 2000) 
120 + 15 
Asthmatics 
PEF 86(21)% predicted. 4 -16 years old. Mean (SD) PIF was 56(15) L/min range 22-82. 
In the 15 PIF ranged from 16-80 L/min – similar bronchodilation to 200mcg salbutamol 
MDI+spacer. 
(Malmstrom et al., 1999) 
93 COPD 
Mean (range) FEV1 51 (18-96)% predicted. The mean PIF was 54 L/min (range 26–95 
L/min) 
(Malmberg et al., 2010) 
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Handihaler 
26 COPD 
Mean FEV1 % predicted 37.6 range of 16-65. Median PIF of 30.0 with a range of 20.4 to 
45.6 L/min 
(Chodosh et al., 2001) 
163 COPD 
Mean FEV1 47.8 (9.9)% predicted. Mean (SD) PIF was 28.6(10.0) l/min Pre counselling 
numbers <20, 20-29, 30-59 were 3251 and 70. 84 patients were verbally trained 20 out of 26 
increased their flow >30L/min. 
Al-Showair et al, 2007 
pMDI 
163 COPD 
Mean FEV1 47.8 (9.9)% predicted. Median (SD) PIF was 110 (75-120) l/min.  Pre training in 
55 out of 84 inhaled >90 and only 7 post training.  
Al-Showair et al, 2007 
48 COPD and 
16 Asthmatic 
16 mild, moderate and severe. Mean (SD) PIF 127.9(5.5), 134.0(8.1) and 142.1(14.7) L/min 
before training and 118.8(3.9), 117.0(5.3) and 115.4(6.2) post training. 22% inhaled 
<90L/min pre and 21% after training. No one <30L/min. Slope significantly increased post 
training. Inhaled volumes were 2.9(0.7(, 2.6(0.2) and 2.3(0.2) litres pre and 2.9(0.7)2.6(0.2) 
and 2.3(0.2) post training. inhalation times of 1.7(0.1),1.6(0.2) and 1.3(0.2) seconds pre and 
1.7(0.1), 1.7(0.2) and 1.5(0.1) post training. 
10 asthmatics mean FEV1 96(7.8) % predicted. mean (SD)  PIFR 149.6(19.2) pre and 
123.3(9.0) post. Inhaling <90L/min decreased from 17 to 13%. Inhaled volumes of 2.7(1.2) 
and 2.7(1.3) litres pre and post with inhalation times of 1.3(0.1) and 1.4 (0.1) seconds 
Broeders et al, 2003 
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2.3.1.2.(e) Acceleration of flow 
Since the de-agglomeration takes place inside the device before the metered dose 
leaves the DPI then acceleration rate at the start of the inhalation through a DPI is 
vital (de Boer et al., 1996; Everard et al., 1997) Hence, a fast initial rate at the start of 
an inhalation is crucial. This can determine the quality of the emitted dose and the 
FPF (Everard et al., 1997), and it has been shown that this correlates to the peak 
inhalation flow achieved by patients (Broeders et al., 2001). 
Figure 2.41 shows two possible inhalations through a DPI that achieve the same PIF.  
One starts immediately and has a fast acceleration while the other starts slowly and 
gradually builds up to the same PIF (Chrystyn and Price, 2009b). Superimposed on 
this is when the dose leaves the inhaler. 
 
Figure 2.41. The inhalation flow against time profiles of two different inhalation 
manoeuvres through a DPI. The two profiles have the same peak inhalation flow. 
The one with the steep acceleration is a forceful inhalation from the start of an 
inhalation (solid line) whereas the profile with a gentler acceleration is an inhalation 
manoeuvre that starts slowly and gradually builds up into a flow that is as fast as 
possible (dashed line). Superimposed onto the profiles is the time period during 
which the dose is de-aggregated and emitted from the DPI. (Chrystyn & Price, 2009). 
Patients should, therefore be instructed to inhale through the DPI forcefully and that 
this should be from the beginning of their inhalation (Laube et al., 2011). 
  
121 
 
The inhalation profile of a patient may have an effect on the drug delivery and 
distribution of drug particle size (Miller et al., 2000). It is important therefore to 
identify the acceleration rate, inhalation flow rate (IFR) and inhalation volume (IV) 
when patients use DPIs because these variables may affect both the FPD and the site 
of lung deposition (Bell et al., 1971) and may consequently influence the desired 
clinical outcome (Ross and Schultz, 1996; Virchow et al., 2008). It has been shown 
that dose delivery and the lung deposition are determined by the patient‟s variable 
inspiratory air flow (Newman et al., 1994; Cegla, 2004). 
A more forceful inhalation will result in a greater fine particle fraction (Borgstrom et 
al., 1994) with a smaller MMAD (Chrystyn, 2003). Each inhalation manoeuvre with 
a DPI should be as fast as the patient can achieve and this maximum forceful 
inhalation should commence from the beginning of the inhalation and continue for as 
long as possible (Laube et al., 2011). 
2.3.1.2.(f) Dose preparation 
Some DPIs are a single unit dose inhaler and therefore, the patient has to prepare a 
dose (capsule), prior to each inhalation as described in the PIL of the device. 
Incorrect performance by patients may result in them inhaling no dose irrespective of 
the inhalation manoeuvre they use. It has been shown that dose preparation errors 
frequently occur with capsule DPIs (Schulte et al., 2008). In general patients have 
more problems using single dose than multi-dose DPIs (Moore and Stone, 2004; 
Wilson et al., 2007). Also the dose from these devices is reliant on the inhalation 
volume to empty the dose out from the capsule thus it is important that the patient 
inhales twice (Laube et al., 2011). In multiple reservoir inhalers, such as the 
Turbuhaler, Easyhaler and the Clickhaler, the device must be kept in the upright 
position when the dose is metered to ensure accurate filling of the dosing cup. 
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A study assessed the inhaler technique of the Turbuhaler, Rotahaler, and Diskhaler 
and found that 40% of patients were unable to perform all steps correctly (van der 
Palen et al., 1995). Other studies have shown the rate of misuse of Turbuhaler ranged 
from 26% to 94% (van der Palen et al., 1999; Hesselink et al., 2001; Molimard et al., 
2003) and confirmed that the most common mistakes when using the Turbuhaler 
included a failure to turn the base (not rotating the basal grip in the upright position) 
before inhalation. Figure 2.42 describes that there is a similar incidence of error 
irrespective of device although these are more common with the pMDI (Molimard et 
al, 2003). This study also reported that the patients‟ GPs were falsely confident that 
their patients were using the correct inhalation procedure when they used their 
inhalers. It is important, therefore, that prescribers are aware of the inhalation 
procedures for each device (Melani, 2007). 
 
 
Figure 2.42. Percentage of patients making one error and the perception of their GPs 
adapted from (Molimard et al 2003). 
Table 2.17 shows some of the common errors that patients make using DPIs 
(Molimard et al., 2003; Melani et al., 2011). Exhaling into the mouthpiece or/ not 
exhaling before an inhalation, not making a forceful inhalation and no breath hold 
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were the most common errors made by patients. Also patients had problems with 
holding the Turbuhaler upright and twisting its base when loading a dose. 
Table 2.17. Errors made by patients using DPIs in real life situations (Molimard et al, 
2003; Melani et al 2011). 
Inhalation 
procedure 
Melani et al, 2011 (n=1664) Molimard et a, 2003 (n=3811) 
 Handihaler Accuhaler Turbuhaler Aerolizer Accuhaler Turbuhaler 
Did not insert 
capsule 
9 n/a n/a 0.7 n/a n/a 
Did not pierce 
capsule 
3 n/a n/a 3.8 n/a n/a 
Did not hold 
upright - 
n/a n/a 23 n/a n/a 18.1 
Did not load a 
dose 
- 7.3 14  7+2.5  
Did not rotate 
grip backwards 
and forwards 
n/a n/a Not reported n/a n/a 14.9 
Exhaled into the 
device 
mouthpiece 
19 22 14 6.9 6.6 5.3 
No exhalation Not reported 
Not  
reported 
Not reported 32.8 26.4 25.4 
Did not inhale by 
mouth 
2 1 0 1.4 1.9 0.9 
Not a forceful 
and deep 
inhalation 
24 28 22 
Not  
reported 
Not  
reported 
Not 
reported 
Breathe out into 
the device 
19 21 11 
Not  
reported 
Not 
 reported 
Not 
reported 
No breath hold 25 32 28 28.4 26.4 31 
No check if any 
dose left in 
capsule after an 
inhalation 
30 n/a n/a n/a n/a n/a 
 
Table 2.17 above shows that many patients exhaled into the DPI before an inhalation. 
Exhaling into a DPI following dose preparation will introduce moisture into the 
device and blow out the metered dose. This will  increase humidity within the device 
which decreases dispersion of the particles, and will result in an impairment of drug 
delivery (Meakin et al., 1993). High humidity will affect the formulation and large 
agglomerates will form. These are not easy to de-agglomerate sufficiently into fine 
particles during an inhalation (Price et al., 2002; Young et al., 2003; Pedersen et al., 
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2010) and so dose emission is reduced (Meakin et al., 1995). Moisture in the 
formulation will also deteriorate powder flow leading to inconsistent dose metering. 
DPIs should be stored in a cool dry place. 
 In the real life study by Melani et al (2011) they found that independent of the 
inhaler older age (p=0.008), lower schooling (p=0.001) and the lack of inhaler 
technique training (p<0.001) was linked to inhaler misuse. This was also associated 
with an increased risk of hospitalisations (p=0.001), and poor asthma control 
(p<0.001) as well as more courses of oral steroids (p<0.001) and antimicrobials 
(p<0.001). It has been suggested that many healthcare professionals, including 
physicians, pharmacists, nurses, and respiratory therapists, lack sufficient knowledge 
on the correct use of pMDIs and DPIs (Self et al., 2007; Kim et al., 2009). 
Consequently, healthcare professionals should be instructed and trained in the use of 
each individual device (Broeders et al., 2009) Patient education as well as training in 
inhaler use is crucial for the effective treatment and long-term control of asthma and 
COPD (Melani, 2007; Kim et al., 2009). Table 2.18 describes the accepted generic 
inhalation technique instructions when using a DPI (Laube et al., 2011). Of these the 
dose preparation instructions are specific for each type of inhaler. Hence, the 
recommendation for the dose preparation is to refer to the Patient Information leaflet. 
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Table 2.18. The most ideal inhaler technique for DPIs (Laube et al., 2011).  
No Most desirable inhaler technique 
1 Take the cap off (some do not have a cap). 
2 Follow the dose preparation instructions in the PIL. 
3 Do not point the mouthpiece downwards once a dose has been prepared for 
inhalation because the dose could fall out. 
4 Exhale slowly, as far as comfortable (to empty the lungs). Do not exhale 
into the DPI. 
5 Start to inhale forcefully through the mouth from the very beginning. Do 
not gradually build up the speed of inhalation. 
6 Continue inhaling until the lungs are full. 
7 At the end of the inhalation take the inhaler out of the mouth and close the 
lips. Continue to hold the breath for as long as possible, or up to 10 s. 
8 
9 
Breathe normally. 
If another dose is required, repeat steps 1–8. 
 
Health care professionals should ensure that the patient is able to use their inhaler 
effectively (Crompton et al., 2006). Also, physicians must ensure that a convenient 
device is prescribed for each individual patient with appropriate instructions and that 
it is an inhaler that they can and will use (Laube et al, 2011). Moreover, regular 
checking of the patient‟s inhalation technique is essential, because inhaler technique 
tends to deteriorate over a period of time (Lavorini et al., 2010). Hence a review of 
each patient‟s inhalation technique should be a regular component of follow-up care. 
Educational and motivation programs are also useful as a supplement to ensure 
correct inhaler technique. (Lavorini et al., 2010). 
To help train patients to use a fast inhalation then the IN-Check Dial (Clement 
Clarke International, UK) is a useful aid. It does show the patient‟s IFR through 
different DPIs and its helps the healthcare professional to prescribe the most 
appropriate inhaler for individual patients (Chrystyn, 2003). 
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2.3.1.2.(g) The IN-Check Dial™ 
The IN-Check Dial
®
 (Clement Clarke Ltd., UK) is a simple and portable instrument 
that is similar to a Peak Expiratory Flow Meter except that patients have to inhale 
forcefully through the device instead of using a forced exhalation. Figure 2.43 shows 
that the IN-Check-Dial has two parts; an inspiratory flow meter calibrated with a  
range of  inspiratory flow rates (15 to 120 L/min), and a rotating dial mouthpiece that 
selects a different resistance corresponding to the Autohaler (3M Health care), 
Accuhaler (GlaxoSmithKline, UK), the Easi-Breath (Teva Pharmaceuticals, UK), 
Clickhaler  (UCB Pharma, UK) and Turbuhaler (AstraZeneca, UK). The instrument 
has been designed to measures IFR by setting the meter‟s dial to mimic the internal 
resistance of a number of DPIs (Van der Palen, 2003; Crompton, 2004). 
 
Figure 2.43. The In-Check Dial® (Clement Clarke Ltd., UK) and The rotating dial to 
select inhaler resistance (Lavorini et al., 2010). 
Although it is claimed that this tool can identify the most appropriate inhaler device 
for patients based on their ability to learn and achieve an optimal flow rate (Broeders 
et al., 2003b; Chrystyn, 2003; Van der Palen, 2003; Amirav et al., 2005) it is not a 
device selection tool because there is no clinical evidence to support this (Azouz and 
Chrystyn, 2012). Although, the IN-Check-Dial does not measure the initial 
acceleration of the inhalation, studies have shown that this correlates with PIF when 
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patients use DPIs provided that they start with a maximal acceleration of their 
inhalation flow (Broeders et al., 2003a; Lavorini et al., 2010). There is a red disk 
indicator that moves along the tube to the fastest flow achieved and thus observation 
of this can identify an immediate forceful inhalation manoeuvre. 
The IN-Check Dial was found to correlate to electronic measurements of IFR 
(Broeders et al., 2003a; Tarsin et al., 2006). Several studies, therefore, have 
highlighted the potential use of the IN-Check-Dial in clinical practice to identify the 
optimal IFR through a DPI (Nsour et al., 2001; Van der Palen, 2003; Amirav et al., 
2005). Generally, patients should be encouraged and instructed to inhale „hard and 
deeply‟ via their DPIs (Nsour et al., 2001; Van der Palen, 2003). This is considered 
as a significant step towards obtaining optimum benefit from a patient‟s prescribed 
medication. 
2.3.1.2.(h) Types of Dry powder Inhalers (DPIs) 
Each DPI has its own unique dose preparation and resistance. In general they should 
not be tilted downwards once a dose has been prepared for inhalation (Laube teal, 
2011) because the dose will fill out. When the DPI is presented as a single dose 
capsule then each dose should be inhaled using two separate inhalations.  
Information about some common DPIs available in the UK is provided in Table 2.19. 
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 Table 2.19. Types of Dry powder Inhalers (DPIs). 
Inhaler Type Resistance Drugs (UK) Dose preparation Comments 
Accuhaler 
 
 
 
Single 
blisters, 
multidose 
Medium Salbutamol 
Salmeterol 
Fluticasone 
Salmeterol / 
fluticasone 
combination 
The mouthpiece is 
exposed by rotating the 
outer case and then 
sliding a lever to open 
the delivering channel 
in the mouthpiece and 
expose the dose in 
blister container. 
Dose emission is not entirely dependent on an 
individual patient‟s inspiratory manoeuvre (Virchow 
et al.,2008). Studies have suggested that the effect of 
flow dependent dose emission is relatively small  
(Palander et al., 2000: Tarsin et al., 2006) 
. 
Aerolizer 
 
Single dose 
capsules 
Low Formoterol A capsule is placed in 
the centre of the 
inhaler well and it is 
then is pierced by 
pressing and releasing 
the button on either 
side of the device 
Wieshammer et al (2008) and Khassawneh et al 
(2008) have evaluated the handling of inhaler devices 
and overall the Aerolizer had low error rates. In-vitro 
(Weuthen et al., 2002) and in-vivo (Nielsen et al., 
1997) studies have shown flow dependent dose 
emission 
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Clickhaler 
 
Reservoir, 
multidose 
High Salbutamol 
Beclometasone 
 
The dose is loaded 
from the hopper by 
clicking or pressing 
the button on the top 
of the device whilst 
holding the inhaler 
upright. The 
Clickhaler has a dose 
counter and lock-out 
mechanism after 200 
doses 
Effective flow rate is within the range of 15 – 60 L/min 
such that the minimum flow can be achieved by children 
> 6 years and adults (Nantel and Newhouse, 1999; 
Newhouse et al., 1999). No difference bronchodilator 
response to salbutamol at various inspiratory flow rate 
(15, 30, and 60 L/min) by patients with stable asthma 
(Newhouse et al., 1999). Similar results were obtained 
in patients with COPD (Morice et al., 2000). 
Furthermore, another study has indicated that the 
majority of children ≥ 3 years were able to inhale 
reliable through the Clickhaler (Iqbal et al., 2003). 
Easyhaler 
 
Reservoir, 
multidose 
High Salbutamol 
Formoterol 
Beclometasone 
Budesonide 
 
The powder flows 
from the drug 
reservoir into the 
metering cup, by 
pressing the top which 
fills the volumetric 
holes in the rotating 
drum. 
Palander et al (2000) shown that the emitted dose and 
the fine particle fraction were less flow dependent from 
the Easyhaler and the Accuhaler than the Turbuhaler 
Palander et al.,(2000), and the total dose emission from 
the Easyhaler was fairly consistent irrespective of the 
inhalation flow (Chrystyn, 2006). Effective at low flows 
(Malmstrom et al, 1999). 
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Handihaler 
 
Single dose 
capsules 
High Tiotropium 
bromide 
The inhaler is loaded 
with a capsule which is 
placed into the capsule 
chamber at the centre 
of the device and then 
pierced by depressing 
the side button, which 
makes the dose ready 
for inhalation. 
Due to its high resistance it  has been suggested that 
patients with COPD may not able to generate a high 
inspiratory sufficient flow to de-aggregate the 
formulation and obtain bronchodilation (Chodosh et al., 
2001). Using an inhalation flow lower than 28.3L /min 
through the Handihaler shows a decline of about 20% in 
the fine particle dose (Chodosh et al., 2001).  Inhalation 
volume has been shown to be important for the dose 
emission of tiotropium from the Handihaler (A. Al-
Fadhl, 2005). COPD patients have problems exceeding 
20L/min during inhalation (Al-Showair et al, 2007). 
Novolizer 
 
Reservoir, 
multidose, 
Disposable 
cartridges 
Medium Salbutamol 
Budesonide 
Pressing the button 
loads a dose. Dose is 
released at 35L/min. 
Audio and visual 
feedback that a dose 
has been inhaled 
The dose has to be inhaled at a flow rate ≥ 35 L/min to 
release the dose (Kohler, 2004; Virchow et al., 2008) 
otherwise the patient will receive no dose and cannot 
prepare another dose for inhalation. Young children with 
stable asthma can generate relatively higher PIFs through 
the Novolizer (Vogelberg et al., 2004). In addition, using 
this device, was found to improve compliance and 
asthma control (Moller et al., 2003). In-vivo flow 
dependent lung deposition (Newman et al. 2001). 
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Spiromax 
 
Reservoir, 
multidose. 
 
Medium/ 
high 
Not yet 
available 
The device has an 
internal pump that 
dispenses an accurate 
dose using a controlled 
air pressure that is 
activated by the 
mouthpiece cap. The 
opening of the 
mouthpiece cover by 
patient also advances 
the dose counter  
(Zeng et al., 2002). 
The Spiromax also contains cyclone separator channels 
that are designed to create turbulent flow during an 
inhalation and provide efficient de-aggregation of the 
lactose- drug particles. The in-vitro dose emission from 
Spiromax has been shown to be less dependent on 
airflow than the Turbuhaler, and has a greater dose 
consistency (Hirst et al., 2002). A dose handling study 
has found that the Spiromax was easier to use and to 
learn how to use compared to the Turbuhaler. (Keating 
and Faulds, 2002). 
Turbuhaler 
 
 
Reservoir, 
Multidose 
Medium / 
high 
Terbutaline 
Formoterol 
Budesonide 
Formoterol / 
budesonide 
combination 
The formulation 
contains spheres of 
drug particles so that it 
has good flow 
properties. Lactose as 
a bulking agent in 
formoterol. Holding 
the Turbuhaler in an 
upright position and 
twisting the base 
forwards, until a click 
is heard, and then 
backwards 
The particle size of the drug that is emitted depends on 
the patient‟s inspiratory flow (Everard et al., 1997). 
Significant flow dependent dose emission (Palander et 
al, 2000). In-vivo flow dependent lung deposition 
(Newman et al, 1991; Borgstrom et al, 1994). In-vivo 
bronchodilator response reduced below 30L/min 
(Pedersen at al, 1990). Young children with asthma 
(Pedersen et al, 1990 and COPD (Al-Showair et al, 
2007) have problems inhaling >30L/min especially when 
obstruction is severe (Chrystyn, 2009)  
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2.4 Patient Compliance with prescribed inhaler medication  
Poor inhalation technique leads to inefficient lung deposition resulting in a reduced 
therapeutic effect. Of these doses preparation errors are very important because these 
are more likely to provide no dose whereas a poor inhalation technique would 
provide some response. Another critical issue is patient compliance because this 
result in no dose delivered to the lungs. An unused inhaler would be the most 
expensive inhaler. Poor compliance by a patient contributes to disease instability and 
may lead to a worsening with an increase in morbidity and mortality rates as well as 
increasing healthcare costs (Chrystyn, 2005; Rau, 2005). A review, in asthmatic 
patients by Cochrane (1992), indicated poor compliance among asthmatic patients 
ranging between 20 - 80%, whilst Hoskins et al (2000) reported 16 to 50%. During 
regular reviews, almost a third of asthmatic patients were not taking their 
prophylactic medication as prescribed (McCowan et al., 2005). The increase of time 
without ICS is associated with poor asthma control, and  increased hospitalisation 
rates (Melani et al., 2011) and appears to contribute up to 61% of deaths from asthma 
(Rau, 2005). To improve compliance several approaches have been suggested with a 
recommendation of a focus to using clear instructions by healthcare personnel as 
well as responding to the patients and their treatment particularly their ICS (Horne, 
2006). It has been shown that patient education improves compliance with ICS 
(Onyirimba et al., 2003). Choosing therapy and inhalers preferred by patient helps 
compliance especially if they find them easy to use. Patient preference is a key issue 
but all studies except one have been sponsored by a pharmaceutical company and 
hence the results are biased. The preference of patients, in the one unsponsored 
study, is described in Figure 2.44. This figure shows that of the seven devices which 
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the patients graded the BA- pMDI was the most favourable while the  pMDI attached 
to a spacer was the least preferred inhaler (Lenney et al., 2000). 
 
Figure 2.44. The preference of patients for seven devices by (Lenney et al., 2000) 
2.5 Summary 
The inhalation technique required to use a pMDI is generally described as a 
manoeuvre that is „slow and deep‟ whilst a more clearer instruction is to inhale 
slowly until the lungs are full of air and to try to ensure that this complete inhalation 
takes 5 seconds. For a dry powder inhaler the instruction is „deep and fast as you can‟ 
whilst a clearer explanation is as fast as possible, from the start, and maintain the 
inhalation as long as possible. In the past studies have focused on the general 
instructions and applied subjective assessment to identify if patient have problems 
using their inhalers. These studies suggest that a large proportion of patient do have 
problems using their inhalers but there is no objective assessment. The studies of this 
Thesis have been designed to provide objective assessments of inhaler technique and 
at the same time to quantify how patients use inhalers with respect to their inhalation 
flows (including the peak inhalation flow), inhalation volumes and inhalation times 
(including the time to the peak inhalation flow). Simple solutions to the main issue 
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with respect to pMDI co-ordination and slow flow and with respect to DPIs using a 
fast inhalation from start will be identified and studied using objective methods.  
 Studies involving children and adults with asthma, those with chronic obstructive 
pulmonary disease and healthy volunteers have been designed when they inhale 
through a pMDI and a DPI. For the pMDI studies the time between the start of an 
inhalation and the pressing of the canister has been included to identify co-ordination 
and for DPI the acceleration of the inhalation flow through different devices has also 
been included.  
2.5 1 Aims and Objectives 
2.5.1 (a) Aims 
 To capture the electronic inhalation profiles of children with asthma, adults 
with asthma and COPD patients together with healthy individuals as well as 
their disease control and spirometry. 
 Identify the inhalation parameters from each profile. 
 Show how simple methods can be used during the inhalation technique 
training session to improve patient inhaler administration when using a pMDi 
and DPI. 
2.5.1. (b) Objectives 
 Measure inhalation parameters (peak inhalation flow, inhalation duration, and 
inhaled volume) in children with asthma, adults with asthma and COPD when 
they inhale through pMDIs and spacers. 
 Identify the impact of using a co-ordination cap and simple counselling to 
increase the duration of an inhalation on the pMDI technique of asthmatics. 
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 Measure inhalation parameters (peak inhalation flow, time to peak inhalation, 
the acceleration rate of each inhalation, inhalation duration and inhaled 
volume) in children with asthma, adults with asthma and COPD when they 
inhale through different DPIs. 
 To identify the impact of focussing on a fast inhalation from the start during 
counselling by measuring inhalation profiles (peak inhalation flow, time to 
peak inhalation, the acceleration rate of each inhalation, inhalation duration 
and inhaled volume) when children with asthma, adults with asthma and 
COPD inhale using two different DPIs. 
 Measure the change in the inhalation parameters when patients with asthma 
and COPD inhale through different DPIs after their recovery following 
hospital admission due to an acute exacerbation. 
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Chapter 3:  
Preliminary investigations on the inhalation 
characteristic of children with Asthma (CHILD), 
adult asthmatics (ADULT) and patients with 
chronic obstructive pulmonary disease (COPD) 
when they use a pressurised metered dose inhaler 
(pMDI) with and without spacers and a Soft Mist 
Inhaler. 
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3.1 Introduction 
In 1976 Crompton started a series of reports (Paterson and Crompton, 1976; 
Crompton, 1982b), describing pMDI inhalation technique problems. Today 
(Crompton, 2006; Melani et al., 2011) these problems are no different to those in 
1976. It is estimated that about 75% of patients make errors when using their pMDIs 
(Molimard et al., 2003), as they need to co-ordinate the device actuation with 
inhalation to receive the intended therapeutic dose. Moreover, 60-92% of patients 
inhale too fast and do not use a slow inhalation when they used their pMDI (Larsen 
et al., 1994; Al-Showair et al., 2007a). Failure to use a slow inhalation was more 
common than good co-ordination between dose actuation and co-ordination (Nimmo 
et al., 1993; Hesselink et al., 2001). It is estimated that approximately 50% of 
patients do not obtain sufficient therapy from their inhalers due to poor inhalation 
technique (Crompton and Duncan, 1989). 
An extensive review has concluded that flows through a pMDI should be < 90L/min 
(Pauwels et al., 1997) whilst a gamma scintigraphy study has shown that a flow of 
90L/min with a co-ordination time of 0.2 seconds resulted in the greatest total and 
peripheral lung deposition (Farr et al., 1995). Previously these criteria had been 
described as the ideal combination (Goodman et al., 1994) and were used by 
Broeders et al (2003). This latter study measured electronic profiles and reported that 
not using a slow flow was a more common mistake than good co-ordination. This 
latter study revealed that the inhalation volume of asthmatics was around 2.7L which 
is less than those reported by Farr et al (1995) in healthy volunteers. Broeders et al 
(2003) reported that inhalation volumes in COPD ranged from means for 2.3 to 2.7L 
with those who had more severe obstruction having the smaller inhalation volumes. 
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Spacers were introduced to help solve pMDI technique problems and to reduce 
oropharyngeal deposition. However, it has been reported that up to 40% of the 
children used their pMDI inadequately even with a spacer (Kamps et al., 2000). 
Training and regular inhaler technique follow up is therefore required (van 
Beerendonk et al., 1998; Kamps et al., 2000; Crompton, 2006). Although spacers 
should be used with a slow inhalation reports do not focus on this. 
Most studies assessing inhalation technique are subjective. Goodman et al (1994) and 
later Broeders et al (2003) used electronic measurements to characterise the 
inhalation profile of patients when they used a pMDI (but not a spacer). Broeders et 
al (2003a) demonstrated the effect of training but inhalation flows remained too fast. 
This study was designed to adapt available methodology to provide a preliminary 
assessment of measuring inhalation parameters of patients when they use a variety of 
inhalers. In this study patients have been asked to use their real life inhalation 
technique and so received no training about inhalation technique. Patients with 
asthma (both children and adults) and COPD when they used a pMDI alone and 
when it was attached to different spacers have been studied. Also inhalation 
parameters for a Respimat
®
 (Boehringer Ingelheim, GmbH) have been obtained. 
3.2 Research Aim and Objectives  
3.2.(a) Aim 
The main aim  was to identify the inhalation parameters of children with asthma, 
(CHILD), adults with asthma (ADULT) and COPD patients when they inhaled 
through a pMDI and when the pMDI was attached to a Volumatic spacer and also 
when attached to an AeroChamber spacer, also to identify the inhalation parameters 
when patients with COPD used a Respimat. 
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3.2.(b) Objectives 
Primary Objectives 
To measure the inhalation profile when the patients inhale through a pMDI alone and 
when attached to a Volumatic and when attached to an AeroChamber as follows. 
 Asthmatic children: peak inhalation flow (PIF in l/min), inhalation volume 
(IV in L) and inhalation time (Ti in sec) through a pMDI alone, a pMDI with 
a Volumatic spacer and attached to an AeroChamber as well as an 
EasiBreathe. 
 Asthmatic adults: peak inhalation flow (PIF), inhalation volume (IV) and 
inhalation time (Ti sec) a pMDI alone, a pMDI with a Volumatic spacer and 
attached to an AeroChamber. 
 COPD patient: peak inhalation flow (PIF), inhalation volume (IV) and 
inhalation time (Ti sec) through a pMDI alone, a pMDI with a Volumatic 
spacer and attached to an AeroChamber and when they inhaled through an 
EasiBreathe and Respimat. 
Secondary Objectives 
 To obtain patient‟s demographic features and measure their peak expiratory 
flow (PEF), forced expiratory volume in one second (FEV1) and Forced Vital 
capacity (FVC). 
 Identify the level of their disease.  
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3.3 Method 
3.3.1 Study Population 
3.3.2 Patient recruitment and sample size 
NRES ethical approval was obtained as well as local R&D (Research and 
Development) approval from each centre [APPENDIX A-1]. Asthmatic adults / 
children and COPD patients attending an outpatient appointment and receiving 
regular care at the respiratory clinics of NHS hospitals (see below for the list of 
hospitals involved) who used a pMDI and a pMDI attached to a spacer were invited 
to take part in this research study. The study procedures were explained to all 
patients using the ethical committee approved Patient Information Leaflet 
[APPENDIX A1, A2, A3 and A4] which they kept. All subjects willing to take part 
gave their signed informed consent and for children their parent / care also gave 
consent (APPENDIX A5). Patients were free to withdraw or terminate, at any time 
from the study, without giving a reason. The data collected and records were kept 
strictly confidential and anonymous. 
The NHS Hospitals which were involved as research sites: 
 Leeds General Infirmary (LGI), Leeds, UK. 
 St. James‟s University Hospital, Leeds, UK. 
 Bradford Royal Infirmary, Bradford, UK. 
 St. Luke‟s Hospital Bradford, UK. 
 Airedale Hospital, UK 
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 (a) Inclusion criteria 
Patients who met all the following criteria were potential candidates for recruitment: 
 Male or female, with stable asthma or COPD. 
 Prescribed inhaled medication through a pMDI and had used a pMDI 
attached to a spacer. 
 Age groups: asthmatic child (4-18 years)[CHILD], adult asthmatic asthma 
(18-55 years) [ADULT] and COPD ( > 55 years)[COPD]. 
 Signed informed consent form. 
(b) Exclusion Criteria 
Patients who met the following criteria were excluded from participation: 
 Prescribed inhaled medication for less than 4 weeks prior to enrolment. 
 Other pulmonary diseases (e.g. Cystic Fibrosis, TB, pneumonia). 
 An acute exacerbation of asthma or COPD or a short course of high dose oral 
prednisone during the last 2 weeks. 
 Participation in another clinical research study in the 3 months prior to 
enrolment. 
3.3.3 Study Design 
A Micro-Loop Spirometer (Cardinal Health, UK) was adapted with an airtight holder 
on the air entry in-let of the spirometer‟s mouthpiece. Specially designed inhaler 
adapters were obtained to fit tightly onto the holders. Adapters unique for the 
mouthpiece of each inhalation method were obtained. These allowed an inhalation 
through the spirometer. The inhalation section of the option to measure a flow 
volume loop with the spirometer was chosen. The data from each profile was 
downloaded into a Microsoft Access spreadsheet to compute the inhalation 
parameters. 
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Each patient‟s demographic data was obtained and their spirometry (PIF, FEV1 and 
FVC) was measured. Disease severity classification for asthma was made according 
to GINA (2008) and for COPD according GOLD (2006)  
The patients were asked to inhale through the Micro-Loop when it was fitted with: 
I. An empty pMDI [pMDI] 
II. An empty pMDI attached to a Volumatic spacer (GlaxoSmithKline, UK) 
[VOLUMATIC]. 
III. An empty pMDI attached to an AeroChamber spacer (Truddell International, 
Canada) [AEROCHAMBER]. 
IV. An Empty EasiBreathe [EASIBREATHE]. 
V. COPD only –an empty Respimat® (Boehringer Ingelheim). [RESPIMAT] 
The order was randomised and each patient made two separate inhalations. Prior to 
inhalation through the Respimate patients were given the patient information leaflets 
to study. 
 
Each patient was instructed to use the same technique as they would use at home – 
their real life inhaler technique. All inhalations were made during one visit. From 
each inhalation profile the following inhalation parameters were obtained: 
 Peak inhalation flow, in litres per minute (PIF). 
 Inhalation volume, in litres (IV). 
 Duration of the inhalation, in seconds (Ti). 
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The profile with the slowest PIF was chosen for data analysis. Patients were also 
asked to complete a questionnaire as follows: 
 Adult asthmatic: the Asthma Control Questionnaire (ACQ – Juniper et al 1999b) 
see [APPENDIX A-6] and Juniper‟s Asthma Quality of Life - mini version (AQLQ) 
– see [APPENDIX A-7] (Juniper et al., 1999a)  
 Children: Paediatric Asthma Caregivers Quality of Life – PACQLQ (Juniper et 
al.,1996b). [APPENDIX A-8] and Asthmatic children: Paediatric Quality of Life – 
PAQL (Juniper et al., 1996a)[A -9] 
 COPD: St George‟s Respiratory questionnaire (SGRQ)- See [APPENDIX A-10] 
(Jones et al, 1992). 
3.3.4 Data Collection 
Quantitative and qualitative data were collected from the 3 groups (children with 
asthma, asthmatic adults and COPD patients) 
Main outcomes were: 
 Peak inhalation flow (PIF). 
 Inhalation volume (IV). 
 Duration of inhalation (Ti). 
The Secondary measures were; 
 Demographic data 
 Level of asthma / COPD control using  quality of life questionnaires (see above)  
 Spirometry (PEF, FEV1, FEV1% predicted and FVC) 
3.3.5 Data Analysis 
The statistical analysis of the study was carried out using the Statistical Package for 
Social Sciences (SPSS) software version 17. The study data was first classified into 
scale, categorical (nominal) or ordinal categories, as appropriate, and an SPSS 
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dataset was then set up for the analysis. The statistical analysis was performed and 
presented as follows 
 Descriptive statistics: mean and standard deviation. 
 For scale data; normal distribution of the data was examined using histograms 
and statistical  tests for normality; the Kolmogorov-Smirnov and Shapiro-Wilk tests 
 Comparisons (differences) of measurements through different inhalers within the 
same group  were performed using the related (paired)-samples t-test (for parametric 
data) and the Wilcoxon test (for non-parametric data) 
 Comparisons (differences) of measurements between different the groups were 
performed using the independent-samples t-test (for parametric data) and the Mann-
Whitney U test (for non-parametric data). 
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3.4 Results  
3.4.1 Study Population 
A total of 109 patients were recruited and completed this study as shown in Table 
3.1. Individual details are presented in APPENDIX B-1, B-2 and B-3, together with 
their % predicted values (refer to the enclosed DVD). 
Table 3.1. Details of all subjects studied. All data is mean (SD) unless indicated.  
Characteristics CHILD ADULTS COPD  
Number  20 57 32 
Age in years  8.6 (2.8) 48.3(15.4) 64.8(12.1) 
Sex (M/F) 15/5 11/46 17/15 
Height (cm) 132.8(20) 165.5(9.01) 168.1(10.3) 
Weight (Kg) 34.8(16.2) 76.5(17.7) 77.8(12.2) 
FEV1 (L) 1.5(0.72) 2.03(0.62) 1.3(0.6) 
FEV1 % predicted 77.4 (18.4) 71.1(17.0) 42.2(17.8) 
PEF ( L/min) 191.2(76.9) 304.1(114.4) 178.9(92.2) 
PEF % predicted 63.1(15.7) 72.6(24.1) 46.1(18.3) 
FVC (L) 1.6(0.7) 2.5(0.7) 2.0(0.8) 
Disease 
severity* 
Mild 9 15 4 
Moderate 8 23 20 
Severe 3 19 8 
Very severe N/A N/A - 
*asthma severity classified was based on GNA (2008) Guidelines 
3.4.2 Inhalation Characteristics  
A summary of the inhalation parameters of the asthmatic children is shown in the 
Table 3.2, adults with asthma in Table 3.3 and COPD patients in Table 3.4. The 
number of patients with slow, fast and very fast PIF values are shown in Table 3.5 
and Figure 3.1. Individual vales are presented in Figures 3.2 to 3.10. 
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Table 3.2. Inhalation characteristics of the asthmatic children when they inhaled through the pMDI, pMDI with Volumatic, pMDI with 
AeroChamber and EasiBreathe. 
D* 
pMDI VOLUMATIC AEROCHAMBER EASIBREATHE 
PIF(l/min) IV(L) Ti(sec) PIF(l/min) IV(L) Ti(sec) PIF(l/min IV(L) Ti(sec) PIF(l/min IV(L) Ti(sec) 
Mean 108.9 1.14 1.44 93.0 1.08 1.38 89.90 1.17 1.52 77.60 1.06 1.43 
SD 40.4 0.59 0.27 49.7 0.61 0.25 40.7 0.59 0.30 41.2 0.66 0.22 
min 62.0 0.5 1.0 37.0 0.3 1.0 38.0 0.3 1.0 36.0 0.3 1.0 
max 224 3.0 1.9 206 2.9 1.9 206 2.6 2.2 211.0 2.9 1.8 
*Devices  
Table 3.3. Inhalation characteristics of the asthmatic adults when they inhaled through the pMDI, pMDI with Volumatic, pMDI with 
AeroChamber and EasiBreathe. 
D* 
pMDI VOLUMATIC AEROCHAMBER EASIBREATHE 
PIF(l/min) IV(L) Ti(sec) PIF(l/min) IV(L) Ti(sec) PIF(l/min) IV(L) Ti(sec) PIF(l/min) IV(L) Ti(sec) 
Mean 146.0 2.1 1.5 145.8 2.1 1.6 136.9 2.0 1.5 100.0 1.6 1.64 
SD 58.8 0.9 0.3 67.5 0.8 0.4 68.9 0.9 0.3 39.0 0.82 0.31 
min 40.0 0.6 1.1 44.0 0.4 1.1 30.0 0.5 0.3 52.0 0.73 1.10 
max 284.0 4.5 2.2 286.0 3.9 2.6 301.0 4.2 2.2 205.0 3.7 2.80 
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Table 3.4. Inhalation characteristics of COPD patients when they inhaled through the pMDI, pMDI with Volumatic, pMDI with Aero-
chamber and the EasiBreathe. 
D* 
pMDI VOLUMATIC AEROCHAMBER EASIBREATHE 
PIF(l/min) IV(L) Ti(sec) PIF(l/min) IV(L) Ti(sec) PIF(l/min) IV(L) Ti(sec) PIF(l/min) IV(L) Ti(sec) 
Mean 107.3 1.8 1.6 115.7 1.8 1.5 117.9 1.8 1.7 83.8 1.8 1.7 
SD 50.6 1.0 0.2 50.4 0.9 0.4 49.1 0.8 0.4 29.1 1.1 0.5 
min 33.0 0.4 1.1 34.0 0.6 1.1 37.0 0.5 1.1 38.0 0.9 1.1 
max 242.0 5.3 1.9 277.0 4.7 2.8 287.0 4.4 2.6 155.0 4.9 3.5 
 
Table 3.5. Summary of patients categorised with respect to their PIF. 
PIFR 
(L/min) 
PATIENTS NUMBER (PERCENTAGE) 
ADULT n (%) CHILD n (%) COPD n (%) 
 pMDI VoL AERO EASI pMDI VOL AERO EASI pMDI VOL Aero- EASIn=14 
>200 
11 
(19.2%) 
12 
(21%) 
14 
(24%) 
12 
(21%) 
1 
(5%) 
1 
(5%) 
1 
(5%) 
1 
(5%) 
3 
(9.3%) 
2 
(6.25) 
1 
(3.1%) 
0 
90-200 
36 
(63%) 
30 
(52.63) 
31 
(54.3) 
31 
(54.3%) 
12 
(60%) 
7 
(35%) 
10 
(50%) 
3 
(15%) 
19 
(59.3%) 
22 
(68.75) 
24 
(75%) 
7 
(5%) 
25-90 
10 
(17.5%) 
15 
(26.3) 
12 
(21.1) 
14 
(24.6%) 
7 
(35%) 
12 
(60%) 
9 
(45%) 
16 
(80%) 
10 
(31.2%) 
6 
(18.8%) 
7 
(21.9%) 
7 
(5%) 
VOL- Volumatic, AERO-AeroChamber, EASI-EasiBreathe 
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Figure 3.1. Summary of patients categorised with respect of their PIF. 
 
 
Figure 3.2. Individual Peak inhalation flow (L/min) for the children with asthma 
when they inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached 
to an AeroChamber and an EasiBreathe. 
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Figure 3.3. Individual Inhaled volume (L) for the children with asthma when they 
inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached to an 
AeroChamber and an EasiBreathe. 
 
Figure 3.4. Individual durations of the inhalation (Ti) of the children with asthma 
when they inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached 
to an AeroChamber and an EasiBreathe. 
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Figure 3.5. The peak inhalation flow (L/min) of each adult with asthma when they 
inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached to an 
AeroChamber and an EasiBreathe. 
 
Figure 3.6. Individual inhalation volumes (IV) of the adults with asthma when they 
inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached to an 
AeroChamber and an EasiBreathe. 
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Figure 3.7. The duration of the inhalations (Ti) of each adult with asthma when they 
inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached to an 
AeroChamber and an EasiBreathe. 
 
 
Figure 3.8. Peak inhalation flow (L/min) of each COPD patients when they inhaled 
through the pMDI, pMDI attached to a Volumatic, pMDI attached to an 
AeroChamber and an EasiBreathe. 
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Figure 3.9. Individual inhalation volumes (IV) of the COPD patients when they 
inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached to an 
AeroChamber and an EasiBreathe. 
 
Figure 3.10. The duration of each inhalation (Ti) by the COPD patients when they 
inhaled through the pMDI, pMDI attached to a Volumatic, pMDI attached to an 
AeroChamber and an EasiBreathe. 
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The range of peak inhalation flows and inhaled volumes of the three patient groups 
with respect to the severity of their disease is presented in Table 3.6 whilst Table 3.7 
presents these ranges for the adults with asthma according to their ACQ. Table 3.8 
shows the range of the PIF and IV for the children with asthma with respect to their 
age. 
Table 3.6. Range of inhalation parameters through the pMDI in all patients according 
to the severity of obstruction 
 CHILD ADULT COPD 
PIF (L/min) 
Mild 65 - 224 55 - 217 33-209 
Moderate 75 - 150 40 - 281 38-242 
Severe 110 - 106 75 - 284 44-146 
Very Severe n/a n/a n/a 
IV (L) 
Mild 0.5 - 3 1 - 3.5 0.7-5.3 
Moderate 1.1- 1.8 0.8 - 4.5 0.8-3.7 
Severe 0.5 - 1.2 0.6 - 3.6 0.81-1.80 
Very Severe n/a n/a n/a 
 
Table 3.7. Range of inhalation parameters through the pMDI in the adult asthmatic 
patients according to their asthma control measured by their ACQ 
 ADULT 
PIF (L/min) 
< 0.7 76 - 284 
0.7-1.5 108 - 238 
> 1.5 40-280 
IV (L) 
< 0.7 1-3.4 
0.7-1.5 1.1-2.5 
> 1.5 0.6 - 4.5 
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Table 3.8. Range of inhalation parameters in the children with asthma according to 
their age 
 pMDI Volumatic AeroChamber 
PIF (L/min) 
5-7 years 62- 190 37-92 38-99 
8-10 years 75-150 49-153 57-147 
> 10 years 85-224 88-260 89-206 
IV (L) 
5-7 years 0.5-1.4 0.3-1.2 0.3-1.4 
8-10 years 0.7-1.8 0.8-2.2 0.8-2.3 
>10 years 1.2-3 0.8-2.9 1.1-2.6 
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3.4.3 The Inhalation Characteristics between the patients groups 
Figure 3.11 shows a comparison of PIF for each group using each different 
inhalation method and a summary of the statistical analysis between each inhalation 
method within each group for the pMDI and spacers are presented in Table 3.9. 
(Using, the non-parametric test (Wilcoxon test)), and between each group for the 
different inhalation methods used non-parametric test (using the independent-
samples, Mann-Whitney U test) is presented in Table 3.10. 
 
Figure 3.11. Mean (SD) peak inhalation flows for the different group of patients 
when they inhaled through pMDI, Volumatic, AeroChamber and an EasiBeathe 
Table 3.9. Statistical comparison of PIF within each group between each inhalation 
method. 
 pMDI v‟s 
Volumatic 
pMDI v‟ 
AeroChamber 
Volumatic v‟s 
AeroChamber 
CHILD 0.286 0.185 0.445 
ADULT 0.429 0.359 0.238 
COPD 0.054 0.02 0.422 
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Table 3.10. Statistical comparison of PIF values between the different groups 
 CHILD v‟s 
ADULT 
CHILD v‟s 
COPD 
ADULT v‟s COPD 
pMDI 0.000 0.191 0.002 
Volumatic 0.0007 0.023 0.067 
AeroChamber 0.003 0.016 0.481 
EasiBreathe 0.003 0.033 0.226 
 
Figure 3.12 shows a comparison of the inhaled volumes (IV) for each group using 
each different inhalation method and a summary of the statistical analysis between 
each inhalation method within each group for the pMDI and spacers is presented in 
Table 3.11. 
 
Figure 3.12. Mean (SD) inhalation volumes for the different group of patients when 
they inhaled through pMDI, Volumatic, AeroChamber and EasiBeathe 
Table 3.11. Statistical comparison of inhaled volumes within each group between 
each inhalation method  
 pMDI v‟s 
Volumatic 
pMDI v‟ 
AeroChamber 
Volumatic v‟s 
AeroChamber 
CHILD 0.262 0.681 0.121 
ADULT 0.222 0.310 0.541 
COPD 0.875 0.430 0.750 
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Table 3.12. Statistical comparison of inhalation volumes between the different 
groups 
 CHILD v‟s 
ADULT 
CHILD v‟s COPD ADULT v‟s COPD 
pMDI 0.000 0.003 0.079 
Volumatic 0.000 0.001 0.077 
AeroChamber 0.000 0.004 0.201 
EasiBreathe 0.001 0.007 0.507 
 
Figure 3.13 shows a comparison of the inhalation times (Ti) for each group using 
each different inhalation method and a summary of the statistical analysis between 
each inhalation method within each group for the pMDI and spacers is presented in 
Table 3.13 and between each group for the different inhalation methods is presented 
in Table 3.14 
 
Figure 3.13. Mean (SD) inhalation times for the different group of patients when they 
inhaled through pMDI, Volumatic, AeroChamber and EasiBeathe 
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Table 3.13. Statistical comparison of the inhalation times within each group between 
each inhalation method, values are the p values. 
 pMDI v‟s 
Volumatic 
pMDI v‟ 
AeroChamber 
Volumatic v‟s 
AeroChamber 
CHILD 0.432 0.329 0.239 
ADULT 0.226 0.738 0.975 
COPD 0.127 0.456 0.042 
 
Table 3.14. Statistical comparison of inhalation times between the different groups 
 
CHILD v‟s 
ADULT 
CHILD v‟s COPD ADULT v‟s COPD 
pMDI 0.995 0.214 0.140 
Volumatic 0.027 0.472 0.154 
AeroChamber 0.842 0.335 0.144 
EasiBreathe 0.000 0.005 0.473 
 
3.4.5. Inhalation Characteristics of COPD patients through Respimat®. 
The inhalation parameters of the COPD patients when they inhaled using an empty 
Respimat® are summarised in Table 3.15 and the numbers using different PIF are 
shown in Table 3.16 
Table 3.15. Inhalation characteristics of the COPD when they inhaled through a 
Respimat
®
. 
 PIF (L/min) IV (L) 
Duration of 
Inhalation(Sec) 
Mean(SD) 49.9(21.1) 1.4(0.9) 1.6(0.5) 
Min 22.0 0.4 1.1 
Max 124.0 4.5 3.5 
 
Table 3.16. Summary of COPD patients categorised with respect to their PIF. 
PIF (L/min) COPD Patients n=32(%) 
> 200 None 
200-90 1(3.12%) 
90-25 28(87.5%) 
< 25 3(9.37%) 
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3.4.6 Quality of Life Questionnaires 
(a) CHILD 
 The Paediatric Asthma Quality of Life (PAQLQ) and Questionnaire the 
Paediatric Asthma Caregivers Quality of Life (PACQLQ) 
The mean (SD) Paediatric Asthma Quality of Life (PAQLQ) and the Paediatric 
Asthma Caregivers Quality of Life (PACQLQ) were 4.35 (1.05) and 4.7 (1.19). The 
symptoms, Activity and Emotional domains of the PAQLQ were: 3.7(1.1), 4.5(1.5), 
4.9 (1.1). Individual values are presented in APPENDIX B-4 (refer to enclosed 
DVD) 
(b) ADULTS 
 Asthma Control Questionnaire–(ACQ) and Asthma Quality Of Life 
Questionnaire – (AQLQ) 
The mean (SD) ACQ scores were 2.1(1.0), Table 3.17 presents the frequencies and 
percentages of the asthmatic adults in different ACQ score. Previously Table 3.7 
presents the ranges for PIF and IV with respect to the ACQ scores of these adult 
asthmatics. A summary of the mean (SD) of AQLQ scores (overall and its three 
domains: symptoms, Activity Limitation, Emotional and Environment) are presented 
in Table 3.18. (Individual values can be found in APPENDIX B-5, B-6 refer to the 
enclosed DVD). 
Table 3.17. ACQ categorises of the adult asthmatics. 
ACQ Categories Frequencies 
≤ 0.75 (well controlled) 5 (8.8%) 
0.75-1.50 (not well controlled 14 (19.2%) 
≥ 1.50 ( uncontrolled) 38 (66.6%) 
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Table 3.18. Mean (SD) (AQLQ) of the asthmatic adults. 
ASTHMA QUALITY OF LIFE QUESTIONNAIRE – (AQLQ). DOMAINS 
Domains Mean (SD) Score-AQLQ Domains for one visit 
Overall AQLQ 4.40 (1.12) 
Symptoms 3.8(1.2) 
Activity Limitation 3.9 (1.1) 
Emotional Function 3.2 (1.3) 
Environment 3.5(1.5) 
 
 (C) COPD 
 The SGRQ Scores 
The SGRQ scores (overall and its three domains: Symptoms, Activity and Impacts) 
are presented in Table 3.19. The detailed SGRQ scores of all COPD patients are 
presented in APPENDIX B-8 (refer to the enclosed DVD). 
Table 3.19. Descriptive Statistics of the SGRQ scores FOR COPD Patients.  
SGRQ (n=32) 
Symptoms 
score 
Activity 
score 
Impacts 
score 
Total 
score 
Mean (SD) 70.2 (24.2) 73.6 (19.5) 50.2 (21.6) 60.6 (18.5)* 
Percentiles 
25 58.3 60.7 34.7 43.5 
50 75.5 76.1 52.4 62.1 
75 90.1 91.2 69.47 78.3 
*SGRQ scores ranges from 0 to 100, zero scores indicate no impairment, with higher scores indicating 
worse health status.  
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3.5 Discussion  
Subjective assessment of each patient‟s inhalation technique was not performed 
because this was a pilot study to identify inhalation parameters and the methodology 
did not allow an electronic measurement of the point of co-ordination.  
The results provide substantial information about the inhalation parameters of asthma 
patients (both adults and children) and COPD patients when they use pMDIs and 
when they are attached to spacers. Poor co-ordination and slow flow are common 
errors made by patients when they use a pMDI (Al-Showair et al., 2007a; Hardwell 
et al., 2010). Not using a slow flow is a more common mistake made by different 
group of patients when they inhaled through a pMDI (Al-Showair et al, 2007a). 
This study shows that the majority of patients inhaled too fast (>90L/min) when 
using their pMDI. The results revealed that 65% of children with asthma inhaled > 
90L/min as well as 82% of the adult 68% of the COPD patients. The COPD findings 
are in accordance with Al-Showair et al (2007). In this 2007 reported study (using 
the IN-Check to measure flow) 59.5% of COPD patients with mild severity 
demonstrated an incorrect flow and their PIFR was > 90L/min with a mean PIF 
>120l/min before training. Another study reported that the majority of adults with 
asthma, children with asthma and COPD patients used a high flow rate >100 l/min 
when they used their pMDI (Chrystyn, 2009).  
The study in this Chapter confirms that not using a slow flow is not only problem 
with pMDIs but also when they are attached to spacers and to some extent when the 
EasiBreathe is used. However the children did decrease their flows when using 
spacers whilst the adults with asthma and COPD patients did not. This could be due 
to the constant training they receive when using their spacers. The lack of a statistical 
difference is due to the small number of children together with the large variability of 
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the results. There was no change in their inhaled volumes when all patients used their 
pMDI or spacers suggesting that they all used a similar complete inhalation during 
each manoeuvre. The prolonged inhalation times of the children when they used 
spacers are probably due to their training and since their volume did not change then 
their flows were slower. Again the lack of a statistically significant change is due to 
the small number of subjects and the variability of the results. 
Inhalation parameters of children with asthma when using pMDIs have not been 
reported before as well as when all asthmatics and COPDs use a pMDI attached to a 
spacer and when they use an EasiBreathe. Also similar data about adults with asthma 
and COPD patients is very limited. Previously Broeders et al (2003) have reported 
that the mean (SD) inhalation flows in adults asthmatics, mild COPD, moderate 
COPD and severe COPD patients when they use a pMDI are 149.6 (19.2), 127.9 
(5.5), 134.0 (8.1) and 142.1 (14.7) L/min. The results reported for the adult 
asthmatics in this Chapter are similar whilst those of the COPD patients were lower. 
Age and disease severity should not affect inhalation flow because this is heavily 
reliant on technique rather than the capability of the individual and could be 
influenced by the amount of training (especially children) and attention to details (in 
COPD patients). This would account for the significantly reduced flows in the 
children and COPD compared to the adults with asthma.  It is this latter group that 
should be targeted for extensive technique training. 
The peak inhalation flows when the pMDI was attached to either a Volumatic or an 
AeroChamber were similar to those of the pMDI. The mean (SD) inhaled volume of 
asthmatic children asthmatic adults and COPD patients through the pMDI were 
1.14(0.5), 2.1(0.9), 1.8(1.0) L. These values compare to 2.7 (1.2) L in adult 
asthmatics and 2.9 (0.7), 2.6 (0.2) and 2.3 (0.2) L in mild, moderate and severe 
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COPD patients when they inhaled through a pMDI (Broeders et al., 2003a). Also 
Farr et al (1995) reported mean (SD) inhalation volumes inhalation volumes ranging 
from 2.3 (0.3) to 3.2 (0.17) L, in healthy volunteers, depending on the inhalation 
manoeuvre used. The results in this chapter suggests that the inhalation volumes are 
related to age for the children. When the children with asthma used the pMDI 
attached to the Volumatic 5 of those 5-7 years used a volume of < 750ml. Hence with 
one inhalation these would not be able to inhale the complete volume of the 
Volumatic. This would be the volume that enters the mouth rather than into the 
lungs. It is advisable therefore that these patients should use the traditional tidal 
breathing method when they use a Volumatic. It has been recommended that as soon 
as a child can use a single deep inhalation though the AeroChamber (Roller et al., 
2007) then they should be encouraged to switch from tidal breathing to one complete 
inhalation. Although all children with asthma used a minimum volume of 280 ml 
with the AeroChamber and this is almost twice its volume then each child should be 
individually assessed. The child with the low volume was 5 years old and the 
smallest subject in the study. 
The duration of an inhalation Ti (Sec) is an inhalation parameter that has largely 
been ignored. Overall these were less than 2 seconds. It has been recommended that 
adult patients should be trained to inhale over 5 seconds and children 2 to 3 seconds 
(Laube et al, 2010). If patients use the same inhalation manoeuvre with respect to a 
gentle exhalation followed by a full inhalation then if the volume does not change 
and the duration of the inhalation increases then flow will be reduced. This theory is 
investigated during the studies in Chapter 5. 
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When using the EasiBreathe the inhalation parameters were similar to those of the 
pMDI. Flows were slightly slower which could be due to the higher resistance in the 
Easibreathe. The resistance was not measured but the air channels of this device are 
smaller than those of the pMDI.  No patient used a flow of < 20 L/min which is the 
threshold for this device to breath actuate. 
The Respimat is designed to emit a soft mist aerosol over 1.6 seconds (Newman et 
al., 1998; Hochrainer et al., 2005). Overall the COPD patients used a slower flow 
rate through the Respimat and only one patient inhaled > 90 L/min. However these 
flows are much faster than those of highly trained volunteers (Newman and 
Newhouse, 1996; Newman et al., 1998) whereas the volumes are similar. This 
suggests that the healthy volunteers may not have made a full inhalation. In this 
study 23 of the 32 (71.9%) patients inhaled over < 1.6 seconds and so these would 
have stopped their inhalation while the dose was still being emitted. The duration of 
the inhalation is critical parameter when using the Respimat®. 
In summary, most patients performed an inadequate inhalation technique because of 
high inhalation flows when using their “real life” pMDI technique. Inhaled volumes 
and inhalation duration were low. This was a pilot study and the methodology did not 
lend itself to make subjective assessments of their technique. This preliminary pilot 
study highlights the value of using electronic methodologies to measure these 
parameters and incorporate an objective measure of co-ordination. The volumes 
indicate that most patients can empty a spacer using a single full inhalation but 
caution should be exercised when switching small and young children from tidal 
breathing to one single full inhalation.  
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Conclusion: 
The study indicates that characterisation of the inhalation flow profile to identify 
aspects of the inhalation could be useful to identify the areas to focus on when 
training a patient to use their pMDI. Overall flows were too fast and inhalation times 
were short. 
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Chapter 4: Inhalation characteristics of children 
with asthma (Child), adult asthmatic and chronic 
obstructive pulmonary disease patients 
 (COPD) using a pressurised  
metered dose inhaler 
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4.1 Introduction 
The pressurized metered dose inhaler (pMDI) is the most widely used delivery 
system and commonly used in the management of asthma and COPD compared to 
other devices (Lenney et al., 2000; Broeders et al., 2003a). In 1965 the problems 
patients have using the correct pMDI technique were first report (Saunders, 1965). 
Subsequent subjective observations of patients using their pMDI have reported that  
these problems have yet to be solved (Orehek et al., 1976; Paterson and Crompton, 
1976; Epstein et al., 1979; Shim and Williams, 1980; Crompton, 1982b; Allen and 
Prior, 1986; Pedersen et al., 1986; Horsley and Bailie, 1988; Crompton and Duncan, 
1989; Manzella et al., 1989; Hilton, 1990; Larsen et al., 1994; van Beerendonk et al., 
1998; Lenney et al., 2000; Hesselink et al., 2001; Molimard et al., 2003; Melani et 
al., 2004; Sestini et al., 2006; Melani, 2007; Melani et al., 2011). These have been 
confirmed by limited objective measurements of inhalation parameters (Goodman et 
al., 1994; Broeders et al., 2003a) and an Aerosol Inhalation Monitor (Sarvis et al., 
2004; Hardwell et al., 2010). 
Not using a slow inhalation followed by good co-ordination between the start of an 
inhalation and dose actuation are the most common errors. Other problems are not 
shaking the pMDI, failure to exhale, the cold-freon effect, not inhaling as much as 
possible and breath holding (Crompton, 1982b). Only 8% of adult asthmatics used 
their pMDI with a slow flow and good co-ordination (Al-Showair et al., 2007a). 
When used correctly, only about 10%-20% of the nominal dose reaches the targeted 
airways (Newman, 1985). However, only a small amount is needed to produce a 
useful clinical effect and despite the consistent problems with pMDI inhaler 
technique these products have and continue to provide significant healthcare benefit. 
  
168 
 
Although the guidelines (BTS/SIGN., 2009; GINA, 2011) do recognise this they do 
appreciate that disease control could be improved without escalating the dose by 
better inhalation technique and compliance. It has been shown that good inhaler 
technique is associated with better asthma control (Giraud & Roche, 2002; Al-
Showair et al, 2007a), reduced inhaled corticosteroids (Kamps et al., 2003) and 
significantly less hospital admissions as well as acute exacerbations (Melani et al., 
2011). Thus patients with poor technique get sub-optimal benefit from their inhalers 
and this could translate into escalating doses and hence prescription item and other 
healthcare costs. It has been estimated that half the patients do not get the full 
therapeutic benefit from their inhalers due to poor inhaler technique (Crompton & 
Duncan, 1989). Improving inhalation technique could be one method of achieving 
the GINA challenge which is to reduce hospital admissions due to asthma by 50% 
over the next 5 years (Fitzgerald et al., 2011). A complete healthcare package that 
includes inhaler technique training in Finland has shown significant healthcare 
benefits and reduction in healthcare costs (Haahtela et al., 2006). 
To compliment traditional subjective assessment of inhaler technique objective 
measurements could be used to target the steps of the inhalation manoeuvre that the 
patient does not perform as recommended. Figure 4.1 describes an inhalation profile 
when a subject uses a pMDI. 
This profile identifies when the patient depressed the pMDI canister (co-ordination) 
where TsIn is the time between the start of the inhalation and actuating a dose. Also 
the peak inhalation flow (PIF), the duration of the inhalation (Ti) and the inhalation 
volume (IV) can be identified. Linking these to spirometry the ratio of the inhaled 
volume to the forced vital capacity could be used to identify if the patient exhaled 
and that during the inhalation they inhaled as much as possible 
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Figure 4.1. The inhalation flow with respect to time when using a pMDI. 
The aim of this study was to measure electronic profiles of patients when they 
inhaled through their pMDIs using their normal, untrained, real life inhalation 
technique. Using these objective methods the errors made with respect to co-
ordination and peak inhalation flow have been identified and an assessment of their 
inhalation volume has been made. Correlations of these parameters to spirometry 
have also been made. 
4.2 Aim and Objectives 
4.2.1 Aim 
 Identify the inhalation parameters of patients (children with asthma, adults 
with asthma and COPD patients) when they inhale through a pMDI. 
 Use the inhalation parameters to identify inhalation technique errors with 
respect to flow, co-ordination and inhaled volume. 
 Evaluate if there are correlations between the inhalation parameters and the 
indices of spirometry. 
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4.2.2 Objective (s): 
 Measure the inhalation profiles of children with asthma (CHILD), asthmatic 
adults (ADULT) and COPD patients (COPD) when they inhale through a pMDI 
using their „real life‟ technique. 
 Identify peak inhalation flow rate (PIF), inhalation volume (IV), length of 
inhalation (Ti) and the time of dose actuation with respect to the start of an 
inhalation. (TsIn). 
 Use the inhalation parameters to identify inhalation technique problems 
 Correlate the inhalation parameters to spirometry. 
 Identify the levels of control (ACQ and AQLQ in asthmatics; SGRQ in COPD). 
4.3 Methods 
4.3.1 Study design 
NRES research ethics approval from the Yorkshire and Humber Research Ethics 
Committee – Bradford was obtained (ref number 09/H1302/64). Stable asthmatic 
(adult and children) and COPD patients who were attending an out-patient NHS 
clinic and were prescribed a pMDI were invited to take part. The study objectives 
and procedure were described to the patients (including the parents/guardians of 
asthmatic children) using relevant patient information sheets [APPENDIX A1-A-2 
and A-3]. All gave signed informed consent. [APPENDIX A 5]. 
The NHS Hospitals were: 
 Airedale General Hospital, Steeton, West Yorkshire, UK. 
 Leeds General Infirmary, Leeds, UK. 
 Bradford Royal Infirmary, Bradford, West Yorkshire, UK. 
 St Luke‟s Hospital, Bradford, West Yorkshire, UK. 
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(a) Inclusion Criteria:  
 Male or female  
 Stable asthma or COPD  
 Asthmatic: children aged 5-17 years and adults 18-70 years 
 COPD patients > 55 years  
 Prescribed a pMDI 
 Signed informed consent form (including the parent/guardian of asthmatic 
children). 
 (b) Exclusion Criteria: 
 Limited ability to understand / implement the study procedures and instructions 
 Other pulmonary diseases (e.g. TB, pneumonia) 
 Acute exacerbation or oral short course of high dose prednisolone during the last 
4 weeks. 
 Patient participating in another clinical research study at the time of or in the 
past 3 months. 
 pregnant 
(C) Design 
Each patient‟s gender, age, height and weight were obtained together with their 
current medication. Their spirometry (PEF, FEV1 and FVC) was measured using a 
MicroLoop Spirometer (Cardinal Health) and their % predicted values were 
calculated (Gore et al., 1995). 
The patients were asked to complete the following; 
 18-55 years: Asthma Control Questionnaire (ACQ) and Juniper Asthma Quality 
Of Life Questionnaire (AQLQ) (Juniper et al 1999d; Juniper et al., 2006) 
[Appendix A-6 and A-7 respectively]. 
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 4-17 years: Paediatric Asthma Quality Of Life Questionnaire (PAQLQ) (Juniper 
et al., 1996a) and Paediatric Asthma Caregiver‟s Quality Of Life 
Questionnaire(PACQLQ) [ APPENDIX A-8, A-9] (Juniper et al., 1996) 
 COPD patients completed the St George‟s Respiratory Questionnaire (SGRQ) 
[APPENDIX A-10].(Jones et al., 1991)  
Each patient, made two inhalations using their normal inhalation technique through 
an empty pMDI that was attached to an inhalation profile recorder. From these 
inhalation profiles the peak inhalation flow (PIF), inhalation volume (IV), the time 
between actuation and the start of an inhalation (TsIn) and the duration of the 
inhalation (Ti) were obtained. The inhalation profile with the slowest peak inhalation 
flow was chosen for the final data analysis. 
Co-ordination was defined as GOOD if TsIn was 0-0.2 seconds (Farr et al., 1995), 
EARLY if < 0 seconds and LATE if > 0.2 seconds. Some patients did not actuate a 
dose during their inhalation (DNA). Flow was classified as SLOW if < 90 L/min 
(Newman et al, 1980, Newman et al, 1982; Farr et al, 1995; Pauwels et al, 1997) and 
FAST if > 90L/min with those > 200 L/min further classified as VERY FAST. Those 
with good co-ordination and slow flow were defined as using a GOOD technique. 
Also a IV/FVC ratio > 60% (Farr et al, 1995) suggested that they used a complete 
inhalation. 
The measurements were made during a single visit and patients were free to 
withdraw from the study at any time. They could also be withdrawn from the study 
by their doctor or at the discretion of the investigator(s) if they violated the study 
plan, were unable to follow the protocol procedures and / or for any other safety or 
clinical reasons. 
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4.3.2 Statistical Analysis 
The statistical analysis of the study data was carried out using the Statistical Package 
for the Social Sciences (SPSS for window version 17) software. The study data was 
first classified into scale, categorical (nominal) or ordinal categories, as appropriate, 
and an SPSS dataset was then set up for the analysis. The statistical analysis was 
performed and presented as follows 
 Descriptive statistics: mean and standard deviation. 
 For scale data; normal distribution of the data was examined using histograms 
and statistical  tests for normality; the Kolmogorov-Smirnov and Shapiro-wilk 
tests 
 Comparisons (differences) of measurements through different inhalers within the 
same group  were performed using the related (paired)-samples t-test (for 
parametric data) and the Wilcoxon test (for non-parametric data) 
 Comparisons (differences) of measurements between different the groups were 
performed using the independent-samples t-test (for parametric data) and the 
Mann-Whitney U test (for non-parametric data). 
 Correlations between the ACQ and the inhalation parameters and between the 
spirometry indices and the inhalation parameters were carried out. The data was 
first tested for normality (as described above) to determine the use of either 
Pearson‟s (Normal data) or Spearman‟s rho (non parametric) tests  
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4.4 Results  
4.4.1 Patients  
Table 4.1 describes the 181 patients that completed this study.  
Table 4.1. Demographic data of the patients. Value are means (SD) unless stated 
otherwise.  
Characteristics CHILD ADULT 
ADULT + 
CHILD 
COPD 
Number (n) 20 130 150 31 
Age (years) 8.9(3.3) 39.7(9.2) 35.6(19.2) 67.2(11.6) 
Sex (M/F) 14/6 33/97 47/103 16/15 
Height (cm) 133.4(20.6) 167.1(9.2) 162.6(16.1) 167.3(10.9) 
Weight (Kg) 35.8(17.7) 75.5(14.8) 70.2(20.3) 77.7(12.3) 
FEV1 (L) 1.74(0.58) 2.58(0.77) 2.47(0.80) 1.27(0.61) 
FEV1 (% pred) 53.9(13.1) 77.9(21.1) 74.7(21.9) 55.2(34.0) 
FVC (L) 1.88(0.61) 3.13(0.95) 3.00(1.00) 2.06(0.81) 
FVC (% predicted) 47.0(21.4) 78.3(22.1) 74.2(24.4) 57.4(19.9) 
PEF (L/min) 201.3(70.7) 339.6(105.2) 321.1(111.6) 178.9(94.1) 
PEF (% pred) 52.0(15.1) 74.4(23.3) 71.4(23.6) 40.2(21.0) 
 
Classification of the severity of their obstruction according to their predicted FEV1 is 
presented in table 4.2. 
Table 4.2. Severity of patients. 
 CHILD ADULT CHILD+ADULT COPD 
Mild 10 63 73 5 
Moderate  7 45 52 7 
Severe 3 22 25 19 
Very Severe N/A N/A N/A 0 
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The mean (SD) ACQ of the adult asthmatics (n=130) was 1.66 (0.93) with 22 below 
0.7, 40 between 0.71 and 1.49, and 68 above >1.5. Their mean (SD) AQLQ was 4.35 
(1.23). The mean (SD) PAQLQ of the children was 4.73(1.19) and PACQLQ 
was 4.35 (1.05). The mean (SD) SGRQ of COPD patients was 60.6(18.5) 
4.4.2 Inhalation parameters and coordination 
A summary of the pMDI inhalation characteristics of the patients is presented in 
Table 4.3.  
Table 4.3. Mean (SD) inhalation parameters.  
 CHILD ADULT CHILD+ADULT COPD 
Profile with slowest PIFR 
PIF (L/min) 70.5(36.4) 131.4(60.8) 123.2(61.7) 70.9(28.1) 
IV (L) 0.88(0.60) 2.04(0.91) 1.99(0.96) 1.05(0.56) 
Duration (Ti) 1.25(0.46) 1.68(0.82) 1.62(0.79) 1.44(0.65) 
IV/FVC ratio (%) 50.0(29.7) 65.9(23.1) 67.4(24.7) 57.3(32.4) 
 
The PIFs of each individual from the slowest profile are presented in Figure 4.2 -4.4. 
Those for the inhalation volume are shown in Figure 4.5-4.7 and the inhalation times 
in Figure 4.8-4.10 with the time between actuation and the start of an inhalation 
(TsIn) in figure 4.11.  
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Figure 4.2. The distribution of the peak inhalation flow, from the fast and slow 
inhalation profiles, through the pMDI by children with asthma.  
 
Figure 4.3. The distribution of the peak inhalation flow, from the fast and slow 
inhalation profiles, through the pMDI by the COPD patients. 
 
Figure 4.4. The Peak inhalation flows, from the fast and slow inhalation flow 
profiles, through the pMDI for the adults with asthma.  
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Figure 4.5. The inhaled volume, from the high and low inhalation profiles, through 
the pMDI by the children with asthma.  
 
Figure 4.6. The inhaled volume, from the high and slow inhalation profiles, through 
the pMDI by the COPD patients. 
 
Figure 4.7. The inhaled volume, from high and slow inhalation flow profiles, through 
the pMDI by adults with asthma.
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Figure 4.8. The inhalation times, from the high and low inhalation flow profiles, for 
children with asthma.  
 
Figure 4.9. The inhalation times, from the high and low inhalation profiles, for 
COPD patients. 
 
Figure 4.10. The inhalation times, from high and low inhalation flow profiles, for the 
adults with asthma.
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Figure 4.11. Inhalation times between actuation of the dose and the start of an 
inhalation (TsIn) for the different group of patients from slow the inhalation profiles. 
Using the inhalation parameters from the profile with the slowest PIF to categorise 
aspects of the inhalation technique into flow, co-ordination, technique and a 
complete inhalation is presented in Table 4.5. 
A comparison between each group presented in figure 4.12, 4.13, and 4.14 and a 
Summary of the comparison between the groups is presented in Table 4.4. 
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Figure 4.12. Peak inhalation flow (PIF) for different group of patients. 
 
Figure 4.13. Inhaled volume (IV) for different group of patients 
 
Figure 4.14. Inhalation time for different group of patients 
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A Summary of the comparison between the groups is presented in Table 4.4. 
Table 4.4. Statistical summary between each group (Mann-Whitney U test for non-
parametric data). 
 CHILD vrs ADULTS CHILD vrs COPD ADULTS vrs COPD 
PIF (L/min) p<0.001 p=0.794(ns) p<0.001 
IV (L) p<0.001 p=0.151(ns) p<0.001 
Ti (Sec) p=0.016 p=0.375(ns) p=0.159 
 
Table 4.5. Classification of inhalation technique.  
 CHILD ADULT CHILD+ADULT COPD 
(a) Flow 
SLOW 15 37 52 24 
FAST 5 72 77 7 
VERY FAST 0 21 21 0 
(b) Co-ordination 
GOOD 5 53 58 10 
EARLY 4 27 31 13 
LATE 9 45 54 8 
*DNA 2 5 7 0 
(c) Good Technique 
GOOD 3 6 9 7 
POOR 17 124 141 24 
(d) IV/FVC ratio 
>60% 7 84 91 15 
<60% 13 46 59 16 
(e) Good technique and IV/FVC ratio >60% 
 0 2 2 3 
*DNA: did not actuate a dose during their inhalation  
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4.3.3 Correlation between ACQ and PMDI technique 
There was no link between asthma control and inhalation parameters. Of the adult 
asthmatics that used a slow inhalation (n=37) only 5 had an ACQ <0.7 whereas 6 had 
an ACQ of 0.7-1.5 and the remaining 26 had >1.5. Figure 4.15 and 4.16 shows the 
relationship between the ACQ for the adults with asthma with peak inhalation (low) 
and inhalation volume (low). Of those with good co-ordination (n=53) 12 had an 
ACQ of < 0.7, 21 between 0.7 and 1.5 and 20 >1.5. The six adult asthmatics with 
good technique (slow flow and good co-ordination) had ACQ scores of 1.57, 1.86, 
1.43, 2.7, 2.17 and 1.50. Two of these asthmatics with good technique had a IV/FVC 
ratio of > 60% and their ACQ scores were 2.7 and 2.17.  
 
 
Figure 4.15. Correlation between the peak inhalation flow (low) and the ACQ for 
adults with asthma (p<0.01). 
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Figure 4.16. Correlation between the IV and the ACQ for adults with asthma 
(p<0.01). 
4.3.4 Correlation between spirometry and inhalation parameters 
The inhalation parameters from the profile with the slowest PIF were chosen for the 
correlations. 
There was no correlation between PEF and PIF for any of the groups. Associations 
between FEV1 and the inhalation parameters as well as FVC and the inhalation 
parameters were significant with the latter being more strongly correlated.  
The only significant correlation between spirometry and the inhalation parameters 
was between FVC and PIF as well as FVC and IV for the adult with asthma group  as 
shown in figure 4.17-4.18 
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Figure 4.17. Relationship between the FVC and PIF for adults with asthma 
(p<0.001). 
 
Figure 4.18. Relationship between the FVC and IV for adults with asthma p<0.001. 
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4.5 Discussion 
The results in this chapter provide substantial data about the inhalation characteristics 
of all patients when they use their pMDI.  The metered dose inhaler (MDI) is the 
most widely used inhaler to deliver drug to the airways (Everard et al., 1995) and the 
efficiency of the pMDI, in terms of the extent and distribution of lung deposition, is 
influenced by many factors (Goldberg and Lourenco, 1973; Newman et al., 1981a; 
Ganderton, 1997). The inhalation technique by patients is one of the main factors that 
affect the fraction of the inhaled aerosol depositing in the lung and the subsequent 
distribution of the inhaled dose in the lungs (Canadian Asthma Consensus Group, 
1999). Inadequate pMDI use adversely affects airways distribution and results in 
poor drug delivery, decreased disease control and increased inhaler use. Many 
studies have found that using the correct inhalation technique through pMDIs results 
in a significant increase in bronchodilator response (Newman et al ,1980), and 
misuse of pMDIs is correlated to reduced asthma control (Giraud and Roche 2002; 
Al-Showair et al, 2007a), increased corticosteroid use (Kamps et al., 2003) and 
hospitalisations  (Melanie et al, 2003). Efficient inhalation technique by patients is 
crucial for the success of therapy. In realty, the majority of asthmatic and COPD 
patients misuse their pMDI and several studies have confirmed that patients fail to 
use the correct technique when using their pMDIs (Paterson and Crompton, 1976; 
Epstein et al., 1979; Larsen et al., 1993; Larsen et al., 1994; Kamps et al., 2000; 
Molimard et al., 2003; Melani et al., 2011). 
There is a growing appreciation of the fact that patients find it particularly difficult to 
use the correct inhalation technique, particularly where device actuation and 
inspiration are concerned (Price et al., 2003). Many previous studies have attempted 
to measure inhalation technique using direct observation. These methods will have 
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limitations and, so throughout this study an inhalation profile manager system has 
been used to obtain reliable quantitative inhalation measurements in order to assess 
technique. 
To signify a good inhalation technique coordination between inhalation and device 
actuation, should be between > 0 and < 0.2 seconds (Farr et al., 1995) and an 
inhalation flow of < 90 L/min was defined as slow flow (Farr et al, 1995; Pauwels et 
al, 1997; Al-Showair et al, 2007). Although many patients fail to exhale before an 
inhalation  (Melani et al., 2011) the definition of a complete inhalation with respect 
to the inhaled volume has yet to be fully defined although there is a suggestion that a 
IV/FVC ratio of > 0.6 could indicate this (Goodman et al., 1994; Farr et al., 1995). 
This study has confirmed that a high percentage of patients have poor co-ordination 
and not using a slow flow is the main problem. Fifty three of the 130 adults with 
asthma used good co-ordination hence 60% demonstrated poor co-ordination. In 
children with asthma, as expected, more had poor co-ordination (75%) but there were 
only 20 subjects which could have influenced this. COPD patients were not much 
better with 68% having poor co-ordination. Again the number (n=31) is much lower 
than the adults asthmatics. These values for poor co-ordination are similar to those 
previously reported (Crompton, 1982b; Nimmo et al., 1993; Cochrane et al., 2000) 
but higher than others (Broeders et al., 2003a; Molimard et al., 2003; Melani et al., 
2004; Sestini et al., 2006; Melani et al., 2011). Of most significance 5 adults with 
asthma and 2 children with asthma that did not depress the pMDI canister. These 
would receive no dose irrespective of how good the inhalation manoeuvre was.  
Furthermore 7 adults pressed the canister, to release a dose, at least one second 
before the start of their inhalation (one patient pressed 3.24 seconds before and 
another 2.4 seconds before). Also two children depressed >1 second before the start 
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of their inhalation (one was 3.24 seconds) and three COPD subjects (all >2 seconds). 
Hence those that did not actuate or inhaled too early are likely to receive no lung 
deposition. The total of asthmatics (adults and children) that did not actuate or 
actuated too early is 16 out of a total of 151, hence 10.6%. The three COPD subjects 
reflect 9.7% although the number of these subjects is small. The results suggest that 
approximately 10% would have received no drug which is the most significant 
clinical error that can be made by these patients. 
Using a high PIF decreases lung deposition, with increased deposition in the mouth 
and central zones of the lung (Dolovich et al., 1981; Newman et al., 1981a; Newman 
et al., 1982; Newman et al., 1994; Newman et al., 1995a). This may affect the 
fraction of the dose reaching the peripheral regions of the lungs, subsequently 
affecting the clinical efficacy of the inhaled therapy (Newman et al., 1981b; 
Newman, 1985). Using a slow inhalation flow has been shown to improve asthma 
quality of life (Al-Showair et al, 2007). Broeders et al (2003) has reported that the 
mean of 12 asthmatics and 36 COPD subjects was in the range of 117 – 149 L/min 
and Al- Showair reported that in 163 COPD subjects the mean was 110 L/min. The 
latter method did not use electronic methods and was constrained by a maximum 
flow of 120 L/min due to measuring instrument used (IN- Check Dial). The PIF 
values of the adult asthmatic are similar to those previously reported whilst the 
COPD PIF values are slower and there is no previous report with children. Overall 
the flows in the children with asthma and in the COPDs were the best with 15 out of 
20 (75%) children and 24 out of 31 (77%) using a flow < 90 L/min. It is amongst the 
adult asthmatics that flow is too fast. Overall 93/130 (72%) used a fast flow with 21 
(16% of the total) inhaling > 200 L/min. 
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The inhalation volumes of the children and COPD subjects were, as expected, lower 
than those of the adult asthmatics. The values in the COPD subjects are much lower 
than those previously reported (Broeders et al, 2003). This also applies to the 
asthmatic adults (Broederes et al., 2003) which is also much lower than that reported 
in healthy volunteers (Farr et al., 1995). In the children the overall mean IV/FVC 
ratio was less than 50% which could suggest that there was a tendency not to make a 
full inhalation. Such a ratio would be irrelevant in COPD because of the severity of 
any obstruction. However the mean value for this ratio was 51% which could suggest 
that they also did not make a complete inhalation.  In the adult asthmatics this ratio is 
around 66% which does indicate that overall these patients were making a full 
inhalation. 
The strong correlations between inhaled volume and the forced vital capacity of the 
adult asthmatics have not been previously reported.  However these strong 
correlations did not occur for the children with asthma or the COPD subjects.  This 
would be due to the size of the children and the reduced lung volumes of the COPD 
patients especially when measuring FVC where there is a tendency for airways to 
collapse during a forced exhalation maneuver. The correlation between inhaled 
volume and forced vital capacity warrants further investigation because if a ratio that 
indicates a full inhalation can be identified then this could be incorporated into future 
electronic inhaler technique aids to indicate how complete the inhalation was.  From 
the results there is a suggestion that a ratio of > 0.66 indicates a full inhalation. A 
similar correlation to the inhalation parameters were noted for the FEV1 (as would be 
expected due to the FVC correlations) but they were not as significant as the FVC. 
Studies have shown that only about 10% of patients use an ideal technique with their 
pMDI (Allen and Prior, 1986; Larsen et al., 1994; Al-Showair et al., 2007a; Hardwell 
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et al., 2011). However some other observational studies suggest that between a 
quarter (Goodman et al., 1994) and a third (Molimard et al., 2003) do not make any 
errors when they use their pMDI. Only 8% of patients used their pMDI with a flow 
 < 90 L/min and with good co-ordination. In this study 3 /20 (15%) children with 
asthma, 6/130 (4.6%) asthmatic adults and 7/31 (23%) COPD subjects met these 
criteria for a slow flow and good co-ordination. When the criteria for an ideal 
technique were extended to an IV/FVC ratio of > 60% then only 2 adult asthmatics 
meet these criteria. Hence when electronic measurements are used only 2 out of the 
total of 151 patients, hence 1.3% used an ideal technique. Although these are very 
precise electronic measurements they do highlight the potential for designing simple 
and portable electronic methodology to help identify the problems patients have 
using their pMDIs. The values obtained would provide valuable feedback on the 
specific inhalation steps to focus on during training sessions. 
These results were available when the ERS / ISAM Consensus statement was in the 
draft stage (Laube et al, 2011). These results informed the recommendation, in the 
Consensus Statement, that the inhalation time of an adult should be towards 5 
seconds and for a child to be 2-3 seconds (Laube et al, 2011).  
However the inhalation times that have been measured fall below these 
recommended. Theoretically if the inhaled volume does not change and the patient 
prolongs their inhalation (as demonstrated by the results in this study) then the 
resultant inhalation flow will decrease. By focusing on increasing the inhalation time 
will naturally slow the inhalation flow. This may be easier for the patients to 
understand than instructing them to use a slow inhalation. This could then be 
extended with information to depress the canister soon after the start of a slow 
inhalation. This instruction could reduce their tension and stress about the co-
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ordination step and enable them to make a relaxed inhalation with their pMDI. Some 
studies have shown that flow does slow down after training (Broeders et al, 2003; 
Sarvis etal, 2004; Al-Showair et al 2007b,) whereas others have demonstrated no 
effect (Hardwell et al, 2011). However patients do revert back to their old habit of a 
poor technique soon after training (Shim & Williams, 1980). A new approach to 
focus on prolonging the inhalation time may provide more long lasting effect with 
improved inhalation technique and hence needs to be investigated. 
The correlations between the ACQ and the inhalation parameters are interesting and 
link to the six asthmatics with slow flow and good co-ordination. The lowest ACQ of 
these 6 asthmatics was 1.43 indicating that they all had poor asthma control.  The 
correlation between ACQ and flow suggest that as asthma control is poorer then their 
flows are slower. This could be due to them concentrating more on their technique 
because their asthma control is not good. Alternatively the results may indicate that 
although their inhalation technique is good their compliance is poor 
Conclusion  
The methodology used in Chapter 3 was extended to include a measure of the co-
ordination between the start of an inhalation and the release of a dose. Only a few 
patients used a slow flow with good co-ordination and again the duration of the 
inhalations were short. The correlation between the inhaled volumes and the forced 
vital capacity could be a useful indicator for an objective assessment of a „full 
inhalation‟. The results suggest that an electronic aid to check a pMDI technique 
could provide the necessary information for the trainer to focus on when training 
patients how to use their pMDI 
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Chapter 5: Improved metered dose inhaler 
technique when a co-ordination Cap is used  
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5.1 Introduction 
The pressurised metered dose inhaler (pMDI) has been the most widely used inhaler 
over the past 40 years (Crompton, 2006) and the problems patients had using the 
correct inhaler technique when it was introduced are the same as they are today 
(Saunders, 1965; Paterson and Crompton, 1976; Molimard et al., 2003; Melani et al., 
2004; Melani et al., 2011). It has been shown that poor pMDI technique is related to 
poor asthma control (Orehek et al., 1976; Giraud and Roche, 2002; Kamps et al., 
2003; Al-Showair et al., 2007a) and hospitalisation (Melani et al., 2011). The 
recommended inhalation procedure for a pMDI involves several steps (see Table 
2.11, section 2.3.1.1) (Laube et al., 2011), of these good co-ordination and a slow 
inhalation flow maintained for as long as possible are particularly important for good 
asthma control (Al-Showair et al., 2007a). Lung deposition is reduced when there is 
poor co-ordination between the actuation of the dose and the start of inhalation 
(Newman et al., 1991b) and when a fast inhalation flow is used (Newman et al., 
1982; Hindle et al., 1993). Only 8% of patients use a good inhaler technique with 
their pMDI (Al-Showair et al., 2007a) and although inhalation technique training can 
be useful, (Al-Showair et al., 2007a) in some cases it has little effect  (Broeders et 
al., 2003a) or improvements are temporary (Shim and Williams, 1980). Breath 
actuated inhalers solve the problem of poor co-ordination (Newman et al., 1991b) 
but the choice is limited to use with salbutamol and beclometasone.  
A flexible co-ordination cap, shown in Figure 5.1 (i-Breathe, Teva Pharmaceuticals), 
has been designed to fit onto a pMDI, with an airtight seal, such that an inhalation 
cannot start until the canister is pressed. Pressing the canister causes slits in the co-
ordination cap to open (as it becomes compressed), and this allows the inhalation to 
be made. The pMDI is converted into a breath actuated device. In this study, we have 
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measured the inhalation parameters of asthma patients using a pMDI to identify if 
these parameters change when the co-ordination cap is fitted. We have extended this 
to determine if a short training session to increase the patients‟ inhalation times helps 
to decrease their inhalation flow. 
 
Figure 5.1. The I-Breathe inhaler ( Teva Pharmaceuticals, Ire). 
5.2 Aims and Objectives  
5.2.1 Aims 
To identify if there is a change in the inhalation parameters when a patient uses a 
pMDI when a co-ordination cap is fitted and whether a simple instruction to prolong 
the inhalation time alters the inhalation parameters. 
5.2.2 Objectives 
 Obtain demographic and spirometry data from mild asthmatics 
 Measure the resistance of a pMDI and when the co-ordination cap is fitted on 
the pMDI 
 Measure inhalation profiles when asthmatic patients use a pMDI, the pMDI with 
the co-ordination cap and the pMDI with the co-ordination cap after an instruction 
to prolong their inhalation time to 5 seconds. 
 Correlate pMDI inhalation parameters to spirometry. 
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5.3 Methods 
5.3.1 Patient demographics and baseline characteristics 
Ethical committee approval was received from the Yorkshire and Humber Research 
Ethics Committee – Bradford (ref number 09/H1302/64) and from the University of 
Huddersfield (SASEC/ 10/01).   
5.3.1(a)Inclusion Criteria 
 Asthma 
 18-45 years old 
 Prescribed a pMDI 
5.3.1(b)Exclusion criteria 
 Acute exacerbation or short course of oral prednisolone in the previous 4 months 
 Not able to understand the inhalation procedure instructions 
 Other pulmonary diseases (e.g. TB, pneumonia) 
 Pregnant 
 All patients provided written, informed consent prior to participation.  
5.3.2 Study design and inhalation parameters  
Patients‟ demographic data and medication usage were recorded. Their spirometry 
was measured using a ONE FLOW (Clement Clarke International, UK) Spirometer 
and they each completed the Asthma Control Questionnaire (ACQ) (Juniper et al., 
1999b). 
An empty pMDI was adapted such that electronic data could capture a patient‟s 
inhalation flow profile as shown in figure 4.1 section - 4.1. 
 From this profile the peak inhalation flow (PIF in L/min), the inhalation volume 
(Vin in L) and the length of the inhalation (Ti in seconds) were determined. A ratio 
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of Vi/FVC was calculated to indicate a deep inhalation. The time between the start of 
an inhalation and pressing the canister was defined as TsIn (seconds). 
Slow flow was defined as PIF < 90L/min (Newman et al., 1980; Newman et al., 
1981a; Hindle et al., 1993; Pauwels et al., 1997; Broeders et al., 2003a) and good 
co-ordination as TsIn of 0–0.2 seconds (Newman et al., 1980; Newman et al., 1981a; 
Goodman et al., 1994; Farr et al., 1995; Gabrio et al., 1999; Broeders et al., 2003a).
 
A deep inhalation was defined as a Vi/FVC ratio of > 0.6 (Farr et al., 1995).
 
 
All procedures were carried out during a single visit. Inhalation profiles were 
measured for each of the following inhalation procedures. 
 pMDI: patients inhaled through an empty pMDI. The inhalation procedure they 
used was their normal real life manoeuvre. 
 pMDI+CAP: Patients used the empty pMDI fitted with the co-ordination cap. 
Again they used their normal untrained inhalation technique. They were 
informed that the cap would not allow them to inhale until it was depressed. 
During use, if the patient did not keep the canister depressed then the slits in the 
cap would close and not allow any further inhalation. If this occurred the patient 
was instructed that they should keep the canister depressed until the end of their 
inhalation. This instruction was only given once. 
 pMDI+CAP+TRAIN: Each patient was then trained to increase the length of 
their inhalation to 5 seconds. This was done by the trainer demonstrating a slow 
inhalation whilst they counted to 5 and this was then practised once by the 
patient. Patients then used the pMDI fitted with the co-ordination cap after this 
training, and inhalation profiles were measured. 
For each inhalation manoeuvre two separate inhalations were made.  The inhalation 
parameters for the profile with the slower PIF were chosen for data analysis. 
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5.3.3 Patient satisfaction 
Following the inhalations, a 5 point Likert scale was used to obtain patient 
satisfaction about using a pMDI with the co-ordination cap. Patients were also asked 
if they perceived any advantages or disadvantages when using the co-ordination cap 
with their pMDI. 
5.3.4 Resistance of devices 
The resistance of the pMDI with and without the co-ordination cap was determined 
by measuring the pressure change corresponding to flows from 10-100 L/min as 
described by Clark and Hollingworth (Clark and Hollingworth, 1993).  
5.3.5 Statistical analysis  
A series of repeated measures analyses of covariance (ANCOVA) models was 
derived to assess the effect of pMDI+CAP and pMDI+CAP+TRAIN (the inhalation 
procedures) on the use of a pMDI, with respect to the primary outcome measure of 
PIF; and the secondary outcome measures of Vin and Ti, and controlling for all 
measured factors and covariates. All covariates were centred to avoid altering the 
main effect of the condition in any cases where covariate variability was large 
compared to condition variability. An additional series of controlled (ANCOVA) 
models was derived using the outcome measure Vin standardised by FVC. In these 
models FVC was not included as a covariate. 
An uncontrolled multivariate general linear model was also performed on baseline 
data, considering the relationship between the single predictor FVC and a linear 
combination of the three outcome measures, with follow-up univariate models 
derived as appropriate 
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5.4 Results  
The measured resistance of the empty pMDI without the co-ordination cap was 
0.0135 (cm H2O)
½
(min L
-1
) and 0.0243 (cm H2O)
½
(min L
-1
) for the pMDI with the 
co-ordination cap while the canister was depressed. 
Patients‟ baseline characteristics and spirometry measurements (n=71 patients, 52 
females and 19 males) are listed in Table 5.1.  
Table 5.1. Mean (SD) Patient demographics and baseline characteristics. 
Characteristic n=71 
Age (years) 31.96 (13.5) 
Weight (Kg) 74.44 (12.8) 
Height (cm 167.45 (9.7) 
PEF 
Actual (L/min) 355.5 (108.1) 
% predicted 74.8 (23.3) 
FVC 
Actual (L) 3.46 (1.04) 
% predicted 82.4 (22.0) 
FEV1 
Actual (L) 2.81 (0.85) 
% predicted 78.31 (21.03) 
ACQ 1.32 (0.71) 
 
Sixteen patients had an ACQ below 0.75, 30 patients between 0.75 and 1.5, and 25 
above 1.5.  
There was no statistical difference between the parameters for the inhalation profile 
with the slowest and the faster PIF. Figure 5.2 shows a distribution of the PIF values 
of each individual from the profile with the slow inhalation whilst figures 5.3 and 5.4 
show inhaled volume and inhalation time distributions.  
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Figure 5.2. The distribution of the individual PIF values for each inhalation 
manoeuvre. 
 
Figure 5.3. The distribution of the individual inhaled volumes for each inhalation 
manoeuvre. 
 
Figure 5.4. The distribution of the individual inhalation times for each inhalation 
manoeuvre.
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Table 5.2 shows a summary of their inhalation parameters for the inhalation profile 
with the slowest PIF. Individual PIF, Statistical analysis revealed pair wise 
differences corrected for multiple comparisons (p< 0.001) between the PIF and Ti 
for each inhalation procedure but not for Vin. 
Table 5.2. Mean (SD) inhalation parameters for patients using a pMDI with or 
without the co-ordination cap. PIF, peak inhalation flow; IV, volume of inhalation; 
Ti, time of inhalation; FVC, forced vital capacity. 
 Profile with slowest PIF 
Parameter MDI alone With Cap 
With cap after 
training 
p value 
PIF, L/min 155.6 (61.5) 112.3 (48.4) 73.8 (34.9) <0.001 
IV, L 2.33 (0.84) 2.26 (0.86) 2.30 (0.79) 0.681 
Ti, sec 1.60 (0.60) 1.92 (0.80) 2.99 (1.03) <0.001 
Vi/FVC 0.70 (0.21) 0.67 (0.22) 0.68 (0.18) 0.847 
 
Table 5.3. Shows the number of patients using a slow flow and Table 5.4 those that 
used a full inhalation. 
Table 5.3. The number (and percentage) of patients who performed a slow (correct) 
inhalation ( < 90 L/min), fast inhalation ( 90–200 L/min) and a very fast inhalation 
(> 200 L/min).  
PIF (L/min) pMDI, pMDI+CAP pMDI+CAP+TRAI 
< 90 (slow) 12 (16.9) 25 (35.2). 50 (70.4) 
90–200 (fast) 41 (55.8) 42 (59.2) 21 (29.6) 
>200 (very fast) 18 (38.0) 4 (5.6) 0 
 
Table 5.4. Patient with a deep inhalation with respect to their Vi/FVC ratio. 
Ratio Vi/FVC pMDI, n (%) pMDI+CAP, n (%) 
pMDI+CAP+TRAIN, n 
(%) 
< 0.6 19 (26.8) 26 (36.6) 21 (29.6) 
> 0.6 52 (73.2) 45 (63.4) 50 (70.4) 
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When using the pMDI alone Figure 5.5 shows the TsIn values. Negative values are 
compared to an early inhalation (actuation before inhalation). 
 
 
Figure 5.5. The co-ordination time (TsIn) in seconds for each patient. 
Seven patients had a negative TsIn (ranging from -0.1 to -2.41 seconds) indicating 
early actuation and 22 a late actuation (TsIn 0.25-1.71 seconds) whilst 42/71 (59%) 
used the pMDI with good co-ordination (TsIn 0-0.2 sec). Of these 42 patients with 
good co-ordination only 2 had a PIF < 90 L/min: therefore 2/71 (2.8%) demonstrated 
good inhalation technique when using the pMDI without the co-ordination cap. 
Patients were asked on a scale of 1 to 5 how satisfied they would be to use the co-
ordination cap with their pMDI in daily life (1 unsatisfied, 5 very satisfied). 7 gave a 
score of 3, 21 a score of 4 and 33 were very satisfied (score of 5). 17 of the 71 
patients had to be instructed to keep the canister depressed throughout the duration 
of their inhalation the first time they used the pMDI fitted with the co-ordination cap.  
The inhalation profile was repeated when this occurred. They did not repeat this 
problem for all the remaining inhalations. 
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An uncontrolled general linear model (GLM) assessing the effect of FVC on baseline 
outcome measures indicated a significant association between FVC and the outcome 
measures assessed jointly (p< 0.001). Subsequent follow-up univariate GLMs 
identified significant associations between FVC and PIF (p=0.006); and between 
FVC and Vin (p=0.001). The association between FVC and Ti was not statistically 
significant. Figures 5.6 and 5.7 highlight that PIF (p=0.006) and IV (p<0.001) were 
significantly correlated with FVC. Ti was not significantly correlated with FVC 
(p=0.073). 
 
Figure 5.6. The correlation between peak inhalation and forced vital capacity. 
 
Figure 5.7. Correlation between inhaled volume and forced vital capacity. 
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5.5 Discussion 
Overall in this study 59% of the patients used their pMDI with good co-ordination 
and 73.2% had a IV/FVC ratio of > 0.6 indicating a full inhalation but only 16.9% 
used a slow inhalation. These and the consistent inhalation volume for each 
procedure indicate that overall the pMDI technique of these patients was good. The 
proportion of patients with poor co-ordination is consistent with previous reports 
which used subjective methods (Hesselink et al., 2001; Molimard et al., 2003; 
Melani et al., 2004; Melani et al., 2011). The results confirm previous studies that 
show that not using a slow inhalation is the commonest mistake made by patients 
(Hesselink et al., 2001; Al-Showair et al., 2007a). Despite the overall good pMDI 
inhalation technique of these patients and that they were mostly mild asthmatics only 
16 had good asthma control (ACQ < 0.70) (Juniper et al., 2006). The study results 
highlight the potential of solving co-ordination problems with the cap and that using 
a simple instruction to increase the inhalation period towards 5 seconds ensures that 
most patients would use a slow flow with good co-ordination. Since asthma control 
is related to inhaler technique (Giraud and Roche, 2002; Al-Showair et al., 2007a; 
Melani et al., 2011) and hospitalisations (Melani et al., 2011) then use of the cap and 
a simple instruction to extend the duration of the inhalation to 5 seconds would 
improve inhalation technique. These improvements could improve patients‟ asthma 
control and thus contribute to the GINA challenge to reduce hospitalisations by 50% 
over a 5 year period (Fitzgerald et al., 2011).
 
 
The very highly significant slower inhalation flow with the cap fitted compared to 
the pMDI (alone – without the cap) would be due to the increased resistance caused 
by the cap. This would also have been the reason for the slightly longer inhalation 
time.  
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(The small difference between the inhalation times explains the lack of any 
statistically significant difference). The lower flows and longer inhalation times with 
unchanged inhaled volumes suggest that new pMDI or new drugs formulated in 
pMDI should be designed with resistance to airflow to naturally reduce the speed of 
the inhalation flow. This phenomena occurs with dry powder inhalers.  
After the short inhalation technique training that focussed on increasing the 
inhalation times towards 5 seconds patient inhalation time did increase by 
approximately 1 second to almost 3 seconds, and since the inhalation volume was 
unchanged then there was a further very highly significant reduction in the inhalation 
flow. This training lasted less than one minute and resulted in a highly significant 
increase in the inhalation time. Although the training was targeted to increase their 
inhalations to 5 seconds the increase from 2 to 3 seconds and the no change in the 
inhaled volumes substantially reduced the inhalation flows.  
The first set of measurements using the pMDI alone showed that only 2 (3%) of the 
patients used a slow inhalation flow with good co-ordination that was consistent with 
previous values (Al-Showair et al., 2007a).
 
Without training this increased to 25 
(35%) patients with slow flow and good co-ordination because of the cap. This was 
further increased to 50 (70%) patients when the co-ordination cap was used together 
with the simple instruction to lengthen inhalation (as near to 5 seconds as possible). 
In clinical use this would represent a large increase in the number of patients with 
good inhaler technique. Previous studies have shown the clinical benefit of a breath 
actuated inhaler (Price et al., 2003) and that poor inhaler technique is due to a fast 
inhalation. (Hesselink et al., 2001; Al-Showair et al., 2007a). With the co-ordination 
cap the focus could be on the exhalation and inhalation steps, thereby keeping the 
training simple without worrying the patient about the co-ordination. 
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When patients used the co-ordination cap they were informed to use their normal 
inhalation technique. They were informed that if they did start their inhalation before 
depressing the canister they would notice an initial vacuum which was released when 
they pressed the canister. It was emphasised that this was not an error. 
On first use, 17 of the patients did not keep the canister depressed throughout the 
duration of their inhalation. This meant that the slits in the cap closed and patients 
were not able to maintain their inhalation. This could be regarded as a critical error. 
When patients had to be instructed to keep the canister pressed, they did not repeat 
this problem. In their open comments no patient mentioned this as a disadvantage. 
This could be due to the strong feedback mechanism of not keeping the canister 
depressed. Nevertheless if this co-ordination cap became available for use by 
patients then the information about keeping the cap depressed is an important step 
that should be highlighted in the Patient Information Leaflet and included in 
counselling. 
We used a ratio of the inhalation volume to the forced vital capacity of 0.6 to 
indicate a deep inhalation (Goodman et al., 1994; Farr et al., 1995) but this value was 
greater in most of the patients. Greater lung deposition occurs when exhaling to 
residual volume compared to functional residual volume (Hindle et al., 1993; Juniper 
et al., 2006). However it has been shown that when using a slow flow and inhalation 
at different stages of the vital capacity does not affect lung deposition (Newman et 
al., 1982; Newman, 1985). Receptors for inhaled bronchodilators are distributed 
throughout the lungs, but they have their greatest effect in the conducting airways 
due to the presence of smooth muscle surrounding the airways (Carstairs et al., 1985; 
Mak and Barnes, 1990). Corticosteroid receptors are also present throughout the 
airways and inflammation has been shown to exist in all regions of the lungs 
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especially in asthma (Hamid et al., 1997; Tulic and Hamid, 2006). For these reasons, 
good penetration of the aerosol dose is required. Patients should exhale before an 
inhalation and the inhalation should continue as long as possible (Laube et al., 2011) 
but many patients make errors with these two simple inhalation steps (Molimard et 
al., 2003; Melani et al., 2004; Melani et al., 2011).  
Previous correlations of inhalation parameters to spirometry have concentrated on 
peak inhalation flow, and peak expiratory flow and not been successful (Engel et al., 
1990; Brown et al., 1995; Broeders et al., 2003a; Derom et al., 2007). Our results  
(Like those in the previous chapter) showed that FVC is a likely predictor of 
inhalation parameters when patients use their pMDI. We did not include FEV1 
because it was correlated to FVC and our preliminary statistical analysis identified 
its use rather than the FEV1. The strong positive correlations enable the use a ratio of 
> 0.6 (inhaled volume: forced vital capacity) to indicate that when patients make a 
full inhalation. 
The methods we have used could easily be incorporated into a simple portable 
electronic aid that can be used in the clinic to identify the errors that are made by a 
patient when they use their pMDI so that a focus on these can be made during any 
inhaler technique training session. 
The study was a repeated measure design rather than the traditional parallel study 
design that could have been used to identify the effect of the cap and also the 5 
second inhalation period. The benefits of the repeated measures design include 
improved efficiency (because fewer subjects are required) and the elimination of 
variability due to individual differences in overall performance, thereby allowing 
treatments to stand out. Against this are possible training effects and other carry over 
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effects which would not occur in a parallel design of a traditional randomised control 
trial (RCT) 
Conclusion 
A co-ordination cap together with a simple instruction to lengthen the inhalation time 
when a patient uses a pMDI ensures that they use the recommended slow inhalation 
flow with good co-ordination. The cap transforms a traditional pMDI into a breath 
actuated inhaler whilst the increased resistance to airflow naturally helps to reduce 
the inhalation flow. Training the patient to extend the duration of their inhalation did 
not alter their inhaled volume so inhalation flows were reduced. Seventy percent of 
patients used the correct pMDI technique with the cap and the simple instruction for 
their inhalation phase to last 5 seconds.  
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Chapter 6: Inhalation profiles of asthmatic 
children, asthmatic adults and COPD patients 
when they use different dry powder inhalers 
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6.1 Introduction 
Dry powder inhalers (DPIs) are breath-controlled devices, and due to their many 
advantages they have over pMDIs, then these devices have increasingly replaced 
pMDIs as the most common devices (Lavorini and Corbetta, 2008). However in the 
UK the pMDI is still more widely used although there is a gradual shift towards DPI 
use. DPIs do not require the need to coordinate actuation and the start of an 
inhalation like the pMDI device which is a mistake that most patients make 
(Broeders et al., 2003a). 
Before a dose is inhaled from a DPI it has to be prepared for inhalation. Each type of 
device has its unique dose preparation requirements. When a dose has been prepared 
for inhalation the formulation does not have the potential for lung deposition. This is 
because the drug particles are either attached to a carrier with large particles (usually 
lactose) or are formulated into spherical aggregates. This is to improve powder flow 
which is essential for accurate inhaler filling during manufacture and for dosing 
metering accuracy prior to an inhalation. During an inhalation each patient‟s 
inhalation reacts with the resistance created by the internal design of the DPI to 
create a turbulent energy that breaks up (de-aggregates) the formulation. Hence the 
emitted drug particles have the potential for lung deposition (Clark and 
Hollingworth, 1993; Chrystyn and Price, 2009a). Each type of DPI has its unique 
resistance with some having low resistance, others medium and some high (Laube et 
al., 2011). Since the turbulent energy is determined by the inhalation flow and the 
internal resistance of the device then inhalation flow should not be considered in 
isolation unless flows with the same DPI are compared (Azouz and Chrystyn, 2012). 
To attain a set pressure change (the turbulent energy) then the inhalation flow 
through an inhaler with low resistance must be higher than that through a DPI with 
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higher resistance (Azouz and Chrystyn, 2012). When comparing different devices 
during patient use then the pressure change should be the focus and not the 
inhalation flow. When comparing patient use through the same DPI then it is feasible 
to compare inhalation flow. This is due to the greater turbulent energy caused by a 
faster inhalation through the same DPI. To ensure adequate de-aggregation then the 
patient should use a forceful and deep inhalation (Borgstrom, 2001; Newman and 
Busse, 2002; Laube et al., 2011). 
It has been shown that the inspiratory effort and thus the inspiratory flow achieved 
by patients through each DPI will significantly affect the emitted dose which is 
related to the clinical efficacy (Engel et al., 1989; Nielsen et al., 1997; Chrystyn, 
2003). Studies have highlighted that some patients have problems achieving a fast 
inhalation rate during routine use of their DPI (Pedersen et al., 1986; Broeders et al., 
2001; Chrystyn, 2009). Asthmatics children (Amirav et al., 2005) and elderly COPD 
patients (Chrystyn , 2009) with acute exacerbations (Engel et al., 1990; Broeders et 
al., 2004) are most likely to have problems achieving sufficient turbulent energy 
inside a DPI due to them only being able to use slow flows. Therefore, the choice of 
an appropriate dry powder inhaler for particular patients should be based on the 
objective measurements of their PIF against a certain resistance (Janssens et al., 
2008).  
For each DPI there will be a minimum turbulent energy threshold for sufficient de-
aggregation to occur during an inhalation (Laube et al, 2011). From this viewpoint, 
more attention needs to be directed to the minimum acceptable PIF achieved through 
each DPI rather than to the optimal PIF of each device. Also it has been suggested 
that the initial acceleration rate during an inhalation in a DPI is more important than 
PIF in the generation of the fine particle dose (Everard et al., 1997; Kamin et al., 
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2002). Similarly, inhaled volume is also considered as an important parameter of the 
inhalation profile and can govern the quality of the emitted dose (Kamin et al., 2002) 
particularly in a capsule formulation (Chrystyn, 2009; Alaboud et al., 2010) because 
of the needed to empty the capsule.  
There is very little data of the turbulent energy (measured as a pressure change), 
inhalation volume and the acceleration rate when patients routinely use DPIs. A 
method has been designed to measure inhalation parameter of patients when they use 
different DPIs.  
6.2 Aim and Objectives 
6.2.1 Aim 
The main aim of this study was to identify the inhalation characteristics of different 
groups of patients (children with asthma, asthmatic adults and COPD patients) when 
they inhaled through different DPIs (Aerolizer, Accuhaler, Novolizer, Spiromax, 
Turbuhaler, Clickhaler, Easyhaler and Handihaler  
6.2.2 Objectives 
The primary objectives were to measure inhalation flow profiles when patients 
inhale through different DPIs. From these profiles the inhalation parameters can be 
obtained. 
The secondary objectives were to obtain each patient‟s demographic features and 
measure their spirometry as well as the level of their disease control. Also to 
investigate if there are any correlations of these to the inhalation parameters 
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6.3 Method 
6.3.1 Study Population 
This was a randomised, open label study completed during one visit. 
6.3.1.1 Patient Recruitment 
Asthmatic adults /children and COPD patients attending an outpatient appointment 
and receiving regular care at the respiratory clinic (see below for the list of hospitals 
involved) and fulfilling the protocol‟s patient definition criteria were invited to take 
part in this research study. For children their parent / carer were included in the 
invitation. The study objectives and procedures were explained to the patients using 
the participant information sheets [APPENDIX A-1, A-2, and A-3 (refer to the 
enclosed DVD)]. After their agreement to take part in the study, a signed informed 
consent form [APPENDIX A- 5 (refer to the enclosed DVD)] was obtained prior to 
performing any protocol related procedures. This study was designed to be 
completed during one visit. 
The NHS Teaching Hospitals involved were: 
 Leeds General Infirmary (LGI), Leeds. 
 St. Luke‟s Bradford Hospital. 
 Bradford Royal Infirmary Hospital, Bradford. 
 Airedale General Hospital, Steeton. 
This study was approved by the NRES Committee Yorkshire and the Humber - 
Bradford and the Research and Development Department within each of the 
involved NHS Hospitals (refer to the enclosed DVD [APPENDIX]) 
6.3.1.2 Patients 
(a) Inclusion criteria 
 Male or female, with stable asthma or COPD 
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 Prescribed a DPI. 
 Groups: 
 Child with asthma (CHILD): 5-18 years 
  Adult asthmatic (ADULT): 18-55 years 
  COPD patients ( > 55years) 
 Signed informed consent form 
(b) Exclusion Criteria 
 Prescribed inhaled medication for less than 4 weeks prior to enrolment. 
 Other pulmonary diseases (e.g. CF, TB, pneumonia) 
 An acute exacerbation of asthma or COPD or a short course of high dose oral 
prednisone during the last 2 weeks. 
 Pregnant 
 Participation in another clinical research study in the 3 months prior to enrolment. 
6.3.2 Study design 
A Micro-Loop Spirometer (Cardinal Health, UK) was modified so that adapters 
could be fitted onto the air inlet end of the spirometer. For each DPI a specially 
designed adapter was used to ensure airtight seals between the adapter and the 
spirometer inlet as well as the adapter and the empty DPI. Inhalation flow profiles 
were measured by asking patients to make their normal (real life) DPI inhalation 
through the spirometer mouthpiece fitted with the adapter and the DPI. To obtain the 
inhalation parameters the spirometer was operated in the flow volume mode and only 
the inhalation phase was used. To obtain complete data from each inhalation flow 
profile the data of each inhalation was transported into Microsoft Access for data 
analysis. Flow rates were converted into pressure changes using the resistance of the 
DPI. 
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Each patient‟s age, gender, height and weight were recorded together with their 
medication. Their spirometry (PEF, FEV1 and FVC) was measured using a 
ONEFLOW Spirometer (Clement Clark International). The patients were asked to 
inhale through the mouthpiece of the Micro-Loop with the empty DPI fitted onto the 
air inlet of the spirometer. They were informed to make each inhalation as if they 
were using their DPI. 
The empty DPIs used were: 
 Accuhaler (GlaxoSmithKline, UK) – ACC 
 Aerolizer (Novartis, Switzerland) – AERO 
 Clickhaler (UCB Pharma, UK) – CLICK 
 Easyhaler (Orion Pharma, Finland)- EASY 
 Handihaler (Boehringer Ingelheim, GmbH) – HANDI 
 Novolizer (Meda, Sweden) – NOVO 
 Spiromax (Teva Pharmaceuticals, Israel) – SPIRO 
 Turbuhaler (AstraZeneca, Sweden) - TBH 
The order of inhalation through each different device was randomised. Each patient 
made three separate inhalations manoeuvres through each DPI. On every occasion 
they were reminded to mimic their normal inhalation manoeuvre when they used 
their DPI. The inhalation profile with the highest PIF through each device was 
chosen for data analysis. The Handihaler was only included for ADULT and COPD 
patients. 
Each patient was given a 5 minute break between each series of inhalations through 
each different device. 
Patients also completed a questionnaire: 
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 ADULT: Asthma Control questionnaire (ACQ – Juniper et al 1999b) see 
[APPENDIX 6] and Juniper Asthma Quality of Life - mini version (AQLQ) – see 
[APPENDIX 7] (Juniper et al., 1999a). 
 CHILD: Paediatric Quality of Life – PAQL (Juniper et al., 1996a) and the 
Paediatric Asthma Caregivers Quality of Life – PACQLQ (Juniper et al.,1996b). 
[APPENDIX 8and 9]. 
  St George‟s Respiratory questionnaire (SGRQ) -see [APPENDIX [10] (Jones et 
al., 1992). 
6.3.3 Inhalation parameters 
Table 6. 1.The resistance of the DPIs in (kPa)
0.5
(min l
-1
). 
The resistance of the DPIs in (kPa)
0.5
(min l
-1
) 
 Aerolizer (AERO) 0.0207 
 Accuhaler (ACC) 0.0249 
 Novolizer (NOVO) 0.0254 
 Spiromax (SPIRO) 0.0313 
 Turbuhaler (TBH) 0.0335 
 Clickhaler (CLICK) 0.0394 
 Easyhaler (EASY) 0.0485 
 Handihaler (HANDI) 0.0495 
 
These resistance values were used to convert inhalation flows into the respective 
pressure change. 
Primary parameters: 
 Peak inhalation flow (PIF) in L/min. 
 Maximum pressure change (∆P) in kPa. 
 Time to peak inhalation flow (Tp) in seconds. 
 Time to 90% of the peak inhalation flow (Tp90) in seconds. 
 Inhaled volume at Tp90 (IV90) in litres. 
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 The acceleration rate (Acc) in kPa/sec. 
 Inhalation volume (IV) in litres. 
 Duration of the inhalation (Ti) in seconds. 
Secondary parameters 
 Inhalation flow when 150 ml had been inhaled (IF150) in L/min. 
 Time when 150 ml had been inhaled (T150) in seconds 
6.3.4 Data Analysis 
The statistical analysis of the study was carried out using the Statistical Package for 
Social Sciences (SPSS 17) software. The study data was first classified into scale, 
categorical (nominal) or ordinal categories, as appropriate, and an SPSS dataset was 
then set up for the analysis. The statistical analysis was performed and presented as 
follows 
 Descriptive statistics: mean and standard deviation. 
 For scale data; normal distribution of the data was examined using histograms 
and statistical  tests for normality; the Kolmogorov-Smirnov and Shapiro-Wilk 
tests 
 Comparisons (differences) of measurements through different inhalers within 
the same group  were performed using the related (paired)-samples t-test (for 
parametric data) and the Wilcoxon test (for non-parametric data) 
 Comparisons (differences) of measurements between different the groups were 
performed using the independent-samples t-test (for parametric data) and the 
Mann-Whitney U test (for non-parametric data). 
 Scatter plots between the inhalation volume and the pressure change (∆P) were 
made for each device  
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 For the Turbuhaler correlations were determined between the PIF when 150ml 
had been inhaled and the PIF as well as the PIF90. These correlations were made 
for each group using the Spearman‟s rho test. 
6.4 Results  
6.4.1 Patients 
A summary of the patients‟ demographic data, lung function (presented as FEV1% 
predicted) and disease severity classification according to GINA 2008 and COPD 
according to NICE 2010 is presented in Table 6.1. Details of the demographic data 
for each individual are presented in APPENDIX B-15, B-16, B-17 (refer to the 
enclosed DVD). 
Table 6.2. Patient details. All values are mean (SD) unless indicated otherwise. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHILD ADULT COPD 
Number (n) 16 53 29 
Sex [M/F] (n) 13/3 11/42 15/14 
Ag in years 8.8 (3.08) 48.7(16.02) 64.6(11.2) 
Height in cm 132.8(20) 165.703 168.4(10.1) 
Weight in Kg 34.8(16.2) 75.4(16.8) 78.0(12.5) 
FEV1 in Litres 1.34(0.67) 2.01(0.6) 1.25(0.8) 
FEV1 % predicted 78.5 (19.5) 72.0(17) 41.5(16.1) 
PEF in L/min 182.8(84.7) 301(115.0) 173.3(89.7) 
PEF % predicted 65.1(21.57) 71.8(24) 44.9(18.5) 
FVC in Litres 1.58(0.73) 2.5(0.8) 2.02(0.6) 
Disease 
severity 
(n) 
Mild 8 17 12 
Moderate 5 22 10 
Severe 3 14 7 
Very severe N/A N/A 0 
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6.4.2 Inhalation characteristics 
The inhalation parameters of the patients are summarised in Table 6.2 
6.4.2.1 Comparison of the Inhalation Profiles through the different DPIs- Child 
with asthma  
The distributions of the inhalation parameters for the different devices are shown in 
Figure 6.1- 6.6. Relationships between the inhaled volume and the pressure drop 
(turbulent energy) at the time of the PIF are presented in Figure 6.7. 
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Table 6.3. Mean (SD) inhalation parameters of the patients when they inhaled through different DPIs. 
 PIF (l/min) ∆P (kPa) Tp (sec) Tp90 (sec) IV(90) (L) Acc(kPa/sec) IV (L) Ti (sec) IF150(L/min) T150(sec) 
CHILD 
AERO 71.4(21.5) 2.36(1.32) 0.40(0.12) 0.36(0.11) 0.195(0.07) 7.19(6.27) 1.222(0.68) 1.69(0.38) 62.4(22.0) 0.33(0.10) 
ACC 53.3(24.2) 2.10(1.70) 0.49(0.19) 0.44(0.17) 0.214(0.11) 5.36(5.52) 1.191(0.76) 1.50(0.46) 50.5(20.3) 0.42(0.22) 
NOVO 59.1(22.3) 2.55(1.82) 0.53(0.22) 0.48(0.20) 0.212(0.12) 4.96(3.92) 1.116(0.77) 1.86(0.72) 48.5(15.1) 0.46(0.20) 
TBH 44.8(15.9) 2.55(1.78) 0.45(0.20) 0.41(0.18) 0.125(0.04) 6.71(5.91) 1.011(0.73) 1.52(0.17) 41.9(15.5) 0.48(0.19) 
CLICK 46.3(13.2) 3.57(1.85) 0.49(0.17) 0.44(0.59) 0.168(0.06) 14.83(17.49) 1.047(0.75) 1.59(0.33) 50.9(20.8) 0.47(0.20) 
EASY 45.5(13.2) 5.26(2.89) 0.52(0.18) 0.47(0.16) 0.161(0.06) 11.67(9.38) 1.00(0.46) 1.62(0.23) 42.4(12.7) 0.47(0.17) 
ADULT 
AERO 93.7(25.9) 4.04(2.2) 0.33(0.12) 0.29(0.12) 0.236(0.21) 12.60(9.80) 1.964(0.8) 1.53(0.3) 82.7(21.6) 0.24(0.09) 
ACC 76.4(23.8) 3.95(2.38) 0.41(0.25) 0.37(0.22) 0.243(0.17) 11.00(8.75) 1.910(0.73) 1.60(0.56) 73.9(24.2) 0.27(0.09) 
NOVO 80.2(22.3) 4.64(2.30) 0.37(0.14) 0.33(0.13) 0.196(0.01) 12.84(8.34) 1.861(0.74) 1.59(0.33) 68.2(20.3) 0.33(0.21) 
SPIRO 71.9(19.7) 5.44(2.92) 0.43(0.22) 0.39(0.20) 0.210(0.11) 14.10(10.16) 1.77(0.78) 1.58(0.31) 64.9(22.8) 0.35(0.17) 
TBH 60.3(16.9) 4.45(2.38) 0.40(0.13) 0.36(0.12) 0.158(0.06) 13.12(13.01) 1.627(0.74) 1.65(0.46) 53.5(16.2) 0.37(0.09) 
CLICK 63.2(15.7) 6.57(3.06) 0.40(0.19) 0.36(0.17) 0.175(0.08) 19.58(16.68) 1.677(0.76) 1.61(0.47) 60.0(18.3) 0.43(0.61) 
EASY 58.3(14.4) 8.48(4.12) 0.42(0.16) 0.38(0.14) 0.168(0.07) 20.84(15.03) 1.683(0.81) 1.55(0.46) 55.2(12.9) 0.39(0.11) 
HANDI 58.6(11.4) 8.72(3.33) 0.44(0.18) 0.40(0.17) 0.193(0.11) 20.91(12.60) 1.720(0.76) 1.56(0.31) 58.7(13.2) 0.34(0.08) 
COPD 
AERO 81.7(25.4) 3.13(1.88) 0.43(0.27) 0.39(0.25) 0.229(0.15) 8.68(6.78) 1.706(0.82) 1.71(0.45) 66.9(20.2) 0.31(0.12) 
ACC 62.1(22.3) 2.68(1.78) 0.45(0.23) 0.41(0.21) 0.195(0.15) 6.62(7.28) 1.789(0.87) 1.53(0.24) 60.3(20.6) 0.44(0.65) 
NOVO 61.0(14.9) 2.53(1.25) 0.42(0.24) 0.37(0.21) 0.169(0.77) 6.90(5.45) 1.616(0.77) 1.61(0.45) 58.5(16.0) 0.35(0.11) 
SPIRO 56.2(15.5) 3.32(1.77) 0.42(0.19) 0.37(0.17) 0.147(0.05) 9.18(6.64) 1.609(0.77) 1.60(0.77) 56.9(18.4) 0.38(0.15) 
TBH 50.9(15.3) 3.19(1.94) 0.44(0.20) 0.39(0.18) 0.143(0.15) 9.55(7.47) 1.502(0.79) 1.56(0.19) 47.2(14.1) 0.48(0.20) 
CLICK 51.1(15.5) 4.40(2.54) 0.48(0.18) 0.43(0.16) 0.159(0.07) 10.43(9.35) 1.483(0.73) 1.63(0.29) 48.9(15.4) 0.43(0.15) 
EASY 49.5(15.0) 6.28(3.54) 0.45(0.14) 0.41(0.13) 0.150(0.01) 14.00(9.10) 1.520(0.80) 1.67(0.59) 45.1(11.8) 0.45(0.14) 
HANDI 53.4(15.7) 7.59(4.40) 0.42(0.16) 0.38(0.14) 0.150(0.01) 20.90(12.6) 1.55(0.82) 1.64(0.63) 58.8(13.2) 0.41(0.09) 
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Comparison of the Inhalation Profiles through the different DPIs – Children with 
asthma 
 
Figure 6.1. The range of peak inhalation flows achieved by the asthmatic children 
when they inhaled through the different DPIs. 
 
Figure 6.2. The range of the pressure change (∆P) inside each DPI during the 
inhalations by the asthmatic children. 
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Figure 6.3. The range of the times to PIF for the children with asthma when they 
inhaled through the different DPIs. 
 
Figure 6.4. The range of the acceleration rates achieved by the children with asthma 
when they inhaled through the different DPIs. 
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Figure 6.5. The range of the inhaled volumes for the children with asthma when they 
inhaled through the different DPIs. 
 
Figure 6.6. The range of the inhalation times for the children with asthma when they 
inhaled through the different DPIs. 
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Figure 6.7. Scatter plots between inhaled volume and maximum pressure changes for 
each of the children with asthma when they inhaled through a) Aerolizer b) 
Accuhaler) Novolizer d) Turbuhaler, e) Clickhaler, f) Easyhaler. 
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6.4.2.2. Comparison of the Inhalation Profiles through the different DPIs – 
COPD 
The distribution of the individual inhalation parameters of the COPD patients is 
presented in Figure 6.8- 6.13. Individual relationship between each patient‟s inhaled 
volume and the maximum pressure change is shown in Figure 6.14. 
 
 
Figure 6.8. The distribution of the peak inhalation flows of the COPD patients when 
they inhaled through the different DPIs. 
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Figure 6.9. The range of the maximum pressure changes that occurred inside each 
DPI during the inhalations by the COPD patients 
 
Figure 6.10. The range for the times at PIF achieved by the COPD patients when 
they inhaled through the different DPIs 
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Figure 6.11. The distribution of the acceleration rate achieved by the COPD patients 
when they inhaled through the different DPIs 
 
 
Figure 6.12. The distribution of the inhaled volumes achieved by the COPD patients 
when they inhaled through the different DPIs 
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Figure 6.13. The range for the distribution of the duration of the inhalations by the  
COPD patients when they inhaled through the different DPIs 
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Figure 6.14. Scatter plots between the inhaled volume and maximum pressure change for each COPD patient when they inhaled through, a) 
Aerolizer, b) Accuhaler, c) Novolizer, d) Spiromax, e) Turbuhaler, f) Clickhaler, g) Easyhaler , h) Handihaler. 
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6.4.2.3. Comparison of the Inhalation Profiles through the different DPIs – 
Asthmatic Adults 
The distribution of the individual inhalation parameters of each adult with asthma are 
presented in Figure 6.15 - 6.20. The relationship between the inhaled volume and the 
maximum pressure change (∆P) is shown in Figure 6.21. 
 
Figure 6.15. The range of peak inhalation flows achieved by the adults with asthma 
when they inhaled through the different DPIs. 
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Figure 6.16. The distribution of the maximum pressure change (∆P) inside each DPI 
during the inhalation by each adult with asthma 
 
 
Figure 6.17. The distribution of the time at the occurrence of the PIF when adults 
with asthma inhaled through the different DPIs 
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Figure 6.18. The range of acceleration rates (kPa/sec) achieved by the adults with 
asthma when they inhaled through the different DPIs. 
 
 
 
Figure 6.19. The distribution of the inhaled volumes achieved by the adults with 
asthma when they inhaled through the different DPIs 
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Figure 6.20. The range of inhalation times for the adults with asthma when they 
inhaled through the different DPIs. 
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Figure 6.21. Scatter plots between the inhaled volume and maximum pressure change for each adult with asthma through a) Aerolizer, b) 
Accuhaler, c) Novolizer, d) Spiromax, e) Turbuhaler, f) Clickhaler, g) Easyhaler, h) Handihaler. 
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6.4.2.5. Subjects with low PIF and >90 l/min 
Table 6.3. Shows the number of the patients that achieved PIF values of < 30 L/min, 
> 60 L/min and > 90 L/min through each the DPI 
Table 6.4. The number of patients achieving different flows through each DPI. 
 
CHILD 
PIF(L/min) 
ADULTS 
PIF (L/min) 
COPD  
PIF(L/min) 
 <30 >60 >90 <30 >60 >90 <30 >60 >90 
AERO Nil 11 4 Nil 50 25 1 9 Nil 
ACC 3 7 1 Nil 33 19 3 12 6 
NOVO 1 8 1 Nil 39 22 Nil 13 1 
SPIRO N/A N/A N/A Nil 34 12 1 9 1 
TBH 2 3 Nil Nil 23 1 2 6 Nil 
CLICK 2 3 Nil Nil 32 1 2 8 Nil 
EASY 1 3 Nil Nil 22 Nil 2 5 Nil 
HANDI N/A N/A N/A Nil 21 Nil 1 7 Nil 
 
6.4.2.6 Comparison of inhalation flow parameters for the Turbuhaler 
Figure 6.22-6.24 show the relationship between inhalation flows (at 90% of the PIF 
and the PIF) to the inhalation flow when 150 ml had been inhaled through the 
Turbuhaler by the children with asthma, COPD patients and Adults with asthma 
respectively. Statistical comparison of PIF90% to the inhalation flow when 150 ml had 
been inhaled revealed no significant difference. 
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Figure 6.22. The relationship between the inhalation flows and the flow when 
IV=150 ml through a Turbuhaler by the children with asthma. 
 
Figure 6.23. The relationship between the inhalation flows and the flow when 
IV=150 ml through a Turbuhaler by the COPD patients. 
 
Figure 6.24. The relationship between the inhalation flows and the flow when 
IV=150 ml through a Turbuhaler by the adults with asthma.
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6.4.2.5 Statistical analysis  
A summary of the statistical comparisons between the Aerolizer, Accuhaler, 
Turbuhaler, and Easyhaler within each group is presented in Table 6.4. The non- 
parametric test (Wilcoxon signed rank test) was used for the comparison  
Table 6.5. Statistical summary (values are p value).  
 AERO 
v‟s ACC 
TBH v‟s 
ACC 
EASY‟vs 
ACC 
TBH v‟s 
AERO 
TURB v‟s 
EASY 
AER v‟s 
EASY 
PIF 
CHILD 0.004 0.011 0.00 0.00 0.00 0.469 
ADULTs 0.000 0.000 0.000 0.001 0.11 0.000 
COPD 0.002 0.000 0.000 0.034 0.117 0.010 
∆P (kPa) 
CHILD 0.196 0.026 0.001 0.535 0.000 0.000 
ADULTs 0.158 0.012 0.00 0.784 0.000 0.000 
COPD 0.002 0.000 0.005 0.000 0.000 0.000 
IV 
CHILD 0.408 0.004 0.070 0.011 0.148 0.015 
ADULTs 0.487 0.000 0.000 0.000 0.95 0.000 
COPD 0.15 0.117 0.10 0.171 0.804 0.459 
ACC  
CHILD 0.379 0.26 0.001 0.011 0.000 0.00 
ADULTs 0.112 0.378 0.000 0.383 0.00 0.00 
COPD 0.033 0.014 0.000 0.787 0.000 0.00 
Inhalation Time 
CHILD 0.202 0.325 0.248 0.100 0.231 0.569 
ADULTs 0.921 0.511 0.719 0.177 0.225 0.980 
COPD 0.202 0.325 0.248 0.569 0.231 0.569 
Time at PIF 
CHILD 0.001 0.469 0.115 0.001 0.187 0.001 
ADULTs 0.05 0.713 0.136 0.006 0.840 0.000 
COPD 0.888 0.161 0.191 0.473 0.770 0.232 
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Quality of Life Questionnaires 
(a) Children with asthma 
The mean (SD) PAQLQ scores (overall and its three domains: symptoms, Activity 
Limitation and Emotional Function) and the PACQLQ scores are presented in Table 
6.5.  
Table 6.6. Mean (SD) PACQLQ and PAQLQ scores. 
PACQLQ  
PCAQLQ  4.33(1.1) 
PAQLQ Domains 
Overall PAQLQ 4.7(1.19) 
Symptoms 3.7(1.1) 
Activity Limitation 4.5(1.4) 
Emotional Function 5.1(1.1) 
 
(b) Adults with asthma 
A summary of the ACQ and AQLQ scores (overall and its three domains: symptoms, 
activity limitation, emotional and environment) are presented in Table 6.6. Table 6.7 
presents the level of asthma control with respect to the ACQ.  
Table 6.7. Mean (SD) scores of (ACQ) and AQLQ for asthmatic Adults.  
 Mean(SD)Scores Minimum Maximum 
ACQ 1.95(1.02) 0.29 4.5 
AQLQ  4.6(1.2) 2.0 6.5 
Symptom 3.6(1.6) 1.4 5.7 
Activity 3.8 (1.3) 0.81 5.7 
Emotional 3.2(1.2) 0.9 5.5 
Environment 3.4(1.16) 1.1 5.4 
 
Table 6.8. Level of asthma control. 
Asthmatic Adults 
(n= 53) 
ACQ Categories Frequencies 
≤ 0.75 (well controlled) 4(7.5%) 
0.75-1.50 (not well controlled) 19(35.8%) 
≥ 1.50( uncontrolled) 30(56.6%) 
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(c) COPD patients 
Summaries of the SGRQ scores (overall and its three domains: Symptoms, Activity 
and Impacts) are presented in Table 6.8. 
Table 6.9. The SGRQ scores of the COPD Patients.  
SGRQ 
Domains(n=29) 
Symptoms 
score 
Activity 
score 
Impacts 
score 
Total  
score 
Mean (SD) 70.27(24.2) 73.68(19.53) 50.20(21.6) 60.66(18.5) 
Median 75.55 76.10 52.40 62.10 
Minimum 19.90 26.50 8.60 25.30 
Maximum 104.50 100.00 85.90 84.20 
Percentiles 25 58.350 60.75 34.72 43.55 
50 75.55 76.10 52.40 62.10 
75 90.070 91.20 69.475 78.35 
*SGRQ scores ranges from 0 to 100, zero scores indicate no impairment, with higher scores 
indicating worse health status 
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6.5 Discussion 
The inhalation characteristics of children with asthma, asthmatic adults and COPD 
patients when they inhaled through different dry powder inhalers, that differ by their 
resistance, that ranging from low to high, have been measured. For these 
measurements patients were informed that they should use the same inhalation 
manoeuvre as they would if they were using a DPI.  
The data is a substantial addition to the limited information that is available 
describing the inhalation parameters of patients when they use DPIs. The only data, 
of this type, that is available is for the Accuhaler and the Turbuhaler and there is no 
emphasis on the pressure changes that occur in the inhalation channel, of the DPI, 
during an inhalation and the acceleration rate with respect to a pressure change per 
time. 
The inhalation parameters that have been measured are the peak inhalation flow and 
when this occurs, the inhalation volume, the pressure change (otherwise referred to 
as the turbulent energy) that occurs at the point of the PIF and the acceleration of the 
flow (in kPa/sec). These latter three parameters allow a true comparison to be made 
between different DPIs rather than PIF. Due to differences in resistance between 
DPIs when using the PIF the only comparison that can be made between devices is 
that if the resistance is low then flows will be faster than when the resistance is high 
(Clark & Hollingworth, 1993).  
The PIF, pressure changes and the acceleration rate results obtained for all three 
groups confirm this. The results also confirm that as expected children with asthma 
generate significantly lower PIF values than COPD subjects and both these are lower 
than the rates achieved by adults with asthma. This is due to their reduced inspiratory 
effort. It has been suggested that a failure to achieve an inhalation flow of 30 L/min 
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within the first 150 ml of the inhalation affects de-aggregation(Everard et al., 1997) 
and thus inhalation characteristics about the first 150ml of the inhaled volume were 
obtained. 
Traditionally PIF has been the focus of attention when patients use DPIs. However 
this is only useful when considering the flows through each DPI (Azouz and 
Chrystyn, 2012).  
This review (Azouz & Chrystyn, 2012) was written after examining the results 
presented in this Chapter.  The statistical analysis (in table 6.4) reveals that the peak 
inhalation flows, as expected, were very significantly faster when using a low 
resistance DPI (eg. Aerolizer and Accuhaler) than a high resistance device 
(Easyhaler and Handihaler). During routine practice this is the parameter that is 
usually used as the indicator if a patient can use their DPI with a fast inhalation. In 
contrast the pressure changes (which represent the turbulent energy) are (very highly) 
significantly greater for the high resistance devices. The acceleration rates mirror the 
pressure change results.  De-aggregation occurs due to the turbulent energy created 
in the inhalation channel, of a DPI, during an inhalation.  It is wrong therefore to 
recommend a low resistance DPI if the measured inhalation flows are slow when 
using a high resistance inhaler. This is a common misconception amongst 
practitioners. 
All DPIs have flow dependent dose emission and some more than others (Palander et 
al, 2000) but even with relatively low flows they do emitted some dose. A more 
important issue is that for each DPI there will be a minimum threshold turbulent 
energy (corresponding to a measured pressure change) for efficient de-aggregation of 
the dose. It has been shown that below 30L/min the turbulent energy generated inside 
a Turbuhaler is not sufficient to efficiently de-aggregate the dose (Nadarassan et al., 
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2010) and that the clinical effect sharply decreases (Pedersen et al, 1980). This flow 
corresponds to a maximum pressure change of 1.02 kPa in a Turbuhaler. This flow is 
also considered to be the minimum for the Accuhaler (Nielsen et al., 1998) whilst 
that for the Clickhaler (Newhouse et al., 1999) and Easyhaler (Koskela et al., 2000) 
are slightly lower. Nevertheless taking 30L/min as the gold standard for the 
minimum flow the results show that when patients use their normal real life 
inhalation technique then no adult asthmatic inhaled below this flow. Three COPD 
inhaled below this flow with an Accuhaler and of these only two of them achieved 
low flows with the Turbuhaler, Clickhaler and an Easyhaler. Three of the 16 children 
with asthma did not achieve 30L/min through the Accuhaler. These were all boys 
aged 5, 7 and 12 years old. The 5 and 12 year old did not achieve this flow through 
the Turbuhaler but there were 4 others with flows of either 31 or 32 L/min. The same 
2 children failed to achieve 30L/min with the Clickhaler but only one of them (the 12 
year old) with the Easyhaler. 
Overall the percentage of numbers exceeding the recognised minimum flow of 
30L/min flow with the Turbuhaler is higher than values previously reported. Nsour et 
al (2001) reported 14 out of 74 COPD patients had problems achieving this flow and 
their predicted FEV1 was similar to the patients in this study. Also another COPD 
study has shown that 23/163 patients inhaled < 30L/min (Al-Showair et al, 2007). In 
contrast others have shown no patients inhaled below this rate (Dewar et al., 1999; 
Broeders et al., 2003a). In children with asthma 25 out of 72 did not achieve this 
recognised minimum flow with the Turbuhaler and were mostly 3 or 4 years old 
(Agertoft & Pedersen, 1998) which confirmed previous results about pre-school 
children using a Turbuhaler (Pedersen et al, 1990). No child in this study was aged < 
5 years. Previously it was reported that 5 out of 24 adults asthmatics did not achieve 
  
241 
 
30L/min with a Turbuhaler (Hawksworth et al., 2000). These patients did have more 
severe asthma (57% predicted FEV1 compared to 71.9% in this study). However in 
20 severe asthmatics that were highly trained no patient inhaled used low flows 
(Tarsin et al, 2006). Previously, when using an Accuhaler no COPD patient 
(Broeders et al, 2003; Al-Showair et al, 2007) achieved < 30L/min with only 2 out of 
129 children (a 5 and a 10 year old) not obtaining this flow (Nielsen et al, 1998). 
When using the Easyhaler 4 children (aged 4, 6, 10 and 16 years) failed to achieve 
30L/min (Malmstrom et al, 1999) but their response to the bronchodilator was 
similar to when they inhaled using a pMDI attached to a Volumatic spacer 
(Malmstrom et al, 1999). Furthermore only 2 out of 93 COPD subjects achieved 
these low flows through an Easyhaler (Malmberg et al, 2010). 
Although only one of the 29 COPD subjects in this study did not exceed 30 L/min 
with the Handihaler others have shown a third of the patients did not produce flows 
above this rate (Al-Showair et al, 2007). The Aerolizer has low resistance and so the 
minimum flow for efficient de-aggregation will be faster. It has been reported that 
this flow could be > 90L/min (Nielsen et al., 1997). Only 4 children with asthma, 25 
adults with asthma and no COPD patients inhaled > 90L/min through the Aerolizer. 
In contrast 73% of adults asthmatics (n=33) inhaled >100L/min and 75% (n=32) 
children with asthma inhaled >80L/min (Bronsky et al., 2004). This together with the 
Accuhaler data suggests that it could be low resistance inhalers that patients have 
problems with respect to efficient de-aggregation. Also when the flow is fast there 
will be a tendency for more oropharynegeal deposition and deposition more towards 
the central zones of the lungs (Newman et al, 1995; Usmani et al, 2005). When using 
a DPI this is counter balanced by the DPI‟s flow dependent dose emission especially 
when it is pronounced. However dose emission form an Aerolizer (Weuthen et al., 
  
242 
 
2002) and an Accuhaler (Palander et al.,2000) is less flow dependent. Hence the low 
resistance of these devices together with the resultant fast inhalation flows will tend 
to provide low lung deposition and high oropharyngeal impaction. Reduced 
peripheral lung deposition has been reported when adult asthmatics and healthy 
volunteers inhaled salbutamol from unit dose blisters in a DPI compared to a pMDI. 
(Melchor et al., 1993). It has been shown that when using a Turbuhaler, that has 
pronounced flow dependent dose emission (Palander et al., 2000) that there is no 
change in the peripheral: central lung deposition ratio when using faster flows 
(Newman et al., 1991b; Borgstrom et al., 1994). It has been reported that high 
resistance DPIs do provide greater lung deposition than those with a lower resistance 
(Borgstrom, 2001). 
The maximum pressure change (∆P) and the acceleration rate of an inhalation (when 
in kPa/sec) allow a comparison between different DPIs whereas the PIF does not.  
PIF values are only valid when considering each DPI in isolation. The maximum 
inhalation flows through the Accuhaler in this study were lower than those 
previously reported in adults with asthma (Broeders et al, 2003; Tarsin et al, 2006).  
In the COPD patients these flows were also lower to previous reports (Broeders et al, 
2003) but one study reported similar flows through an Accuhaler (Al-Showair et al, 
2007).  When using the Turbuhaler the PIF values were similar to other studies 
involving children (Pedersen et al, 1990; Agertoft & Pedersen, 1998) but lower than 
another (Stahl et al, 1996). The flows of adult asthmatics using a Turbuhaler, in this 
study, were faster than those attending a community pharmacy (Hawksworth et al, 
2000) but lower than highly trained severe asthmatics (Tarsin et al, 2006) and 
untrained mild asthmatics (Broeders et al, 2003) but similar to those with an acute 
exacerbation of asthma (Brown et al, 1995). In COPD patients although the PIF 
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through the Turbuhaler in this study were lower than mild, moderate and severe 
COPD patients in one study (Broeders et al, 2003) overall they were similar to others 
(Dewar et al, 1999; Al-Showair et al, 2007; Derom et al., 2007). 
In contrast to PIF values the pressure changes (hence the turbulent energy) that 
occurs inside each DPI during an inhalation allows a comparison to be made between 
different devices. The results show that the pressure changes were greater for the 
DPIs with a higher resistance than those with a lower flow. Figures 6.2, 6.9, 6.16 for 
the children with asthma, adults with asthma and the COPD data, respectively, show 
that when the resistance is low to medium high there is little difference between the 
inhalers and that for high resistance inhalers the pressure changes are much greater. 
This is due to the non linear relationship between this pressure change with flow and 
the resistance as reported by Clark and Hollingworth (1993) and later by Clark 
(1994). Previously these maximum pressure changes (∆P) have not been reported. 
The acceleration of the flow has been shown to be critical for de-aggregation of the 
formulation in a DPI (de Boer et al, 1997; Everard et al, 1997; Kamin et al, 2002). It 
has been shown that achieving a flow of >30L/min before the first 150ml has been 
inhaled through a Turbuhaler is important for the de-aggregation of the formulation 
in a Turbuhaler. The very strong relationships in Figures 6.22, 6.23, 6.24 show that 
the inhalation flow at 90% of the PIF (PIF90) correlates to that of the inhalation flow 
when 150 ml had been inhaled. The time that this flow occurs also correlates to the 
time for 150 ml to be inhaled. The inhalation flow at 90% of PIF and when this 
occurred was therefore used to calculate the acceleration of the inhalation flow. 
Although there is also a strong correlation between the PIF and the inhalation flow 
when 150 ml occurred this was not used for calculating the acceleration flow because 
the individual results showed that for some the time to PIF90 was 0.3 seconds 
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whereas PIF occurred at 0.5 seconds. Use of these would result in a big difference in 
the acceleration rates. Nevertheless when the PIF was fast then the acceleration rates 
were steeper than when the PIF was slow. This agrees with information published by 
Broeders et al (2001). Previously only Broeders et al (2003) has reported acceleration 
rates when asthmatics and COPD patients inhaled through an Accuhaler and a 
Turbuhaler. Overall the acceleration rates of the adults with asthma were similar to 
those reported by Broeders et al (2003) while the COPD rates were lower. The 
results also show that consistent with the inhalation flow and pressure changes that 
occur during the inhalations the acceleration rates were lower in children with 
asthma than COPD patients which were both lower than the adults with asthma. 
The inhaled volume has two functions. First the dose has to be emptied from the 
device and then the airstream delivers the particles into the airways. The inhaled 
volume has to be sufficient for both to occur. Some DPIs require a higher volume to 
empty the dose than others. It has been reported that capsule based DPI inhalers 
require 4L to completely empty their dose (Chrystyn, 2009; Alaboud et al., 2010), 
the Turbuhaler at least 1L (Kamin et al, 2002) and the Accuhaler 150ml (Kamin et al, 
2002). These differences are due to the design of the device. Capsules have to be 
emptied. The inhalation channel in the Turbuhaler is relatively long and includes a 
cyclone whereas the inhalation channel of the Accuhaler is very short (Azouz and 
Chrystyn, 2012). Overall within the groups the inhaled volumes were similar for the 
different devices with a tendency for a slightly larger volume for DPIs with lower 
resistance. Also as expected inhaled volumes were lower in the children with asthma 
than the COPD patients and both these were lower than the adults with asthma. 
When using the Aerolizer only one child inhaled >2L and more than half <1L, 7 
COPD patients inhaled >2L (one > 4L) and 5 < 1L whilst 17 adults with asthma 
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inhaled >2L but no one inhaled > 4L and 7 inhaled < 1L. These values highlight the 
ERS / ISAM Consensus statement recommendation that when using capsule DPIs the 
patients should make two separate inhalation for each dose (Laube et al, 2010). 
However the results show, in this chapter that some patients should use more than 2 
separate inhalations or be prescribed a different dry powder inhaler. Nine of the 
children with asthma inhaled < 1L through the Turbuhaler as well as 7 of the COPD 
patients and 12 of the adult asthmatics which suggests that some importance should 
be placed on the inhaled volume. Overall in COPD (Broeders et al, 2003; Derom et 
al, 2007), asthma (Newman et al, 1991; Broeders et al, 2003; Tarsin et al 2006) and 
healthy volunteer (Farr et al, 1995) studies the volumes they reported were higher 
than those in this study but one study involving adult asthmatics using a Turbuhaler 
in a community pharmacy reported similar volumes (Hawksworth et al, 2000). 
Previously, the patient‟s peak inhalation flow (PIF) through a DPI has been the focus 
of attention but the results of this study suggest that the achieved turbulent flow (∆P), 
the acceleration of the flow (in kPa/sec) and the inhaled volume may be more 
important. The inhalation manoeuvre of these patients was not trained so these values 
should improve with training. The turbulent energy and the acceleration should 
increase when patients are trained to use a fast inhalation and that this forceful 
inhalation should commence immediately whilst the inhaled volume would change 
with the instructions of maintaining the inhalation for as long as possible and also to 
exhale gently before each inhalation. Whether acceleration rates, peak inhalation 
flows and pressure changes improve following technique training is investigated in 
the next Chapter. 
Compendial methods recommend that dose emission and the aerodynamic 
characteristics of the emitted dose should be measured using a pressure change (∆P) 
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of 4 kPa and an inhaled volume of 4L. The scatter plots in figures 6.7, 6.14 and 6.21 
show that most patients do not achieve a pressure drop of 4kPa and an inhalation 
volume of 4L when they use any DPI. Furthermore no individual replicated an 
inhalation profile that was the same as a square wave produced by a vacuum pump. 
These results highlight the need to modify the compendial methodology.  This could 
be achieved by using a computerised vacuum pump to replay an inhalation profile 
instead of using the traditional square inhalation profile currently provided by a 
vacuum pump.  Further adaptations would have to be made to the method to ensure 
sonic flow during the dose emissions and capture of the emitted dose. Preliminary 
work, in this University‟s laboratories, has shown that this is feasible 
Conclusion  
The methodology has provided an insight into the inhalation manoeuvre when 
patients use their DPI. The results indicate that the internal turbulent energy 
(measured by a pressure change) and the acceleration of the patient‟s inhalation 
(measured as a pressure change over time) are greater for high resistance DPIs 
whereas inhalation flows are lower. These results highlight that inhalation flow 
should not be used to compare different DPIs but should only be used as an indicator 
that a patient can achieve the minimum flow required for a DPI. As expected the 
inhalation characteristics of children with asthma were lower than those with adults 
and similar to those of COPD patients. The significance of the inhalation volumes 
needs to be investigated. 
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Chapter 7: Training DPI users to improve their 
inhalation manoeuvre when using a Spiromax 
and a Turbuhaler Dry Powder Inhaler. 
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7.1 Introduction 
All DPIs are passive devices in that a turbulent energy (measured as a pressure 
change) is required to de-aggregate the formulation of the dose that has been 
prepared for inhalation. This energy is generated by an interaction between the 
patient‟s inhalation flow and the resistance of the device (Clark and Hollingworth, 
1993; Steckel and Muller, 1997b; Chrystyn, 2009). In-vitro studies have highlighted 
the flow dependent dose emission characteristics of DPIs (Ross and Schultz, 1996; 
Hill and Slater, 1998; Prime et al., 1999; Palander et al., 2000; Tarsin et al., 2004; 
Tarsin et al., 2006) and that this translates to higher lung deposition with faster flows 
(Newman et al., 1991a; Borgstrom et al., 1994; Newman et al., 2001) and altered 
response (Pedersen and Mortensen, 1990; Engel et al., 1992; Nielsen et al., 1997). 
Training the inhalation manoeuvre of children with asthma (Agertoft & Pedersen, 
1998), adults with asthma (Hawksworth et al, 2000; Broeders et al, 2003) and COPD 
patients (Nsour et al, 2001; Broeders et al, 2003; Al-Showair et al, 2007b) has been 
reported to be useful although the changes in COPD patients were small (AL-
Showair et al, 2007b). The training should include information that the fast 
inhalation should commence immediately from the beginning of an inhalation 
(Laube et al, 2011) because de-aggregation and dose emission occurs in the initial 
phase of the inhalation manoeuvre (de Boer et al., 1997; Everard et al., 1997; Kamin 
et al., 2002). Everard et al (1997) showed that this occurs during the first 150 ml of 
the inhalation. Hence the acceleration of the flow is an important parameter. This is 
explained in Figure 7.1 
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Figure 7.1. Inhalation Flow profiles of two different patients through DPIs (Chrystyn 
and Price, 2009). 
This figure shows two different profiles with the same PIF and superimposed onto 
these is when the dose leaves either a multidose reservoir DPI or a multidose device 
which contains each dose in a separate blister. This figure shows that the acceleration 
of the flow while the dose leaves the DPI is much greater when the fast inhalation 
commences immediately compared to a gradual increase to the PIF. The acceleration 
of the flow can be measured with respect to volume or the turbulent energy. The 
latter, in kPa/sec units, is preferred because it relates to the increase in the pressure 
changes during the initial part of an inhalation and can be used to compare different 
devices.   
In this current research work inhalation pressure profiles before and after training the 
inhalation manoeuvre when using a DPI have been measured. It was decided to use 
two different devices which had a similar resistance to rule out any affect caused by 
the appearance of the DPI.  
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7.2. Aim and objectives  
(a) Aim 
To identify if training the inhalation manoeuvre when subjects inhale through DPIs 
alters the inhalation parameters. 
(b) Objectives 
 Measure inhalation pressure profiles of children with asthma, adults with asthma 
and COPD patients as well as healthy volunteers when they inhale using a 
Spiromax DPI and a Turbuhaler DPI. 
 Train patients to inhale faster through each DPI using the IN-Check Dial 
[ENHANCED TRAINING]. 
 Re -measure the inhalation profiles after the training 
 Compare each inhalation parameter before and after training. 
7.3 Methodology 
This was a randomised, open label, cross-over study using a Spiromax DPI and a 
Turbuhaler DPI. Ethical approval was obtained from the NRES Committee 
Yorkshire and The Humber – Bradford and all subjects gave signed informed 
consent. Ethical committee approval for the healthy volunteers was obtained from 
the School of Applied Sciences Ethical Committee. 
 7.3.1. Study population  
Stable asthmatic (adults and children) and COPD patients attending respiratory out-
patient clinics and receiving regular inhaled therapy were studied. The study 
procedures and measurements were carried out during one visit. In addition healthy 
volunteers were included. These were recruited locally from the University. As far as 
possible these healthy volunteers were matched to those of the adult asthmatics and 
so these were recruited after the entire adult asthmatics had completed the study. 
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The study objectives and procedure were described to the patients and healthy 
subjects using relevant patient information sheets [APPENDIX A1, A2 , A3and A4]. 
Each participant kept a copy of the information sheet and was given as much time as 
they required to consider participating. For the patients attending the clinic they were 
informed that if they wanted to reflect about their decision then they were given a 
contact should they wish to take part. All consultations and recruitment of those < 18 
years was made with them and their parent / carer. After their agreement to 
participate in this study, a signed informed consent form was obtained [APPENDIX 
A-5] (refer to the enclosed DVD). 
On the basis of other studies (Bisgaard et al., 1998; Broeders et al., 2001; Burnell et 
al., 2001; Broeders et al.,2003; Broeders et al., 2004; Vogelberg et al., 2004; Tarsin 
et al., 2006) this study was designed to include 50 asthmatic children, 50 adult 
asthmatics, 50 COPD and 50 healthy volunteers. Hence, 50 x 4 groups of patients 
(total 200 subjects) were recruited into this study.  
The NHS Teaching Hospitals which were involved as research sites were: 
 Airedale General Hospital, Steeton, West Yorkshire, UK. 
 Leeds General Infirmary, Leeds, UK 
  St. James‟s University Hospital, Leeds, UK 
 Bradford Royal Infirmary, Bradford, West Yorkshire, UK 
 St. Luke‟s Hospital, Bradford, West Yorkshire, UK. 
 (a) Inclusion criteria:  
 Male or female, with stable asthma or COPD or healthy volunteer 
 Groups:  
 Children with asthma (CHILD): 4-17 years 
 Adults with asthma (ADULT): 18-45 years 
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 COPD patients (COPD): >55 years 
 Healthy adults (HEALTHY): 18-45 years. 
 Prescribed inhaled medication including a DPI. Healthy adults were inhaler 
naive. 
 Signed informed consent (including the parent/guardian in case of an asthmatic 
child). 
(b) Exclusion criteria:   
 Prescribed inhaled medication for less than 4 weeks prior to enrolment. 
 Limited ability to understand/implement the study procedures and instructions. 
 Other pulmonary diseases (e.g. pneumonia, TB) at study enrolment or any 
other severe conditions that may adversely affect the respiratory system or 
quality of life. 
 An acute asthma or COPD exacerbation or oral prednisolone use during the 4 
weeks prior to enrolment. 
 Patient participating in another clinical research study at the time of or in the 
past 3 months prior to enrolment. 
 Females who were pregnant. 
7.3.2. Study Design 
(a) Baseline assessments  
Subjects attended a single study visit. Age, height and weight were measured and 
baseline lung function recorded by spirometry. For subjects with asthma their asthma 
status was assessed using the Asthma Control Questionnaire (ACQ) (Juniper et al. 
1999; Juniper et al. 2006). The status of the subject‟s COPD was assessed using the 
total dyspnoea scale score [see section (2.2.2.2, Table 2.5)] (Fletcher 1960; Garrod et 
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al. 2006). Details values can be found in Appendix B 46-48 refer to the enclosed 
DVD) 
(b) Initial training 
All subjects in each group (n=50) were randomly assigned to standard training using 
placebo Spiromax or Turbuhaler DPI devices. This consisted of verbal instruction on 
correct usage according to the instructions for use contained in the patient 
information leaflet (PIL) supplied by the manufacturer for both the devices. 
Each subject was required to perform two consecutive inhalation manoeuvres with 
the first DPI device. Subjects then repeated the process with the other DPI device. 
The DPIs were attached to an inhalation pressure profile recorder so that the 
maximum pressure change (∆p), peak inhalation flow (PIF), inhalation volume (IV), 
time to reach the PIF (Tp), the acceleration rate (ACC) and the duration of the 
inhalation could be recorded. For each inhalation manoeuvre through a DPI device, 
the profile with the highest PIF was selected for analysis. 
(c)Inhalation manoeuvre training 
Following the initial inhalation manoeuvres, all subjects received enhanced 
inhalation technique training. An inhalation airflow meter - the IN-Check Dial™ 
(Clement Clark International, UK), set to the resistance of the Turbuhaler, was used 
to improve inhalation technique (Nsour et al. 2001; Chrystyn 2003). Subjects were 
asked to perform inhalation manoeuvres as described above, and were then shown 
their PIF value displayed on the IN-Check Dial™. They were then encouraged to 
inhale faster during a second attempt. This was repeated until each subject had 
increased their PIF by >10 L/min. Following enhanced training, subjects then 
performed two consecutive inhalation manoeuvres through each DPI device (with the 
inhalation profile recorder re-attached) in the same order as before enhanced training 
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but using the faster inhalation technique. As before, the inhalation profile with the 
highest PIF was selected for analysis.  
7.3.3 Inhalation profiles measurements 
Each DPI was adapted so that a small tube was connected between the inhalation 
channel of the device and pressure sensors. The connection was airtight and did not 
interfere with the inhalation manoeuvres. The pressure changes with respect to time 
were electronically downloaded into an EXCEL spreadsheet to compute the 
inhalation parameters. 
The resistance of the Spiromax and the Turbuhaler was 0.0313 and 0.0335 
(kPa)
0.5
(min l
-1
), respectively. 
Pre training inhalation parameters are described as Turbuhaler A [TBH-A] and 
Spiromax A [SPIRO-A] whilst the post training parameters are Turbuhaler B [TBH-
B] and Spiromax B [SPIRO-B].  
7.3.4 Statistical Data Analysis 
The statistical analysis of the data was carried out using the Statistical Package for 
Social Sciences (SPSS for windows, version 17) software. A SPSS dataset was then 
set up and the analysis was performed and presented as follows: 
 Descriptive statics: presented as mean (standard deviation) 
 Normal distribution of the data was examined using histograms and the 
statistical tests for normality: Kolmogorov-Smirnov and Shapiro- Wilk tests  
 Comparisons of measurements within the same study group were performed, 
using the related (paired) - sample- test for parametric data, or the Wilcoxon 
signed rank test for non-parametric data. 
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7.4 Results  
7.4.1 Study population 
A total of 200 patients were recruited and completed this study. A summary of their 
demographic, lung function (presented as FEV1% predicted) and disease severity 
classification is presented in Table 7-1. Individual details of the demographic data 
are presented in APPENDIX B-42.B-43.B-44, B-45 together with their % predicted 
values respectively (refer to the enclosed DVD). A complete summary of their 
inhalation parameters through the Spiromax and Turbuhaler DPIs before and after 
training is presented in Table 7.2. The range of the individual inhalation parameters 
of the children with asthma, before and after training, is presented in Figures 7.2-7.7.  
Table 7.1. Study participant details. All values are mean (SD) unless indicated 
otherwise. 
Characteristics 
Asthmatic 
Children 
Asthmatic 
Adults 
COPD 
Healthy 
Subjects 
Number (n) 50  50 50 50 
Sex [M/F] (n) 28/22 21/29 22/28 21/29 
Age in years 11.6 (3.6) 34.7 (7.6) 66.8(7.9) 32.6 (7.3) 
Height in cm 147.7 (19.7) 168.0 (4.9) 168.7(6.9) 171.2 (7.8) 
Weight in Kg 47.6(17.1) 75.4(10.4) 78.1(13.6) 73.8(14.1) 
FEV1 2.0(0.7) 2.5(0.72) 1.5(0.6) 3.6(0.75) 
FEV1 % predicted 57.1 (16.9) 69.2(16.4) 51.8(21.9) 95.7 (14.3) 
PEF in L/min 251.8(115.0) 329.5(101.1) 216.5(93.3) 479.3(127.6) 
PEF % predicted 55.9 (18.8) 65.9 (16.5) 46.1 (20.5) 99.7 (20.4) 
FVC in Litres 2.5(1.0) 3.1(1.0) 2.3(0.9) 3.9(0.9) 
Disease 
severity 
Mild 7 18 25 N/A 
Moderate 19 20 17 N/A 
Severe 22 12 8 N/A 
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Table 7.2. Mean (SD) inhalation characteristics of asthmatic children, adult with asthmatic, COPD patients and healthy subjects when they 
inhaled through the Turbuhaler and Spiromax DPIs before and after training. 
 PIF (l/min) ∆P (kPa) Tp (sec) IV (L) Ti (sec) ACC (l/sec2) Acc(kPa/sec) 
CHILD 
TBH-A 57.6(13.4) 3.92(1.84) 0.75(0.55) 1.451(0.72) 2.08(0.84) 3.03(1.74) 11.32(7.72) 
TBH-B 71.8(14.7) 6.02(2.38) 0.47(0.20) 1.529(0.61) 1.82(0.62) 4.75(2.11) 21.73(12.47) 
SPIRO-A 67.9(15.7) 4.75(2.30) 0.68(0.33) 1.711(0.80) 2.15(0.8) 3.23(1.96) 12.48(9.86) 
SPIRO-B 81.0(16.4) 6.69(2.57) 0.51(0.35) 1.841(0.721) 1.95(0.71) 5.31(2.81) 24.23(16.73) 
ADULT 
TBH-A 65.4(14.4) 5.14(2.55) 0.49(0.26) 2.131(1.00) 2.69(1.20) 2.69(1.21) 13.0(12.0) 
TBH-B 76.7(15.0) 6.85(2.50) 0.27(0.12) 2.121(0.90) 2.31(0.85) 5.17(3.13) 25.95(20.28) 
SPIRO-A 74.4(18.1) 5.74(2.56) 0.936(0.66) 2.390(1.03) 2.74(1.27) 3.55(2.79) 15.66(15.55) 
SPIRO-B 85.5(14.6) 7.35(2.33) 0.292(0.17) 2.377(1.11) 2.32(1.03) 6.19(4.38) 30.02(25.29) 
COPD 
TBH-A 50.1(16.2) 3.10(1.9) 0.96(0.86) 1.577(0.69) 2.94(1.36) 2.42(1.88) 8.44(9.46) 
TBH-B 60.1(17.0) 4.4(2.4) 0.6(0.3) 1.665(0.71) 2.54(1.01) 3.9(2.5) 15.7(14.0) 
SPIRO-A 57.5(21.0) 3.66(2.70) 0.677(0.38) 1.819(0.87) 2.71(1.0) 3.04(2.2) 11.01(12.84) 
SPIRO-B 68.1(18.5) 3.94(2.1) 0.55(0.33) 1.897(0.89) 2.55(1.09) 4.67(3.1) 18.89(17.01) 
Healthy 
TBH-A 78.0(11.8) 6.98(2.05.) 1.19(0.70) 2.71(0.81) 3.02(1.03) 2.58(1.67) 12.84(9.55) 
TBH-B 90.36(10.9) 9.29(2.085) 0.55(0.3) 2.794(1.01) 2.71(0.8) 5.37(2.43) 30.11(14.3) 
SPIRO-A 85.01(13.58) 7.25(2.2.5) 1.02(0.53) 2.984(1.01) 2.94(1.1) 3.34(2.42) 15.85(13.53) 
SPIRO-B 98.68(9.15) 9.62(1.64) 0.54(0.51) 3.069(1.04) 2.67(0.82) 6.06(2.96) 32.21(17.17) 
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7.4.2.1 Inhalation Profiles of the children with asthma before and after training  
 
 
Figure 7.2. The distribution of the individual peak inhalation flows through the 
Turbuhaler and Spiromax, before (A) after training (B) achieved by the children with 
asthma. 
 
Figure 7.3. The distribution of the maximum pressure changes occurring in the 
Turbuhaler and Spiromax before (A), after training (B) during the inhalation of the 
children with asthma. 
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Figure 7.4. The range of the times to PIF when the children with asthma inhaled 
through a Turbuhaler and Spiromax before (A), after training (B). 
 
 
 
Figure 7.5. The distribution of the acceleration rates achieved by the children with 
asthma when they inhaled through the Turbuhaler and Spiromax before (A), after 
training (B). 
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Figure 7.6. The distribution of the inhaled volume achieved by the children with 
asthma when they inhaled through the Turbuhaler and Spiromax before (A), after 
training (B). 
 
 
 
Figure 7.7. The range of the individual inhalation times when the children with 
asthma inhaled through the Turbuhaler and Spiromax before (A), after training (B). 
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7.4.2.2. Inhalation Profiles of the adults with asthma when they through the 
Spiromax™ and Turbuhaler DPIs before and after training. 
 
The range of the inhalation characteristics is presented in Figures 7.8 to 7.13. 
 
Figure 7.8. The distribution of the individual peak inhalation flows achieved by the 
adults with asthma through the Turbuhaler and Spiromax, before (A) and after 
training (B). 
 
Figure 7.9. The distribution of the maximum pressure changes occurring in the 
Turbuhaler and Spiromax, before (A) after training (B), during the inhalations by the 
adults with asthma.  
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Figure 7.10. The range of the times to PIF when the adults with asthma inhaled 
through a Turbuhaler and Spiromax before (A) after training (B). 
 
 
 
Figure 7.11. The distribution of the acceleration rates achieved by the adults with 
asthma when they inhaled through the Turbuhaler and Spiromax before (A) after 
training (B). 
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Figure 7.12. The distribution of the inhaled volume achieved by the adults with 
asthma when they inhaled through the Turbuhaler and Spiromax, before (A) after 
training (B).  
 
 
 
Figure 7.13. The range of the individual inhalation times when the adults with 
asthma inhaled through the Turbuhaler and Spiromax, before (A) after training (B). 
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7.4.2.3. Inhalation characterisation for COPD patients when the inhaled 
through the Turbuhaler and Spiromax before and after training  
 
The range of the inhalation characteristics is presented in Figures 7.14 to 7.19. 
 
 
Figure 7.14. The distribution of the individual peak inhalation flows through the 
Turbuhaler and Spiromax, before (A) after training (B), achieved by the COPD 
patients 
 
Figure 7.15. The distribution of the maximum pressure changes occurring in the 
Turbuhaler and Spiromax, before (A) after training (B), during the inhalations by the 
COPD patients  
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Figure 7.16. The range of the times to PIF when the COPD patients inhaled through 
a Turbuhaler and Spiromax before (A) after training (B) 
 
 
 
 
Figure 7.17. The distribution of the acceleration rates achieved by the COPD patients 
when they inhaled through the Turbuhaler and Spiromax before (A) after training (B) 
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Figure 7.18. The distribution of the inhaled volumes achieved by the COPD patients 
when they inhaled through the Turbuhaler and Spiromax before (A) after training (B)  
 
 
 
Figure 7.19. The range of the individual inhalation times when the COPD patients 
inhaled through the Turbuhaler and Spiromax before (A) after training (B). 
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7.4.2.4. Inhalation characterisation for healthy subjects when the inhaled 
through the Turbuhaler and Spiromax™ DPIs before and after training  
 
The range of the inhalation characteristics is presented in Figures 7.20 to 7.25. 
 
Figure 7.20. The distribution of individual peak inhalation flows achieved by the 
healthy volunteers through the Turbuhaler and Spiromax, before (A) after training 
(B).  
 
Figure 7.21. The distribution of the maximum pressure changes occurring in the 
Turbuhaler and Spiromax, before (A) after training (B), during the inhalation of the 
healthy volunteers. 
Pe
ak
 in
ha
la
tio
n 
flo
w
(L
/m
in
)
Turbuhaler A Turbuhaler B Spiromax A Spiromax B
  
267 
 
 
 
 
 
Figure 7.22. The range of the times to PIF when the healthy volunteers inhaled 
through a Turbuhaler and Spiromax, before (A) after training (B). 
 
 
 
Figure 7.23. The distribution of the acceleration rates achieved by the healthy 
volunteers when they inhaled through the Turbuhaler and Spiromax, before (A) after 
training (B). 
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Figure 7. 24. The distribution of the inhaled volumes achieved by healthy volunteers 
when they inhaled through the Turbuhaler and Spiromax, before (A) after training 
(B).  
 
 
Figure 7.25. The range of the individual inhalation times when the healthy volunteers 
inhaled through the Turbuhaler and Spiromax, before (A) after training (B). 
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7.4.3. Comparison of the Inhalation Profiles through the different DPIs 
Spiromax and Turbuhaler  
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the parameters were not normally distributed. Comparison, therefore, 
between the various parameters of the inhalation profiles through the different DPIs:  
was made using the two related-samples, nonparametric Wilcoxon signed rank test. 
Table 7.3 shows the comparison between the means of the different inhalation 
parameters 
Table 7.3. Statistical analysis (p values are quoted). 
PIF TURB(A)v‟s 
SPIRO(A) 
TURB(A)v‟s 
(B) 
SPIRO A v‟s 
B 
TURB B‟vs 
SPIRO B 
CHILD 0.000 0.000 0.000 0.000 
ADULTs 0.000 0.000 0.000 0.000 
COPD 0.000 0.000 0.000 0.000 
Healthy 0.000 0.000 0.000 0.000 
PkPa     
CHILD 0.000 0.000 0.000 0.000 
ADULTs 0.016 0.000 0.000 0.004 
COPD 0.002 0.000 0.169 0.039 
Healthy 0.585 0.000 0.000 0.490 
IV     
CHILD 0.000 0.045 0.004 0.000 
ADULTs 0.001 0.709 0.178 0.000 
COPD 0.006 0.067 0.534 0.067 
Healthy 0.005 0.950 0.178 0.000 
ACC     
CHILD 0.191 0.000 0.000 0.000 
ADULTs 0.201 0.000 0.000 0.029 
COPD 0.735 0.000 0.000 0.029 
Healthy 0.057 0.000 0.000 0.585 
Inhalation Time     
CHILD 0.000 0.011 0.825 0.212 
ADULTs 0.521 0.007 0.010 0.712 
COPD 0.735 0.124 0.126 0.836 
Healthy 0.164 0.002 0.041 0.809 
Time at PIF     
CHILD 0.000 0.000 0.000 0.560 
ADULTs 0.732 0.000 0.000 0.444 
COPD 0.018 0.000 0.014 0.000 
Healthy 0.158 0.000 0.000 0.069 
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7.4.4 Asthma control Questionnaires (ACQ) 
(a) Children with asthma 
The mean (SD) ACQ scores are presented in Table.7.4. Table 7.5 presents the level 
of asthma control of child with asthma with respect to the ACQ. Details of each 
individual‟s ACQ are presented in APPENDIX B-4 6(refer to the enclosed DVD) 
Table 7.4. Mean (SD) scores of (ACQ) for children with asthma.   
 Mean(SD)Scores Minimum Maximum 
ACQ 1.68(0.99) 0.33 4.83 
 
Table 7.5. Level of asthma control (Child with Asthma). 
Asthmatic Children 
(n= 50) 
ACQ Categories Frequencies 
≤ 0.75 (well controlled) 5(10.0%) 
0.75-1.50 (not well controlled 25(50.0%) 
≥ 1.50( uncontrolled) 20(40%) 
 
(b) Adults with asthma 
A summary of the ACQ is presented in Table 7.6 and Table 7.7 presents the level of 
asthma control with respect to the ACQ. Details of each individual‟s ACQ are 
presented in APPENDIX B-4 7(refer to the enclosed DVD) 
Table 7.6. Mean (SD) scores of (ACQ) for asthmatic Adults.  
 Mean(SD)Scores Minimum Maximum 
ACQ 1.84(0.90) 0.67 4.50 
 
 
 
 
  
271 
 
Table 7.7. Level of asthma control. 
Asthmatic Adults 
(n= 50) 
ACQ Categories Frequencies 
≤ 0.75 (well controlled) 2(4.0%) 
0.75-1.50 (not well controlled 22(44.0%) 
≥ 1.50( uncontrolled) 26(52%) 
 
(c) COPD patients 
A summary of the MRC scores for COPD is presented in Table 7.8. Details of each 
individual‟s MRC scores are presented in APPENDIX B-48 (refer to the enclosed 
DVD) 
The MRC “Degree of Breathlessness” 
 
Degree of breathlessness using the MRC Dyspnoea Score (reflects exercise tolerance 
and functional limitation). The frequencies of the COPD patients in the MRC 
“Degree of Breathlessness” categories for one visit study and the frequencies of 
COPD patients in the MRC “Degree of Breathlessness” categories are presented in 
Table 7.8. 
Table 7.8. Dyspnoea (MRC Score) for COPD patients.  
*Degree of breathless related to activities 
Grade 1 2 3 4 5 
Total average  
COPD no.=50  
Non 2 3 4 5 
Pt. No. (%) Non 9/50(18%) 18/50(36%) 15/50(30%) 8/50(16%) 
M/F Non 6/3 4/14 9/6 2/6 
*Degree of breathlessness using the MRC Dyspnoea Score 4 (reflects exercise tolerance and 
functional limitation)
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7.5 Discussion 
Although DPIs are breath actuated many patients have problems preparing a dose for 
inhalation and with using the recommended inhalation manoeuvre (Molimard et al, 
2003, Chrystyn & Price, 2009; Haughney et al, 2010; Melani et al, 2011). Hence the 
ERS / ISAM Consensus Statement recommends that patients are made aware of the 
dose preparation procedures for each DPI and that the inhalation should be as 
forceful and long as possible and that this manoeuvre should commence immediately 
at the start of the inhalation (Laube et al, 2011). These inhalation manoeuvre 
instructions are based on the need to de-aggregate the dose and that this occurs 
during the initial phase of an inhalation when using a DPI (de Boer et al., 1996; de 
Boer et al., 1997; Everard et al., 1997; Kamin et al., 2002).  
It is important therefore to train patients on how to use their DPI. These results were 
available during the draft stage of the ERS / ISAM Consensus Statement and were 
used to inform the recommendation to focus on the initial phase of the inhalation 
during DPI technique training. 
In this study, which was a repeated measure design, all subjects received the DPI 
training that they would have received routinely in the clinic. This included the 
technique instructions recommended in the patient information leaflet.  The first set 
of measurements represents those that would be achieved from standard DPI 
technique training in the clinic. The subjects then received the enhanced training with 
the IN-Check Dial which is not part of routine inhaler technique training.  The very 
highly significant improvements highlight realistic changes in the peak inhalation 
flow and more important in the pressure change (hence turbulent energy) and the 
acceleration of the inhalation (with respect to the pressure changes).  An alternative 
study design would have been to randomise the subjects after the standard training to 
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one group that received the enhanced training and another that received a repeat of 
the standard training.  Although this randomised control trial design would require 
more subjects due to the parallel groups the results would not reflect a training effect.  
However the differences in this repeated design study are very significantly better 
after the intervention and so suggest that any training effect did not influence the 
results. 
Studies have shown that patients with stable asthma (Hawksworth et al, 2000; 
Broeders et al, 2003) and COPD (Nsour et al, 2001; Broeders et al, 2003; Al-Showair 
et al 2007) as well as children with asthma (Agertoft & Pedersen, 1998) do improve 
their inhalation flows after routine training and that highly trained asthmatics (Tarsin 
et al, 2006) and COPD (Derom et al, 2007) patients do inhale with faster flows. The 
results in this chapter confirm that patients can improve their inhalation manoeuvres 
even further with enhanced training using the IN-Check Dial. This training tool 
provides objective feedback about the inhalation manoeuvre rather than the 
subjective response provided during standard inhalation technique training. Two 
different DPIs that had a similar resistance were used so that it could be identified 
that the changes were due to the training and not a device effect. As expected the 
healthy adults produced the best set of inhalation parameters followed by the adults 
with asthma with the children with asthma slightly higher than the COPD patients. 
The pressure changes (hence the turbulent energy), the acceleration rates and the 
inhalation flows were greater for Spiromax than the Turbuhaler in all 4 groups 
although there was little difference in the resistance of the two DPIs. This is 
consistent with the results in Chapter 6. The faster flows would be due to the slightly 
lower resistance of the Spiromax. In Chapter 6 it was found that the influence of the 
higher resistance with respect to the pressure changes and the acceleration flows was 
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not linear and there was the suggestion of a cut-off point when resistance dominates 
the pressure changes. It may be that the resistance of the Spiromax and the 
Turbuhaler is such that inhalation flow influences the pressure changes (and 
turbulent energy) more than the resistance of the device. Inhalation volumes were 
significantly greater when using the Spiromax DPI which would be due to its lower 
resistance. 
Very highly significant improvements (p<0.001) in the maximum pressure change 
(equivalent to the maximum turbulent energy) were obtained after the enhanced 
training in all 4 groups for both DPIs except for the COPD patients when using the 
Spiromax. The lower values in the COPD subjects would be due to the reduced 
inspiratory effort of these patients. All acceleration rates, PIF values and the time to 
the PIF all significantly (p<0.001) improved post enhanced training. The 
improvements in the acceleration rate when using the Turbuhaler were much more 
pronounced in the asthma and COPD patients than those obtained from similar 
patients who received specific and additional verbal instructions using the patient 
information leaflet (Broeders et al, 2003). In this 2003 study the training these 
patients received was similar to standard training that patients would receive in the 
clinic and thus similar to the initial training given to the patients in this study. These 
differences highlight the importance of using more objective methods during 
technique training. The improvements also highlight the value of the IN-Check dial 
as a training aid (Azouz & Chrystyn, 2012). 
In Chapter 6 the patients used their normal real-life technique whereas in this study 
they received standard and enhanced inhalation technique training. This would have 
contributed to the difference between the inhalation parameters measured in the two 
studies. Some differences in the demographics of the patients would also influence 
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the different parameters measured. The baseline inhalation characteristics of the 
children with asthma (age range 5 to 16 years) when they inhaled using the 
Turbuhaler in this Chapter was greater than those in Chapter 6. In addition to the 
training these children were older and taller than those of the study in Chapter 6. 
However their acceleration rates were slower than those of Chapter 6 even though 
they had received verbal and written instructions to inhale as fast as possible. The 
inhalation characteristics of the adults with asthma in this Chapter were also higher 
but compared to the children the difference was smaller (overall less than 10%). 
There was only a small difference in the FEV1 % predicted between the adult 
asthmatics in the two studies. Their acceleration rates were very similar but 
inhalation volumes were higher which could be due to instructions to exhale before 
the inhalation manoeuvre. There were smaller difference between the results in this 
chapter and those in Chapter 6 when COPD patients inhaled using than Spiromax 
and the Turbuhaler. 
The PIF values with the Turbuhaler after the enhanced training was similar to those 
of highly trained COPD (Derom et al, 2007) and asthma (Tarsin et al, 2006) patients. 
In patients receiving standard training the PIF values through the Turbuhaler are 
similar to those reported for COPD patients (Dewar et al, 1999; Al-Showair et al; 
2007), adults with asthma (Meijer et al, 1996; Broeders et al, 2003) and children with 
asthma (Stahl et al 1996). Four COPD patients and 1 adult with asthma but no 
children with asthma used a PIF < 30L/min with the Turbuhaler. All these 
significantly improved above >30L/min post training. Improvements in inhaled 
volume were only small indicating that the participants always made a full 
inhalation. Studies have shown that volume is important when using a DPI with upto 
1L required through a Turbuhaler (Kamin et al, 2002). After the enhanced training 10 
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children with asthma (two 5 years old, two 6 years, three 7 years and one 9, 10 and 
13 year old), 4 adults with asthma (FEV1 43, 52, 72 and 78 % predicted) and 9 
COPD patients (FEV1 21, 25, 26, 32, 35, 42, 45, 52 and 60 % predicted) did not 
inhale greater than 1L. Inhalation volume may be more important to consider that 
any other inhalation characteristic when choosing a DPI. 
The inhalation characteristics shown in the scatter plots (relationships) highlight that 
the compendial methods for in-vitro testing using a pressure change of 4kPa with an 
inhaled volume of 4L are unrealistic. These relationships confirm that focus should 
be directed to methodologies that can use patient inhalation profiles during in-vitro 
testing in place of the vacuum pump that can only replicate a square wave. 
The results show the value of training patients to use a faster flow rate and 
encouraging them that their fast inhalation should begin as soon as they start to 
inhale. Using the IN-Check Dial as a training aid to achieve faster inhalation flows is 
useful. The similar increases of the Spiromax and the Turbuhaler show that the 
improvements in training were due to the method and were not influenced by the 
different design or appearance of the devices. 
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Chapter 8: Summary  
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8.1 Summary and Conclusion 
Pressurised metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) are 
routinely used in the management of asthma and COPD. The pMDI was first 
introduced in 1956 followed by the single dose DPI in 1967 and multidose DPIs in 
1987 (Sanders, 2007). Although some of these devices were introduced over 50 years 
ago patients have problems using the correct technique (Crompton et al., 2006; 
Laube et al., 2011; Melani et al., 2011). The correct inhalation technique by patients 
is crucial for maximum lung deposition and the success of therapy (Laube et al., 
2011). Studies have shown that poor technique is related to poor disease control in 
asthma (Giraud & Roche, 2002; Al-Showair et al., 2007; Melani et al. 2011) and 
COPD patients (Melanie et al., 2011) and is linked with more hospitalisations 
(Melani et al., 2011). National and World guidelines on the management of asthma 
(BTS / SIGN, 2011; GINA 2011) and COPD (NICE, 2010; GOLD, 2011) all stress 
that before a patient‟s inhaled therapy is altered then their inhalation technique and 
their compliance should be checked first. 
A pMDI should be used with good co-ordination and a slow inhalation flow whereas 
a DPI should be used with a fast inhalation and that this forceful inhalation should 
commence from the beginning (Laube et al., 2011). The inhalation phase for both 
inhaler types should last as long as possible so that the emitted particles have a 
greater chance to be deposited throughout the airways (especially the peripheral 
regions of the lungs). 
Despite the differences in the instructions when using a pMDI and a DPI for efficient 
delivery of the particles from the emitted dose the inhalation flow should be similar. 
It has been suggested that this inhalation flow should be >30 L/min <90L/min 
(Pauwels et al., 1997). The pMDI is an active device because the particles are 
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generated by the device in that when the canister is depressed a valve opens and as 
the propellant evaporates the particles are emitted. There is no resistance to flow in a 
pMDI and so to achieve < 90L/min patients should be encouraged to inhale slowly. 
DPIs are passive devices in that an external source is required to emit the dose from 
the device and generate particles with the potential for lung deposition. This external 
source is the patient‟s inhalation flow interacting with the internal resistance of the 
DPI to create a turbulent force / energy (measured as a pressure change) which de-
aggregates (breaks up) the formulation into particles that have the potential for lung 
deposition (Clark & Hollingworth , 1993). 
De-aggregation takes place during the inhalation manoeuvre because when the dose 
of a DPI has been prepared for inhalation the formulation does not have the 
characteristics for its drug particles to be deposited in the lungs (Chrystyn, 2003). 
During manufacture and dose metering good powder flow is essential and so the 
particles in the formulation are attached to a large particle lactose carrier or 
formulated into spherical agglomerates. The resistance to airflow in each DPI means 
that to achieve the required inhalation flows patients need to use a forceful inhalation 
(Chrystyn, 2003). Also the de-aggregation and dose emission from a DPI occurs in 
the first part of an inhalation (de Boer et al, 1997; Everard et al, 1997; Kamin et al, 
2002) and so the forceful inhalation should commence from the start of each 
inhalation (Laube et al, 2011). Also for each DPI there is a threshold below which 
the turbulent energy generated during an inhalation is not sufficient to efficiently de-
aggregate the dose (Laube et al, 2011). Overall this minimum flow is assumed to be 
30L/min but will be higher in those DPIs with a lower resistance and vice versa 
(Laube et al, 2011). 
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Many patients have problems using their pMDIs. These problems first surfaced in 
1965 (Saunders, 1965) but it was from 1976 in the studies by Crompton (Paterson 
and Crompton, 1976; Crompton 1982) that the problem of poor co-ordination were 
realised and still remain today (Melani et al, 2011). Until recently not using a slow 
flow was not realised as a problem mainly because studies had used bronchodilators 
which would benefit from more central lung deposition (which occurs when using a 
fast flow) as well as high doses. It has been shown that slow flow through a pMDI 
improves asthma control without any changes in the spirometry (Al-Showair et al., 
2007). This reflects better particle penetration of the corticosteroids into the 
peripheral zones of the lungs. Slow inhalation flow improves lung deposition 
especially in the peripheral zones of the lungs (Usmani et al, 2005). Only 8% of 
asthmatics use a slow flow with good co-ordination (Al-Showair et al, 2007). 
Training pMDI and DPI technique can help but patients do revert back to their old 
technique soon after the training session when they leave the clinic (Shim and 
Williams, 1985). Although patients do not always use the correct inhalation 
technique they do receive some benefit from their inhalers but this would be 
improved when using a good technique. There is a need, therefore, to identify simple 
methods that could be used during inhaler technique training that help patients use 
the correct technique and that this trained technique is then used by them at home. 
All the studies in this Thesis used the patients‟ untrained inhalation technique (there 
were two studies that assessed the effect of training but the starting point was their 
untrained technique). 
In the first study the inhalation characteristics of 20 children with asthma, 57 adults 
with asthma and 32 COPD patients was measured electronically when they inhaled 
through a pMDI. These patients routinely used a pMDI and they received no training 
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in the inhalation technique that they should use. The results provide a significant 
contribution of data that describe the inhalation characteristics of patients when they 
use their pMDI. No studies have reported values on children when they use pMDIs 
and spacers 
Previously it had been shown that an inhalation flow of < 90 L/min (Farr et al., 1995; 
Pauwels et al., 1997) indicated slow flow. The mean (SD) inhalation flows of these 
patients were 108.9(40.4), 146.0(58.8) and 107.3(50.6) L/min. Only 7 children, 10 
adults and 10 COPD patients inhaled using a slow flow of < 90L/min. The mean 
(SD) inhalation times were 1.4 (0.27) seconds for the children with asthma, 1.5(0.3) 
seconds by the adults with asthma and 1.6(0.2) seconds by the COPD patients. 
Overall these are shorter than the 5 seconds for an adult and 2-3 seconds by a child 
that has been recommended by the ERS Consensus Statement on the use of inhalers 
(Laube et al, 2011). It is the results of this Thesis that informed the ERS Consensus 
statement to include the recommendation about the focus on the length of the 
inhalation. Inhalation volumes were a mean (SD) of 1.14 (0.6), 2.1(0.9) and 1.8(1.0) 
(L), respectively. The clinical significance of these values is not known. This was a 
preliminary study and the methodology could not measure the point when the patient 
actuated a dose with respect to the start of their inhalation. The methodology of the 
second study was designed to capture co-ordination data. In general the inhalation 
parameters when these patients used their pMDI were similar to those when they 
inhaled through a pMDI attached to a spacer. Overall all inhaled volumes were 
greater than the volume of an AeroChamber but some young children did not achieve 
an inhaled volume greater than that of the Volumatic confirming the standard 
practice for these patients to use tidal breathing rather than one full inhalation. The 
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methodology used in this study did not allow a measure of the time between pressing 
the canister and the start of an inhalation. 
The second study included methodology to measure the co-ordination of dose 
actuation and with the start of their inhalation. Like study one this was a data capture 
study to describe how patients with asthma (both children and adults) and COPD 
patients use their inhalers. Like study one there is no such published data to describe 
how children with asthma and similar data on asthma patients and COPD subjects are 
limited. Previously it had been shown that 0.2 seconds between the start of an 
inhalation and the actuation of the dose was an indicator for good co-ordination 
(Goodman et al., 1994; Farr et al., 1995). 20 children with asthma, 130 adults with 
asthma and 31 COPD patients completed the study. Their mean (SD) inhalation 
flows were 70.5(36.4) 131.4(60.8) adults and 70.9(28.1) L/min. Overall the flows in 
the children with asthma and in the COPDs were the best with 15 out of 20 (75%) 
children and 24 out of 31 (77%) using a flow <90 L/min. It is amongst the adult 
asthmatics that flow was too fast. Overall 93/130 (72%) used a fast flow with 21 
(16% of the total) inhaling >200 L/min. Five children, 53 of the adults and 10 of the 
COPD patients were good co-ordinators but of these only 3, 6 and 9 patients also 
used a slow flow. Their mean (SD) inhalation times were similar to those of the first 
study; 1.25 (0.46) seconds by children with asthma, 1.68(0.82) seconds by the adults 
and 1.44 (0.65) seconds for the COPD patients. The studies suggest that when 
patients use a pMDI their inhalation times are too short (Laube et al, 2011) so they 
should be trained to inhale for longer. Theoretically when the patient makes a full 
inhalation then the inhaled volume should not change and so their flow will decrease.  
There were no clinical endpoints to this study because the data was collected at one 
visit. However it was possible to classify the patient‟s disease severity and 
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investigate if this was related to technique. Only a small number of patients achieved 
a good technique and so a comparison of their disease control to those with good 
technique was not possible. Furthermore all the patients with good technique were 
clinically not well controlled. This could be due to compliance or that their asthma 
was so severe and affected them so much that they focussed more on their technique 
to ensure they obtained as much therapeutic benefit as possible. In this study good 
correlations were found between the inhaled volume and the forced vital capacity of 
the adult asthmatics with a ratio of around two thirds between the inhaled volume 
and the forced vital capacity. This could be an indicator about the full inhalation that 
patients are recommended to use (breathe out gently from the start and then inhale 
until the lungs are full of air). Electronic aids are in development to help with the 
training of patients by identifying the mistakes they are making (for example AIMS2 
by Vitalograph, UK). Thus by entering the patient‟s spirometry and checking this to 
the inhaled volume then this ratio would indicate to the trainer if a full inhalation has 
been made 
The two studies in these chapters confirm that not using a slow flow with a pMDI is 
the most common mistake made by patients (Al-Showair et al, 2007). They also 
show that the duration of the inhalation is short. There has never been any mention in 
previous literature or recommendations of inhaler technique that one major problem 
is that the inhalation phase is too short when patient use a pMDI. For this reason this 
was included in the investigations of the third pMDI study. 
The previous two studies had shown that overall patients inhaled too fast and that 
their inhalation phase was relatively short 
. Chapter 5 of this thesis investigated the inhalation parameters of asthmatic adults 
when a co-ordination aid was used and then including an instruction to length the 
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inhalation phase. The co-ordination aid increased the resistance of the pMDI and so 
it would naturally slow inhalation flows. The inhalation profiles of 71 stable 
asthmatic patients were measured, their mean (SD) FEV1 was 78.31 (21.03) % 
predicted. The order of inhalations was the pMDI, pMDI+CAP (the cap is the co-
ordination aid) and pMDI+CAP+TRAIN (the train was the instruction to prolong the 
inhalation phase to 5 seconds). Their mean (SD) inhalation flows were 155.6(61.5), 
112.3 (48.4) and 73.8 (34.9) L/min, respectively (p< 0.001). Inhalation volumes did 
not change and the duration of the inhalations was 1.60 (0.21), 1.92 (0.80) and 2.99 
(1.03) seconds (p<0.001). Thus the increased resistance from the co-ordination aid 
naturally decreased their flow and by prolonging the inhalation time with no change 
in the inhalation volume reduced their flows even further. Overall 70% percent of 
patients used the correct pMDI technique with the cap and the simple instruction for 
their inhalation phase to last 5 seconds. Excellent correlations were found between 
the inhalation volumes and the forced vital capacity. The mean inhaled volume to 
forced vital capacity ratio when using the pMDI on its own was 70%. This suggests 
that such a ratio can be used to indicate a „full inhalation‟ (exhale gently as far as 
comfortable followed by an inhalation until the lungs are full of air). 
This study was in progress when the ERS Consensus statement was in the draft stage.  
These results like that of the two previous studies informed the ERS consensus 
statement about the importance of recommending patients to use a long inhalation 
(upto 5 seconds) when they use a pMDI. The correlations are consistent with those 
identified in second study and consolidate the recommendation that the inhaled 
volume to forced expiratory volume ratio could incorporated into electronic inhaler 
training aids to indicate a full inhalation 
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Figure 8.1 shows why inhalation flow decreases when the inhalation volume does not 
change and the inhalation time is increased. Also the results suggest that when a new 
pMDI is designed or a new chemical entity is introduced in a pMDI, then some 
resistance should be included because this will naturally slow down the inhalation 
flow. 
 
 
Figure 8.1. The effect of lengthening the time of the inhalation phase (dashed line)  
This third pMDI study was a repeated measure design instead of a more traditional 
parallel trial.  The benefits of this design are that it improves efficiency (since fewer 
subjects are required) and it eliminates variability due to individual differences in 
overall performance thereby allowing the outcome data to stand out.  The changes in 
the peak inhalation flow and inhalation times are very highly significant hence they 
were realistic changes.  However it is possible that there is an element of a training 
effect with the 5 second inhalation. A different approach would have been that after 
they inhaled through the pMDI and the pMDI cap there could have been a 
randomisation of the patients for one group to receiving the training to prolong the 
inhalation time to 5 seconds and the other group to receive to training 
Two studies involving DPIs are presented in Chapters 6 and 7. The first study in 
Chapter 6 again involved children with asthma (n=16), adults with asthma (n=53) 
and COPD (N=29) patients. The DPIs used ranged from low to high resistance DPIs 
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(Laube et al, 2011) and the main reason for the study was to provide data on the 
inhalation characteristics of patients when they use different DPIs. 
For these measurements patients were asked to use the same inhalation manoeuvre to 
that when they used their own inhaler. Their peak inhalation flow was measured as 
well as the pressure changes (hence turbulent energy) and the acceleration of their 
flows. Measurement of pressure changes in kPa units and acceleration rates in 
kPa/sec units allows a comparison to be made between different DPIs when used by 
patients (Azouz and Chrystyn, 2012). Previously there has not been any emphasis on 
these measurements. The time to the peak inhalation flow, inhaled volume and the 
duration of each inhalation were also measured. Also these chapters provide 
substantial data on the inhalation parameters of patients when they use different DPIs 
The results in these studies confirm that when inhaling through the same DPI 
children with asthma generate lower PIF values than COPD patients and both these 
are lower than the rates achieved by adults with asthma. Another important issue is 
that for each DPI there will be minimum threshold energy for efficient de-
aggregation of the dose. It is universally recognised that the flow through a DPI to 
exceed this minimum threshold energy is 30 L/min. Three of the 16 asthmatic 
children did not achieve 30L/min through the Accuhaler. These were all boys aged 5, 
7 and 12 years old. The 5 and 12 year old did not achieve this flow through the 
Turbuhaler but there were 4 others with flows of either 31 or 32 L/min. The same 2 
children failed to achieve 30L/min with the Clickhaler but only one of them (the 12 
year old) with the Easyhaler. This suggests that it may be the low resistance inhalers 
that patients have problems with exceeding the minimum required flows rather that 
high resistance DPIs.  
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It has been suggested that a failure to achieve an inhalation flow of 30 L/min within 
the first 150 ml of the inhalation affects de-aggregation (Everard et al., 1997) and 
thus inhalation characteristics about the first 150 ml of the inhaled volume were 
obtained. The results show that the PIF at 90% of the inhalation flow corresponded to 
when 150 ml had been inhaled through a Turbuhaler and so this portion of the 
inhalation profile was used to calculate the acceleration rates. The acceleration rates 
were greater in DPIs with high resistance. This together with the pressure changes 
suggest that more efficient de-aggregation occurs in these DPIs and may explain why 
these provide higher lung deposition than low resistance DPIs (Borgstrom, 2001). 
Pressure changes, acceleration rates and volumes were lower in the children and the 
highest values were the adults with asthma. The inhalation flows through DPIs with 
high resistance were lower than those with low resistance but the pressure changes 
were greater. The results highlight the value of including the pressure change 
measurements and the acceleration of the flow when examining inhalation profiles. 
As expected inhaled volumes were lower in the children with asthma than the COPD 
patients and both these were lower than the adults with asthma. When using the 
Aerolizer only one child inhaled > 2 L and more than half < 1 L, 7 COPD patients 
inhaled >2L (one >4L) and 5 < 1 L whilst 17 adults with asthma inhaled >2L but no 
one inhaled >4L and 7 inhaled < 1L. These values highlight the recommendation that 
when using capsule DPIs then patients should make two separate inhalations for each 
dose (Laube et al, 2010). Also many patients (especially children and COPD 
patients) did not achieve an inhaled volume of >1 L through a Turbuhaler. It has 
been suggested that a minimum of 1L is required to be passed through a Turbuhaler 
to efficiently empty the dose from the device (Kamin et al, 2002). 
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The study highlights the misunderstanding during the routine clinical practice that 
focuses on the inhalation flow.  As expected inhalation flows were significantly 
faster when the DPI had a lower resistance and vice versa for high resistance DPIs. 
To make a comparison of flow between inhalers is flawed because it is the turbulent 
energy created by the inhalation manoeuvre inside the inhalation channel of the DPI 
that is critical for the de-aggregation of the dose. The data in this study shows that 
this turbulent energy is higher for the DPIs with higher resistance.  This concept is 
not understood during routine practice and was the reason for the review that has 
arisen from this thesis (Azouz & Chrystyn, 2012) 
It has been recommended that patients use DPIs with a forceful and deep inhalation 
manoeuvre for as long as possible and that this should commence immediately at the 
start of the inhalation (de Boer et al, 1996; ibid, 1997; Everard et al, 1997; Kamin et 
al, 2002: Laube et al, 2011). It is important therefore to train patient on how to use 
their DPI (Laube et al, 2011). The final study, in Chapter 7, describes the changes in 
the inhalation parameters that occur when the inhaler technique training of patients is 
focussed on getting them to use a forceful inhalation that begins at the start of their 
inhalation. Two different DPIs (Spiromax and Turbuhaler) with a similar resistance 
were used so that changes were due to the training rather than the resistance or the 
device.  
All subjects that entered this study received the same routine DPI training that they 
would have received in the clinic (usually from the nurse). This training included 
instructions with reference to the information contained in the Patient Information 
leaflet. Hence the subjects would have been trained to exhale and then use an 
inhalation manoeuvre that is as deep and fast as they can. After the measurements 
enhance training was provide by including the IN-Check Dial as a training aid. 
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Patients were children with asthma, adults with asthma and COPD as well as healthy 
volunteers. There were 50 in each group 
The healthy subjects in this study produced the best set of inhalation parameters 
followed by the adults with asthma with the children with asthma slightly higher than 
the COPD patients. The acceleration rates (pressure change over time), the pressure 
changes (hence the turbulent energy), and the inhalation flows were greater for 
Spiromax than the Turbuhaler in all 4 groups. This study showed that highly 
significant improvements (p<0.001) in the maximum pressure change (equivalent to 
the maximum turbulent energy) were obtained after the enhanced training in all 4 
groups for both DPIs except for the COPD patients when using the Spiromax. All 
acceleration rates, PIF values and the time to the PIF all significantly (p<0.001) 
improved post enhanced training. The improvements in the acceleration rate when 
using the Turbuhaler were much more pronounced in the asthma and COPD patients 
than those obtained from similar patients who received verbal instructions using the 
patient information leaflet (Broeders et al, 2003). Hence, using objective methods 
during inhalation technique training is useful and should be encouraged and the 
results show the value of using the IN-Check Dial as a training aid with a focus on 
the initial part of the inhalation. This enhanced training is extra to that provided in a 
routine clinical setting. Again the study was designed as a repeated measure 
approach starting with standard DPI training with the patient information leaflet 
followed by the enhanced training with the In-Check Dial. A different approach 
would have been to randomise the patients into two groups following the routine DPI 
training.  One group would receive the enhanced training and for the other the 
routine clinic training would be repeated.  
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Figure 8.2 explains the value of using such a technique compared with a slower 
inhalation that starts slowly and gradually builds up. The results in Chapter 7 show 
why patients should be encouraged to use a fast inhalation and that this should 
commence from the start of each inhalation.   
 
Figure 8.2. A fast (continuous line) and a slow (dashed line) inhalation flow profile 
through a DPI. Dose emission is superimposed onto the profiles  
In conclusion when using a pMDI the focus of the training should be increasing the 
inhalation time towards 5 seconds (3-4 seconds in a child) and then instructing them 
to depress the canister, to release a dose, soon after they start to make their slow 
inhalation. When using a DPI patients should be encouraged to inhale as fast as they 
can for as long as possible and that this forceful inhalation should start from the 
beginning of the inhalation. To achieve this, the IN-Check dial is a useful training 
aid. These simple modifications to how patients are trained to use their inhalers 
should improve their disease control and help meet the GINA challenge (Fitzgerald 
et al, 2011) to reduce hospital admissions. 
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Chapter 9: Future Work  
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9.1 Future Work  
The research studies in this thesis have used electronic measurements to objectively 
highlight the problems patients have using their pMDI and DPIs during real life use. 
Incorporated into the studies were a novel co-ordination aid for use with a pMDI and 
a novel approach to train patients how to solve the common problems with the 
inhalation manoeuvre. The focus of this was to concentrate on getting patients to 
prolong their inhalation time. For the DPI the training used was enhanced by using 
the IN-Check Dial as a training aid. All these studies generated inhalation profiles 
that have demonstrated that there is a large inter-patient variability of the inhalation 
manoeuvre when using all inhalers. The studies involved children with asthma, 
adults with asthma and patients with COPD. 
All the measurements were completed at one visit so future studies need to 
investigate if the training methods provide lasting changes to the patients‟ inhalation 
manoeuvre and whether this improves their disease control. For asthma as well as 
spirometry the asthma control questionnaire (ACQ) would be used whilst for COPD 
the newly introduced COPD Assessment Test (CAT) would be a suitable method. 
Long term studies would include GP visits and hospitalisations. These would need to 
be randomised into trained and not trained patients (both patients would receive 
standard inhaler technique training in addition according to routine patient 
management).  
The first study would be to determine the clinical outcomes that occur when patients 
are trained to prolong their inhalation to 5 seconds. The classical group to use would 
be adult asthmatics but a similar approach could be adopted for the children with 
asthma and the COPD subjects. The length of the study in asthma would have to be 
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>12 weeks so that any changes due to better anti-inflammatory control could be 
identified. The schematic design of such a study is presented in the figure below 
 
 
Figure 9.1.Schematic design of the study to determine the clinical outcome of the 5 
second inhalation instruction 
A longer study with visits at 6 months and 12 months would enable the impact of 
training to be evaluated and also allow the inclusion of acute exacerbations. This 
design could also be used in children with the same outcome measures.  Similarly the 
study design could be used with COPD patients with CATS replacing ACQ.  For 
COPD a 12 month study (or longer) would be desirable.  
Clinical studies using the co-ordination cap are required if this aid is to be 
introduced. These would include an evaluation of the potential critical error that was 
identified during the study. It was noted that some patients do not keep the canister 
depressed throughout the duration of their inhalation. This causes the slits in the cap 
to close thereby preventing any further inhalation. This is a strong feedback 
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mechanism and so patients should quickly realise that the canister has to be kept 
depressed for the entire duration of their inhalation. Whether this is a potential 
critical error or not needs to be identified. Also the methodology to measure the 
electronic inhalation profiles needs to be adapted such that co-ordination with the co-
ordination aid can be measured. This was not measured in the study because of the 
need to maintain an airtight seal within the inhalation system. However this problem 
has been overcome. 
In this study the patients would be divided into standard pMDI and pMDI plus cap 
groups. To further investigate the effect of the 5 second inhalation then each group 
could then be further randomised into one half that received the extra training and the 
other half that did not.  A schematic representation of the randomised groups is 
described in Figure 9.2. 
 
Figure 9.2. Schematic design of the randomisation process. 
Like the study above the length of the study could be 12 weeks with a 2 week 
running period before the study start and the randomisation. Outcome measures 
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would be spirometry and ACQ as well as the inhalation parameters.  In COPD 
subjects CATS would replace ACQ.  
The DPI study in Chapter 7 also warrants further investigation as a clinical study.  
One limitation was that it was a repeated measures design and that instead of 
providing enhance training then one half could have had the standard training 
repeated.  After randomisation into these two groups then clinical studies could then 
be extended to 12 or 52 weeks with the same endpoints as the two studies described 
above. A schematic representation of this study is shown in figure 9.3 
 
 
Figure 9.3. Schematic design of the DPI enhanced training study 
For all the above three studies the data from the studies in this Thesis together with 
other clinical studies can be used to inform the number of patients to be included.  It 
is anticipated that due to the parallel design of the studies that large numbers will be 
required. 
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Finally the different inhalation profiles and the parameters achieved by patients show 
that the in-vitro compendial methods to characterise the aerodynamic characteristics 
of the emitted dose are not realistic. The scatter plots in Chapter 6 show that this 
applies to all DPIs. The compendial methods use a vacuum pump that can only 
produce a square wave inhalation profile and are set at an inhalation volume and a 
pressure change (hence flow) that is not achieved by most patients. At present the 
results generated by these methods are quality control measures. For DPIs (and even 
pMDIs) it is possible to replay the inhalation flow profile using a computer 
controlled vacuum pump. This should replace the standard square wave and be 
incorporated into in-vitro compendial methodologies.  
Figure 9.4 shows a schematic diagram of the in-vitro methodology that could be 
used. The Andersen Cascade Impactor (ACI) method described in the 
Pharmacopoeias is adapted so that dose emission from an inhalation profile can be 
determined. This is achieved by using a mixing inlet that inputs supplementary air, 
airflow at 60L/min, whilst the vacuum pump draws air at 60L/min through the ACI - 
see figure 9.4. Hence when the inhaler is in situ there is no flow through it. The 
inhalation profile is introduced into the supplementary which results in this profile 
being replayed as an inhalation through the inhaler in situ. This method is classified 
as an ex-vivo, technique and can be used for a selection of patient profiles to provide 
in-vitro dose emission data about the dose the patient would have inhaled. 
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Figure 9.4 Schematic design of in-vitro methodology to incorporate inhalation 
profiles. 
Although the work in this thesis can suggest other further studies the ones described 
above are those that are recommended because these will consolidate the results 
presented in the thesis 
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